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Abstract 
Hepatitis B virus (HBV), the prototype member of the family Hepadnaviridae, is 
hepatotropic and replicates by reverse transcription. HBV is responsible for the chronic 
infection of more than 240 million people worldwide, of which 65 million reside in Africa. 
The nine HBV genotypes (A to I) identified to date, are geographically distributed and exhibit 
different clinical manifestations and treatment responses. The term occult HBV infection 
(OBI) refers to a HBV infection in which HBV surface antigen (HBsAg) cannot be detected 
by conventional serological assays as has been defined by the Taormina expert panel. . HBV 
and human immune deficiency virus (HIV) are both endemic in many parts of the world and 
share common transmission routes. Worldwide, 10% of those infected with HIV are also 
chronically infected with HBV.  HIV co-infection has been shown to be a risk factor for the 
development of OBI in individuals infected with HBV. 
The aim of this study was to characterize, at the molecular level, HBV from mono-infected 
and HBV/HIV co-infected individuals in Sudan  
The objectives of this study were the systematic and comparative analysis of HBV genotype 
D sequences, available in the public databases; the molecular characterization of HBV from 
mono-infected Sudanese liver disease patients and from HBV/HIV co-infected Sudanese 
patients; and the   development and testing of bioinformatics tools to explore HBV sequence 
data generated using ultradeep pyrosequencing (UDPS) and comparison of UDPS results 
with those obtained from cloning based sequencing (CBS). 
All available complete genomes of genotype D of HBV from the GenBank database were 
analyzed. The intra-group divergence of the subgenotypes ranged from 0.8% + 0.5 for 
subgenotype D6 to 3.0% + 0.3 for subgenotype D8. Phylogenetic analysis of genotype D 
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showed separation into six distinct clusters (subgenotypes D1, D2, D3/D6, D4, D5 and 
D7/D8), with good bootstrap support. The mean intergroup divergence between subgenotype 
D3 and subgenotype D6 was 2.6%, falling below the accepted threshold of 4% required to 
define a subgenotype. This suggests that subgenotypes D3 and D6 are the same subgenotype 
because they also share signature amino acids. Furthermore, subgenotype D8 is a genotype 
D/E recombinant, which clusters with subgenotype D7. This analysis provided an update on 
the classification of the subgenotypes of genotype D of HBV.   
Although HBsAg seroprevalence in Sudan, a central-African country, is greater than 8%, the 
only sequencing data for HBV, available prior to our study, was from asymptomatic blood 
donors, where genotype E predominates, followed by genotype D and subgenotype A2. 
Ninety-nine HBV-positive liver disease patients were enrolled in our study, including: 15 
with hepatocellular carcinoma (HCC), 42 with cirrhosis, 30 asymptomatic carriers, 7 with 
acute hepatitis and 5 with chronic hepatitis.  The surface and basic core promoter/precore 
(BCP/PC) regions, and the complete genome of HBV were sequenced.  Eighty-two percent of 
the samples from HBV mono-infected liver disease patients were genotyped. Fifty-nine 
percent were infected with genotype D (74% D1, 10% D2, 3% D3 and 13% D6), 30% with 
genotype E, 8.5% with genotype A and 2.5% with a genotype D/E recombinant. Patients 
infected with genotype E had a higher frequency of HBeAg-positivity (29.2%) and higher 
viral loads compared to patients infected with genotype D. BCP/PC region mutations, 
including the G1896A mutation, seen in 37% of the HBeAg-negative individuals, could 
account for the HBeAg-negativity. 
A total of 358 Sudanese HIV-positive patients were enrolled.  HBsAg was detected in 11.7% 
of the participants, indicating chronic HBV infection. HBV DNA was detected in 26.8% of 
the participants: 11.7% were HBsAg positive (overt infection) and the remaining 15.1% were 
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HBsAg-negative (OBI). Fifty serum samples from the HBV/HIV DNA-positive co-infected 
participants were selected for genomic analysis of HBV. Of these, the HBV genotype of 37 
was determined. The genotype distribution of HBV isolates from the HBV/HIV co-infected 
participants did not differ significantly from those from the HBV mono-infected patients: 
genotype D (46%), E (21.6%), A (18.9%) and a D/E recombinant (13.5%). Compared to the 
HBV isolates from mono-infected liver disease patients, the frequency of the D/E 
recombinant and genotype A was higher in HBV/HIV co-infected patients, as was the intra-
group divergence of genotype E.  No difference in BCP/PC mutations affecting HBeAg 
expression at the transcriptional and translational levels between genotype D and E was 
observed. The following mutations could account for the HBsAg-negativity: sM133T, 
sE164G, sV168G and sS174N. No primary drug resistance mutations were found. 
Two online bioinformatics tools, the ―Deep Threshold Tool (DDT)‖ and the ―Rosetta Tool‖, 
were built to analyze data generated from UDPS and CBS of the BCP/PC region of four 
Sudanese serum samples, infected with either genotype D or E of HBV, from HBeAg-
positive and HBeAg negative patients. A total of 10952 reads were generated by UDPS on the 
454 GS Junior platform. The Threshold was calculated using DDT based on probability of 
error of 0.5%.  In total, 39 unique mutations were identified by UDPS, of which 25 were non-
synonymous. The ratio of nucleotide substitutions between isolates from HBeAg-negative 
and HBeAg-positive patients was 3.5:1. From the sequences analyzed, compared to genotype 
E isolates, genotype D isolates showed greater variation in the X, BCP/PC/C regions. Only 
18 of the 39 positions identified by UDPS were detected by CBS. 
 
Using the specific criteria, that have been suggested previously, to define 
genotypes/subgenotypes of HBV, we determined that genotype D has six and not eight 
subgenotypes. The importance of HBV genotypes in clinical consequences of infection and 
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response to antiviral treatment has led us to characterize HBV genotypes circulating in 
Sudan. HBV mono-infected patients and HBV/HIV co-infected individuals, were mainly 
infected with genotype D or E.   HBV mono-infected patients, infected with genotype E, had 
higher HBeAg-positivity and higher viral loads than those infected with genotype D. The 
ratio of genotype A to non- A, as well as the genotype E intra-group divergence were higher 
in HBV/HIV co-infected individuals compared to HBV mono-infected individuals. OBI was 
found in 15.1% HBV/HIV co-infected patients and its clinical relevance remains to be 
determined.  In order to overcome the limitations of   Sanger sequencing, which include its 
high cost and inability to detect minor populations in quasispecies, next generation 
sequencing techniques have been developed.  It was demonstrated that correct analysis of 
UDPS data required appropriate curation of read data, in order to clean the data and eliminate 
artefacts and that the appropriate consensus (reference) sequence should be used in order to 
identify variants correctly. CBS detected fewer than 50% of the substitutions detected by 
UDPS. This new technology may allow the detection of minor variants between the different 
genotypes of HBV and provide biomarkers for the prediction of clinical manifestation of 
HBV and response to antiviral therapy.   
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CHAPTER 1: INTRODUCTION 
Hepatitis B virus (HBV) infects the liver and causes acute and chronic liver disease. The 
majority of acute HBV infections are self-limiting, whereas chronic HBV infection usually 
has a lifelong course that may lead to the development of cirrhosis and hepatocellular 
carcinoma (HCC; liver cancer) (Donato et al., 1998). Despite the presence of an effective 
prophylactic vaccine it is estimated that there are 2 billion people who have been infected 
with HBV during their lifetime and over 240 million are chronic carriers of the virus (WHO, 
2012), with 65 million chronic carriers residing in Africa (Kramvis and Kew, 2007). 
 
1.1 The Hepatitis B Virus  
1.1.1 Classification 
HBV, with a genome of 3.1-3.2 kb is the smallest DNA virus infecting man and is the 
prototype member of the family Hepadnaviridae. This family consists of 2 genera: the 
Orthrohepadnaviridae, which infect mammals and the Avihepadnaviridae, which infect birds. 
The members of the genus Orthohepadnavirus include: HBV, the woodchuck hepatitis virus 
(WHV) (Hodgson and Michalak, 2001), the ground squirrel hepatitis virus (GSHV) (Marion 
et al., 1980), the arctic squirrel hepatitis virus (ASHV) (Testut et al., 1996), the chimpanzee 
HBV (ChHBV) (Takahashi et al., 2000), the gorilla HBV (GoHBV) (Makuwa et al., 2003), 
the gibbon HBV (GiHBV) (Norder et al., 1996), the orang-utan hepatitis (OuH) (Takahashi et 
al., 2000), the woolly monkey hepatitis B virus (WMHV) (Lanford et al., 1998), the Barbay 
macaques hepatitis virus (Gheit et al., 2002), the tree shrew hepatitis virus (Cao et al., 2003) 
and recently, Dickens et al., 2013 provided evidence for occult HBV infection (OBI) in  
chacma baboons (Dickens et al., 2013).  The genus Avihepadnavirus consists of the duck 
hepatitis B virus (DHBV) (Mason et al., 1980), the heron hepatitis B virus (HHBV) 
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(Sprengel et al., 1988), the snow goose HBV (SGHBV) (Chang et al., 1999), the Ross‘s 
goose HBV (RGHBV) (Pult et al., 2001), the white stork HBV (STHBV) (Pult et al., 2001) 
and grey crowned crane HBV (CHBV)  (Prassolov et al., 2003). 
 
1.1.2 HBV virion structure   
HBV is an enveloped DNA virus with a diameter between 42 - 47 nm (Tiollais et al., 1985). 
The viral DNA and DNA polymerase  are contained in the icosahedral nucelocapsid  
composed of core protein (HBcAg), enclosed by the outer lipid membrane (envelope) in 
which large (LHBs), middle (MHBs) and small (SHBs) surface proteins are embedded 
(Kann, 2002). This complete infectious virion is known as the Dane particle (Dane et al., 
1970, Seeger and Mason, 2000, Locarnini et al., 2003).  In addition, non-infectious 
filamentous and spherical particles, 22 nm in diameter, which lack the core protein and viral 
nucleic acid, can circulate in the serum.  These are composed only of the lipid membrane 
containing the surface proteins (Seeger and Mason, 2000, Locarnini et al., 2003). The HBV 
virion structure is illustrated in Figure 1.1. 
  
3 
 
Figure ‎1.1: The Structure of the Hepatitis B Virion  
Reproduced with permission from [Hepatitis B Virus, Human Virus Guide, Second 
Edition, (Lai and Locarnini, 2002). © International Medical Press]. 
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1.1.3 HBV Genome Structure  
As shown in Figure 1.2 the HBV genome is composed of circular, partially double-stranded 
DNA, ranging in size between 3182 to 3248 nucleotides, depending on the genotype 
(Feitelson, 1994). The partially double-stranded DNA is composed of a full-length negative 
strand (3020 to 3320 nucleotides) and an incomplete positive strand (1600 to 2800 
nucleotides) (Beck and Nassal, 2007, Seeger and Mason, 2000). This compact genome 
consists of four partially overlapping open reading frames (ORFs), which include: 
(i) Precore/Core gene (PreC/C), which encodes the hepatitis B e antigen (HBeAg) and 
the core protein (HBcAg). 
(ii) Polymerase gene (P), which encodes the viral polymerase (reverse transcriptase).  
(iii) PreS/Surface gene (PreS/S), which encodes: LHBs, MHBs, SHBs envelope proteins  
(iv) X gene, which encodes the small regulatory hepatitis B X protein (HBx) (Tiollais et 
al., 1985, Ganem and Varmus, 1987). 
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Figure 1.2: Structure and organization of hepatitis B virus genome. Coordinates are 
relative to genotype D (GU456684).  Modified from (Lin and Kao, 2010), with 
permission from Elsevier.  
1.1.4 HBV Replication  
The exact mechanism by which HBV replicates is not fully understood. The replication cycle, 
as illustrated in figure 1.3, begins when the infectious virion attaches to a hepatocyte-specific 
preS1 receptor (Yan et al., 2012). Evidence, from a recent study, revealed that the  receptor-
binding region of pre-S1 interacts specifically with sodium taurocholate cotransporting 
polypeptide (NTCP), which is a multiple trans-membrane transporter, expressed mainly in the 
liver (Yan et al., 2012).  The virus enters the cell in one of two ways: either by fusion and 
penetration at the plasma membrane or by endocytosis of the viral nuclocapsid followed by 
fusion to the cell (Pawlotsky, 2005, Xie et al., 2010, Urban et al., 2010).  Entry of the virus is 
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followed by the release of the viral nucleocapsid into the cytoplasm (Urban et al., 2010). The 
nucleocapsid is transported to the nucleus, where the relaxed circular DNA (rcDNA) is 
released into the nucloplasm (Kann et al., 2007). Here the rcDNA is repaired by the viral 
polymerase, which completes the synthesis of the positive strand (Nassal, 2008). Thereafter 
the ligation of both positive and negative DNA strands occurs and the covalently closed 
circular DNA (cccDNA) is formed (Nassal, 2008), which serves as the transcriptional 
template for RNA polymerase II to produce six genomic and subgenomic RNAs: 
(i) 3.5 kb pregenomic RNA (pgRNA) translated into the HBcAg and polymerase. 
(ii)  3.5 kb preC/C mRNA translated into the HBeAg. 
(iii) 2.4 kb preS1 mRNA translated into LHBs (preS1/preS2/S). 
(iv) 2.1 kb preS2 mRNA translated into MHBs (preS2/S). 
(v)  2.1 kb S mRNA translated into the SHBs (S). 
(vi) 0.7 kb X mRNA translated into the X protein ((Summers and Mason, 1982, Moolla et 
al., 2002, Feitelson, 1992, Ganem and Varmus, 1987, Beck and Nassal, 2007). 
This transcription is regulated by both viral and host factors such as viral proteins (core, the 
regulatory X protein) and CCAAT/enhancer-binding protein (C/EBP)/hepatocyte nuclear 
factors (HNF), respectively (Levrero et al., 2009). 
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Figure 1.3: Hepatitis B virus replication cycle. Reproduced with permission from 
(Ganem and Prince, 2004), Copyright Massachusetts Medical Society. 
 
1.1.4.1  Cis-acting elements 
The synthesis of the six RNA transcripts is controlled by cis-acting elements including four 
promoters and two enhancers that regulate the promoters (Kramvis and Kew, 1999). These 
promoters are: 
(i) The core promoter (CP), which is 232 bp long (1591-1822 from EcoR1 site) directs 
the transcription of the 3.5 kb preC/C mRNA and the 3.5 kb pgRNA. It consists of the 
basic core promoter (BCP), whose function is to initiate transcription of both pre/C 
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mRNA and pgRNA. The second part of the CP is the upstream regulatory region 
(URR), which is made up of core upstream regulatory sequences (CURS) that are 
known to activate the BCP (Yuh et al., 1992, Kramvis and Kew, 1999, Moolla et al., 
2002). In addition, the CP modulates core protein synthesis at post-transcriptional or 
translational level without affecting polymerase expression (Baumert et al., 1996, 
Baumert et al., 1998, Kramvis and Kew, 1999). 
(ii) The PreS1 promoter, located between bp 2710–2800 from the  EcoR1 site, regulates 
the transcription of preS1 mRNA (2.4 kb transcript). 
(iii) The PreS2 promoter, at 2960 – 3180 from the EcoR1 site, regulates the transcription 
of preS2 mRNA (2.1 kb transcript). 
(iv) The X promoter regulates the transcription of 0.7 kb mRNA (Lu et al., 1995). 
The two enhancers that control the promoters are: 
(i) Enhancer I, located between bp 1074-1234 from the  EcoR1 site, which functions to 
activate the CP (Guo et al., 1991). 
(ii) Enhancer II, located 600 nucleotides downstream of enhancer I, between bp 1636 - 
1741 from the EcoR1 site, which functions to stimulate the transcriptional activity of 
the two surface promoters and the X promoter (Yuh and Ting, 1993, Yuh and Ting, 
1990, Moolla et al., 2002). 
All transcripts are exported from the nucleus to the cytoplasm, where seven proteins are 
translated (Urban et al., 2010, Kann, 2002, Ganem and Prince, 2004). 
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1.1.4.2 Viral gene products  
1.1.4.2.1 Surface proteins 
Three distinct surface proteins, LHBs, MHBs and SHBs are embedded in the lipid membrane 
and serve to protect the nucleocapsid from lysis. These three proteins are translated in the 
endoplasmic reticulum (ER) of the host cell from three separate start sites and all terminate 
the same stop codon. The surface proteins exist in two forms, a glycosylated and an 
unglycosylated form, and are covalently linked to the HBcAg by disulphide bridges formed 
by cysteine residues (Kann, 2002, Seeger and Mason, 2000). 
(i) SHBs: The 226 amino acid S protein (HBsAg) (unglycosylated 24 kD; glycosylated 
27 kD) (Gerlich et al., 1992) is the most abundant protein of all three surface proteins 
and is encoded by the SHBs domain. The loop located between amino acids 124 - 
147, forms the major antigenic determinant, known as the ‗a‘ determinant, which is 
the initial target of the anti-HBs immune response during acute hepatitis (Carman et 
al., 1990).  Amino acid substitutions within this determinant, can lead to 
conformational changes affecting the binding of neutralising antibodies (Lada et al., 
2006, Chongsrisawat et al., 2006, Locarnini et al., 2003, Seeger and Mason, 2000). 
(ii)  MHBs: The 281 amino acid MHBs protein (preS2/S), encoded by the MHBs domain, 
consists of the SHBs and a 55 amino acid preS2 (Ganem and Schneider, 2001). MHBs  
contains overlapping B and T cell epitopes and a binding site for neutralizing 
antibodies,  located between amino acids 120 to 145 (Chisari and Ferrari, 1995) and 
the transactivation domain (Hildt et al., 2002). 
(iii) LHBs: The LHBs is the largest surface protein, encoded by LHBs domain 389 - 400 
amino acids in length, which depending on the genotype, can be between 108 and 119 
amino acids long. The LHBs is more prevalent than MHBs in virions and filaments 
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but less prevalent in HBs spheres. The preS1 has two main functions: the binding of 
the Dane particle to the hepatocyte during the infection and providing a ligand for the 
core particle during assembly of the viral envelope (Seeger and Mason, 2000). 
  
1.1.4.2.2 HBcAg and HBeAg 
The core protein or the HBcAg (21.5 kD) is translated from the pgRNA and composed of 183 
to 195 amino acids, depending on the genotype. Dimers of HBcAg assemble spontaneously 
into the icosahedral viral capsid (nucleocapsid) in the cytoplasm of hepatocytes (Kann, 2002). 
The major HBc epitope appears to be a conformational epitope, which requires HBc 
aggregation because when the aggregates are denatured, HBc antigenicity disappears 
(Yokosuka and Arai, 2006). 
The HBeAg (17 kD) is translated from the preC/C mRNA start codon and differs from the 
core protein in that it contains an extra 29 amino acids at the amino end (Jean-Jean et al., 
1989). The HBeAg  is post-translationally modified by cleavage of 10 amino acids from the 
N-terminus, and at variable sites on the carboxyl end (Kramvis et al., 1997) and  is a soluble, 
non-particulate protein that is secreted in the serum (Kramvis et al., 1997, Jean-Jean et al., 
1989) or expressed on the surface of the hepatocyte. Conventionally, HBeAg expression is an 
indicator of active HBV infection and ongoing viral replication (Locarnini et al., 2003, 
Kramvis et al., 1997); however, the presence of mutations affecting HBeAg expression, 
results in the absence of HBeAg expression, when active viral replication is occurring.   
1.1.4.2.3 Polymerase  
The polymerase protein (95 kD) is encoded by the polymerase ORF, the longest ORF, 
spanning almost 80% of the genome and overlapping the other ORFs (Kann, 2002, Seeger 
  
11 
and Mason, 2000). Opinion on the mechanism by which the  polymerase is translated remains 
controversial (Kann, 2002). Some studies showed that translation of the polymerase protein is 
initiated at the first start codon of the polymerase ORF (Roychoudhury and Shih, 1990, Lin 
and Lo, 1992); while others showed that polymerase synthesis may involve leaky scanning 
that does not result in core protein translation (Kozak, 1989, Lin and Lo, 1992). 
The polymerase protein is between 833 - 846 amino acids long, depending on the genotype, 
and has four domains (Beck and Nassal, 2007), (Figure 1.4). 
(i) The terminal protein (TP) spans amino acids at the N-terminus of the protein. It 
remains covalently linked to the minus strand DNA during replication, eventually 
preventing phosphorylation of the minus strand DNA (Bosch et al., 1988). TP has no 
sequence similarity to any other protein in the public databases (Ferrer-Orta et al., 
2006).  
(ii) The spacer domain (SP)  joins the (TP) and the reverse transcriptase (RT) domain. It 
is a highly variable region and has an important function in maintaining the 
heterogeneity of the polymerase and providing flexibility for conformational changes 
and response to immune selective pressure (Chen et al., 2013).  
(iii) The RT contains the YMDD motif, which is the catalytic domain essential for reverse 
transcriptase activity. 
(iv) RNase H domain (RH) encompasses amino acids in the C-terminus and serves to 
degrade pgRNA (Bosch et al., 1988). The RT and RNase H domains together are 
required as structural components for pgRNA encapsidation. 
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Figure 1.4:  A schematic representation of the hepatitis B virus polymerase shows the 
different lengths of each polymerase domain in amino acids for the different genotypes. 
TP: Terminal protein, SP: Spacer, RT: Reverse transcriptase and RH: RNase H 
1.1.4.2.4 HBx protein 
The X protein,  154 amino acids in length, is encoded by the X ORF and translated from the 
0.7 kb X mRNA (Moolla et al., 2002, Locarnini et al., 2003).  Although this protein is 
essential for in vivo HBV infection, its exact function is poorly understood (Seeger and 
Mason, 2000).  Among other functions, the X protein is known to activate various signal 
pathways in vitro and to  bind to p53 (Locarnini et al., 2003). Carboxyl terminally truncated 
forms of X ORF have been known to integrate into the host genome of chronically infected 
individuals and these integrants are believed to play a role in the development of HCC 
(Yokosuka and Arai, 2006).  
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1.1.4.3 Encapsidation  
The penultimate step in the HBV replication cycle is  encapsidation, which is the packaging 
of the pgRNA,  together with the reverse transcriptase, into the capsid to form the core 
particle (Hu et al., 2004). Reverse transcription occurs in this particle and  starts by the 
binding of the polymerase to the bulge of the  encapsidation signal (ε)  of the pgRNA (Seeger 
and Mason, 2000). Later the polymerase/ε interaction was found to constitute the first step in 
the initiation of reverse transcription as well (Wang and Seeger, 1993, Nassal and Rieger, 
1996, Beck and Nassal, 2007) (Figure 1.5). ε is a stem-loop structure initially defined as the 
sequence at the 5‘ end of HBV pgRNA that mediates polymerase-dependent encapsidation of 
pgRNA, and also of heterologous transcripts to which it is fused (Junker-Niepmann et al., 
1990). Reverse transcription of the pgRNA leads to the formation of the negative strand DNA 
and then the pgRNA is gradually degraded by the RNaseH activity of the polymerase, leaving 
18 nucleotides (Seeger and Mason, 2000). These 18 nucleotides are used as the template for 
the synthesis of the partial length positive-strand DNA, which is prematurely terminated 
because of the depletion of nucleotides within the capsid. Encapsidation and reverse 
transcription within the capsid result in the maturation of the core particle (Seeger and 
Mason, 2000). The mature core particle can be either enveloped by host-derived lipids and 
viral envelope proteins in the ER and secreted/budded out of the hepatocyte; or recycled to 
the nucleus, where it replenishes the cccDNA pool.  This cccDNA pool constitutes a risk 
factor for chronic infection, and serves as a reservoir for viral reactivation, when antiviral 
therapy is interrupted (Beck and Nassal, 2007, Urban et al., 2010).  
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Figure 1.5: The structure of the encapsidation signal of Hepadnaviridae. Reproduced 
from (Kramvis and Kew, 1998), with permission from John Wiley and Sons. 
 
As a result of the lack of the viral polymerase proofreading activity, HBV exhibits 
considerable sequence heterogeneity, hence its classification into genotypes. 
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1.1.5 HBV genotypes   
The genotypes of HBV are defined by inter-genotypic differences of more than 7.5% in the 
complete nucleotide sequence of the genome (Okamoto et al., 1988, Norder et al., 1992a, 
Kramvis et al., 2005a) and  more than 4% in the S gene (Norder et al., 1992b, Kramvis et al., 
2005a, Kramvis et al., 2008). Four genotypes, A to D, were recognized initially (Okamoto et 
al., 1988), with genotypes, E and F (Naumann et al., 1993, Norder et al., 1994, Norder et al., 
1992b), G (Stuyver et al., 2000),  H (Arauz-Ruiz et al., 2002) and I (Yu et al., 2010), being 
recognized subsequently.  A tenth genotype, J, isolated from a single individual, has been 
proposed (Tatematsu et al., 2009) (Figure 1.6).  
 
Figure 1.6: HBV genotypes. Phylogenetic tree showing the 9 genotypes of HBV. 
 
Subgenotypes are defined by the inter-group difference of more than 4% and less than 7.5% 
in the complete nucleotide sequence and significant bootstrap support following phylogenetic 
analysis (Kramvis et al., 2008). Subgenotypes, recognized in genotypes A, B, C, D, F and I,  
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are named numerically, with the letter of the genotype followed by a number (Kramvis et al., 
2008). 
Table 1.1: Virological characteristics of HBV genotypes 
  
Genotype A B C D E F G H 
Length 3221
¶
 3215 3215 3182
€
 3212
£
 3215 3248
¥
 3215 
HBV DNA level NS
a
 b c NS NS NS NS NS 
Frequency of precore G1896A 
 mutation 
    NS NS NS NS 
Frequency of basic core promoter 
T1762A/A1764G mutation 
    NS NS NS NS 
Frequency of pre-S deletion  
mutation 
NS   NS NS NS NS NS 
Serotype 
ayw2 •   • •         
ayw3     • •   •     
ayw4       • • •     
ayr     •           
adw2 • • •       •   
adw3   •   •         
adw4 •         •   • 
adrq-   • •           
adrq+     •           
Adapted from Kramvis et al 2005, Purdy et al 2007 and Schaefer, 2007a 
¶  
Six nucleotides insertion in the core region,  
€ 
33 nucleotides deletion at the start of preS1 region, 
£ 
Three 
nucleotides deletion at the start of the preS1 region, 
¥  
Three nucleotides deletion at the start of the preS1 region 
and 36 nucleotides insertion at the core region,  
a
NS:  Not studied,  
b  Low, 
c  High. 
Before the identification of the HBV genotypes, HBV was classified according to serological 
subtypes. Ten serological subtypes were identified: ayw1, ayw2, ayw3, ayw4, ayr, adw2, 
adw3 adw4, adrq− and adrq+ (Okamoto et al., 1988, Norder et al., 1992a). These serological 
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subtypes are classified according to the amino acid substitutions on the HBsAg at positions 
122, 127, 134 and 160 (Norder et al., 1992a). There is a limited correlation between the HBV 
genotypes and the serological subtypes because several serological subtypes are encoded by 
more than one genotype (Norder et al., 1994, Norder et al., 2004, Kramvis et al., 2008). Table 
1.1 summarizes the virological characteristics and the consequences of the infection of 
different HBV genotypes, which are discussed subsequently. 
 
1.1.5.1  Genotype A   
Genotype A (3221 bp), (eg: AY233275),  has a characteristic 6 nucleotide insertion at the 3‘ 
end of the core gene, which results in an additional two amino acids at positions 153 and 154 
at the core gene. These are not found in the other genotypes (Kramvis et al., 2005a). The first 
subgenotype of A, A1 was discovered using analysis of preS/S sequences of South African 
isolates (Bowyer et al., 1997). This  was later confirmed using whole genome sequencing 
(Kramvis et al., 2002, Kimbi et al., 2004).  Subgenotype A1 has subsequently been found in 
Malawi (Sugauchi et al., 2003), Somalia (Sánchez et al., 2002), Brazil (Moraes et al., 1996), 
Philippines (Sugauchi et al., 2004), India and Nepal {Gopalakrishnan, 2013 #5545;Sugauchi, 
2004 #987}, Yemen (Sallam and William Tong, 2004), Haiti (Andernach et al., 2009b), 
Zimbabwe (Gulube et al., 2011), Kenya (Ochwoto et al.), Martinique (Brichler et al., 2013),  
Uganda (Hannoun et al., 2005) and Tanzania (Hasegawa et al., 2006).    Subgenotype A2 has 
been reported to be widely distributed outside Africa, in European countries and the USA 
(Sugauchi et al., 2004). In the BCP/PC region, subgenotype A1 can be differentiated  from 
subgenotype A2 by TCAT, instead of GCAC at the Kozak sequence 1809-1812, and 1888A 
instead of 1888G (Kramvis et al., 2008). Subgenotype A3 has been identified in the 
Cameroon and Gabon (Kurbanov et al., 2005). Subgenotypes A4 and A5  circulate in Mali 
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and Nigeria, respectively (Olinger et al., 2006). Subgenotype A6 was isolated from three 
African-Belgium patients (Pourkarim et al., 2010b) and subgenotype A7 from Cameroonians 
(Hübschen et al., 2011). However, the existence of subgenotypes A4, A5 and A7 has been 
questioned. Based on extensive phylogenetic and divergence analyses of complete genomes 
sequences, Pourkarim and colleagues found that there is misclassification of the 
subgenotypes of A and proposed that genotype A should be classified into subgenotypes A1, 
A2, quasispecies A3 (A3, A4, A5 and A7)  and A4 (previously A6) (Pourkarim et al., 2011a). 
 
1.1.5.2  Genotype B  
Initially genotype B (3215 bp) was classified into 2 subgenotypes, B1 (Bj) mainly distributed 
in Japan, and B2 (Ba), which is a B/C recombinant at preC/C genes, found predominatly in 
the rest of Asia (Sugauchi et al., 2002, Norder et al., 2004). Subsequently 7 additional sub-
genotypes of B have been identified (B3 to B9) (Norder et al., 2004, Sakamoto et al., 2006, 
Sakamoto et al., 2007, Nurainy et al., 2008, Mulyanto et al., 2009, Thedja et al., 2011). How-
ever, recent analyses questioned the validity of this classification. Based on phylogenetic 
analyses and divergence calculations of the entire genomes, genotype B has been reclassified 
into 5 subgenotypes: B1, B2, B4, B6 and quasi-subgenotype B3 of Southeast Asian and Chi-
nese origin, which includes the previously described: B3, B5, B7, B8 and B9. Furthermore, 
previously described B6 from the Arctic was reclassified as B5 (Shi et al., 2012a). 
 
1.1.5.3  Genotype C  
To date genotype C (3215 bp) has been classified into 16 subgenotypes distributed 
geographically in Southern Asia, East of Asia, Australia, Philippines, Indonesia  and Papua 
province of Indonesia (Depamede et al., 2010, Mulyanto et al., 2012, Huy et al., 2004, 
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Norder et al., 2004, Kramvis et al., 2008, Sugauchi et al., 2001, Sakamoto et al., 2006, 
Utsumi et al., 2009, Cavinta et al., 2009a, Cavinta et al., 2009b, Mulyanto et al., 2011). 
However, whether the number of sample sequences used to define these subgenotypes can be 
considered as sufficient, remains controversial. 
 
1.1.5.4  Genotype D 
Compared to the other genotypes, D has the shortest genome length of 3182 nucleotides and 
is characterized by a 33-nucleotide deletion at the beginning of the preS1 region (Kramvis et 
al., 2005a, Norder et al., 2004). Genotype D is found worldwide, with its subgenotypes, 
showing distinct geographical distribution. This genotype predominates in the Mediterranean 
region and is also found in many parts of Africa, northern and central Americas, India and 
Australia (Kramvis et al., 2008, Meldal et al., 2009, Abdou Chekaraou et al., 2010, Norder et 
al., 2004, Utsumi et al., 2009, Banerjee et al., 2006, Ghosh et al., 2012). 
Until 2008, genotype D was classified into four subgenotypes (D1-D4) (Norder et al., 2004, 
Kramvis et al., 2008). Since then an additional five subgenotypes of D have been identified, D5 
isolated from India in 2006 (Banerjee et al., 2006), D6 from the Papua province of Indonesia in 
2009 (Utsumi et al., 2009), D7 from Tunisia in 2009 (Meldal et al., 2009) and D8 from Niger in 
2010 (Abdou Chekaraou et al., 2010). However, an extensive updated analyses presented in 
Chapter 2, revealed that there are 6 subgenotypes of D, D1 to D6.  Subsequently,  
subgenotype D9 was described from India in 2012 (Ghosh et al., 2012). 
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1.1.5.5  Genotype E  
Genotype E (3212 bp) is characterized by a three nucleotide deletion in preS1 (Norder et al., 
1994, Kramvis et al., 2005b). The amino acids of the preS1, preS2 and S genes are well 
conserved, with signature motifs specific for genotype E: Leu, Ser, Trp, Thr, Val, Pro, Leu, 
Glu and Trp at positions 3 to 11 of the preS1 (Kramvis et al., 2005b). In addition, signature 
amino acids are also found in the preS1: Thr, Arg, His, Thr, Met, Lys and Thr at positions 18, 
38, 44, 52, 83, 85 and 108, respectively. This genotype has no subgenotypes and encodes for 
serological subtype ayw4 (Kramvis et al., 2005b, Norder et al., 2004). Genotype E 
predominates in Western and Central Africa reviewed in (Kramvis et al., 2005b). Studies 
have shown that genotype E has low genetic diversity in a large geographical area and this 
has led to this suggestion that this genotype emerged recently (Andernach et al., 2009a, 
Odemuyiwa et al., 2001, Suzuki et al., 2003, Mulders et al., 2004, Kramvis et al., 2005b).  
 
1.1.5.6  Genotype F 
Genotype F (3215 bp) has the highest intergroup divergence value (14%) and may represent 
the first split from the human hepadnaviral ancestor (Norder et al., 1994, Kramvis et al., 
2005a, Naumann et al., 1993). It has been classified into four subgenotypes. Subgenotype F1 
is found mainly in Central America, and subgenotype F2 mainly in South America (y Leone 
et al., 2003, Devesa et al., 2004, Mbayed et al., 2001, Norder et al., 1993, Arauz‐Ruiz et al., 
1997). Subgenotype F3 and F4 are found in Bolivia and Argentina, respectively (Devesa et 
al., 2004, Huy et al., 2006). Subgenotype F1 has characteristic of T1858 at the PC gene and 
sT45 at the S region, while subgenotype F2 has characteristics of C1858 and sL45 (Norder et 
al., 2003, Kramvis et al., 2005a). 
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1.1.5.7  Genotype G  
Genotype G bp (3248) is characterized by a 36 nucleotide insertion in the core gene and a 
three nucleotide deletion in the preS1 region (Norder et al., 1994, Kramvis et al., 2005b, 
Kramvis et al., 2005a, Stuyver et al., 2000). This genotype circulates in  Mexico, USA and 
Europe (Stuyver et al., 2000) and has no subgenotypes. A distinctive characteristic of this 
genotype is the absence of HBeAg expression caused by the presence of two translational 
stop codons at positions 2 and 28 of the precore region (Kato et al., 2002). 
 
1.1.5.8  Genotype H 
Genotype H (3215 bp) has been isolated from Nicaragua, Mexico and California (Arauz-Ruiz 
et al., 2002). It was classified previously as genotype F (Arauz‐Ruiz et al., 1997), but upon 
sequencing of the complete genome, this genotype was found to have unique amino acids 
substitutions separating it from genotype F (Arauz-Ruiz et al., 2002). 
 
1.1.5.9  Genotype I  
Initially genotype I was described as a recombinant of genotypes A and C in Vietnamese 
HBV strains (Hannoun et al., 2000). Later a single HBV strain, a recombinant of genotypes 
A, C and G was isolated in Vietnam and found to be phylogentically closely related to the 
strains isolated by Hannoun et al., (2000).  This strain was assigned to the ninth genotype (I) 
(Huy et al., 2008).  Kurbanov and colleagues (2008), however,  questioned the existence of 
this genotype, because of the limitations of the methods used in the analysis (Kurbanov et al., 
2008). Recently, a similar recombinant strain was found in northwest China and analyzed 
using more advanced methods, including TreeOrderScan, GroupScan, unique amino acids 
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signature and in vitro experiments. This study provided conclusive evidence for  the existence  
of the new genotype I (Yu et al., 2010). Genotype I is divided into two subgenotypes I1 and 
I2 (Yu et al., 2010). 
1.1.5.10 Genotype J 
An isolate from a single Japanese HCC patient, has been proposed to belong to the 10
th
 
genotype, J (Tatematsu et al., 2009). The designation for genotype J was based on its 
sequence divergence and unique phylogenetic position relative to  human and ape genotypes 
and the absence of recombination (Tatematsu et al., 2009).  Additional isolates would be 
required to confirm the presence of this 10
th
 genotype.   
 
1.1.6 Clinical relevance of the HBV genotypes 
There are several factors that can affect the clinical manifestation of HBV infection. Host 
factors such as age and immunological status and viral factors such as the genomic variability 
of the virus (Kao, 2002b). Global heterogeneity of the HBV genotypes may  play a 
significant role in the clinical outcome of  infection (Kramvis and Kew, 2007).  HBV 
genotypes have demonstrated significant impact on the severity of liver disease and  response 
to antiviral therapies and vaccination (Kramvis and Kew, 2005). The co-distribution of HBV 
genotypes has made it possible to reliably compare genotypes A and D in Western Europe, 
the USA and southern Africa and genotypes B and C in south-eastern Asia in terms of their 
association with clinical characteristics (see Table 1.2).   
Comparative studies in Asia have shown that patients infected with genotype C generally 
have more severe liver disease, including cirrhosis and HCC, than patients infected with 
genotype B (Kao, 2002b, Yuen et al., 2004). Patients infected with genotype C experience 
delayed HBeAg seroconversion to anti-HBe compared to patients infected with genotype B.   
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This usually increases the duration of viral replication, which may ultimate result in fibrosis, 
cirrhosis and HCC (Lin and Kao, 2011). In Taiwan, genotype B is associated with the early 
onset of HCC, while HCC develops later in those infected with genotype C (Kao, 2002b, Lin 
and Kao, 2011).  This, however,  is not the case in Japan where genotype B is associated with 
the  later development of HCC compared to genotype C (Orito et al., 2005). This may be as a 
result of  the different prevalence of the subgenotypes of B, with subgenotype B2 circulating 
in many parts of Asia and subgenotype B1 confined to  Japan (Sugauchi et al., 2002).  
In sub-Saharan Africa, subgenotype A1 is the predominant subgenotype (Bowyer et al., 1997, 
Kramvis et al., 2002, Kimbi et al., 2004) and has it been associated with high rates of HCC  
(Kew et al., 2005).  Patients infected with subgenotype A1 have a  higher rate of HBeAg 
negativity, low HBV DNA levels (Tanaka et al., 2004) and develop HCC at a younger age 
compared to patients infected with other genotypes (Kew et al., 2005).  A South African case 
control study showed a 4.5 times higher relative risk of HCC in carriers infected with 
genotype A compared to those who infected with other genotypes (Kew et al., 2005). 
Furthermore, the course of infection with subgenotype A2, which is found in Europe and 
USA, is different to that of subgenotype A1, with HBeAg seroconversion occurring at a later 
stage of infection and HCC found to occur in older patients (McMahon, 2009).  
Genotype D has a worldwide distribution.  Most patients infected with genotype D generally 
seroconvert to  anti-HBe positivity at a more advanced age; which means they may  undergo 
multiple hepatitis flares, which accelerates the progression of chronic hepatitis to cirrhosis 
(McMahon, 2009, Lin and Kao, 2011). This however was found not to be the case in India, 
where genotype D correlates with severe liver disease and the development of HCC in 
younger patients (Thakur et al., 2002). In a study carried out in the USA, genotype D was 
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found to be an independent risk factor for fulminate hepatitis (Wai et al., 2005).  These 
differences may be the result of different subgenotypes of D circulating in the different  
geographical regions of the world.   
Genotype E predominates in Africa, particularly west and central Africa.  However, very few 
studies have looked at the clinical outcome of genotype E infection.  
 
Table 1.2: Clinical characteristics associated with HBV genotypes 
Adapted from (Lin and Kao, 2010).  
 
1.1.7 HBV recombination  
When two or more genotypes co-circulate in one geographical region, co-infection with  
more than one genotype may occur and lead to the  recombination events between these 
genotypes and provide a variation within individuals and in the population in general 
(Kramvis et al., 2005a). Recombination may also help the virus evade the host‘s immune 
response by changing the antigenetic configurations (Owiredu et al., 2001, Shi et al., 2012b). 
Several papers report recombination events between genotypes:  A and D in Africa (Owiredu 
 
 
Genotype  A B C D E F G H 
Mode of transmission 
 
Horizontal •     • • • • • 
Perinatal   • •           
 
Tendency of chronicity 
 
 
High •   •           
Low   •   •         
Not studied         • • • • 
 
Positivity of HBeAg 
 
 
High •   •           
Low   •   •         
Not studied         • • • • 
HBeAg seroconversion 
 
 
Early • •             
Late     • •         
Not studied         • • • • 
 HBsAg seroconversion 
  
More • •             
Less     • •         
Not studied         • • • • 
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et al., 2001),  B and C in Asia (Sugauchi et al., 2002), C and D in Tibet (Cui et al., 2002), A, 
C and G in Vietnam  (Tran et al., 2008) and D and E in Niger and Sudan (Abdou Chekaraou 
et al., 2010, Mahgoub et al., 2011). Recombination events increase genetic diversity in the 
HBV population and lead to the designation of an increased number of 
genotypes/subgenotypes.  Although a number of researchers have suggested that recombinant 
strains should not be classified as novel subgenotypes, but be reported separately instead, this 
suggestion has not been followed widely (Shi et al., 2013, Kramvis et al., 2008, Pourkarim et 
al., 2010a).   
 
1.1.8 HBV mutation 
A mutation can be defined as a random error occurring in the genome, which may lead to  
genetic variation in the organism (Bonhoeffer and Sniegowski, 2002).   Because of the lack of 
proof reading activity by the HBV reverse transcriptase,  the  mutation rate of HBV is 
relatively high with the nucleotide substitution rate per site per year estimated at 1.5×10
−6
 to 
3.0×10
−6
(Paraskevis et al., 2013). Errors in genomic replication play a critical role in viral 
evolution and survival because may they allow the virus to escape host immune responses 
(immune/vaccine escape mutants) and to withstand of antiviral treatment (drug resistance 
mutants)  (Bonhoeffer and Sniegowski, 2002). There are a number of mutations that can 
affect the virus by affecting HBeAg expression, its infectivity and its sensitivity to antiviral 
drugs.   
 
1.1.8.1  Mutations that can affect expression of HBeAg 
There are two types of mutations that affect HBeAg expression, the precore and BCP 
mutations.  The G to A mutation at 1896 (G1896A), located in the ε structure, creates a stop 
codon (TGG to TAG) in the second last codon of the precore gene.  This mutation  truncates 
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the HBeAg precursor at 28 amino acids abolish HBeAg expression (Carman et al., 1989). In 
order to maintain the stability of the ε signal, the G1896A mutation requires a T at position 
1858, to form a Watson-Crick base-pair. This mutation is genotype specific because T1858 
occurs in genotypes B, D, E G and some strains of C, while C1858 only occurs in genotypes 
A, F, H and some strains of genotype C. This is the reason for the absence of G1896A in 
genotypes A, F, H and some strains of genotype C (Tong et al., 2013, Locarnini et al., 2003, 
Kramvis et al., 2005a, Li et al., 1993, Lok et al., 1994). Mutations that can abolish the 
translation of  HBeAg include the precore start codon mutations at 1814, 1815 and 1816 
(Günther et al., 1999). Mutations at 1817, 1874 and 1897 cause HBeAg truncation (Günther 
et al., 1999). The silent mutation G1899A frequently occurs together with the precore stop 
codon mutation G1896A (Günther et al., 1999).  
G1862T, which occurs in the bulge of the ε signal, may affect HBeAg expression (Kramvis et 
al., 1997, Kramvis et al., 1998).  This mutation results in a valine to phenylalanine mutation 
in the precore region of HBV, interfering with post-translational modification of the HBeAg 
precursor,  causing intracellular retention and impaired secretion of HBeAg (Chen et al., 
2008). G1862T occurs more frequently in genotype A and particularly in subgenotype A1 
(Kramvis et al., 1997). 
The BCP mutations were discovered by Okamoto and colleagues (Okamoto et al., 1994). The 
most common mutation is the double mutation A1762T/G1764A, which results in the down 
regulation of transcription of pre-core mRNA, thereby decreasing HBeAg production up to 
70%, while increasing pre-genomic RNA packaging and viral progeny production (Buckwold 
et al., 1996, Takahashi et al., 1995, Hunt et al., 2000, Laskus et al., 1995). This mutation is 
seen more often in HBV isolated from HCC patients compared to asymptomatic carriers 
(Baptista et al., 1999, Kramvis and Kew, 1999). The A1762T/G1764A mutation coupled with 
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the T1753 mutation may be a marker for advanced liver disease (Kramvis and Kew, 1999). 
Other mutations at C1653, T1753, T1766, and A1768 have been reported to reduce HBeAg 
production and when occurring together with the A1762T/G1764A may increase the risk of 
HCC and fulminant hepatitis (Kramvis and Kew, 1999, Tsai et al., 2009, Cao, 2009).  
The region (1809-1812), which precedes the pre-core start codon, is termed the ―Kozak‖ 
sequence and is critical in the initiation of translation (Ahn et al., 2003, Baptista et al., 1999). 
Mutations in the Kozak sequence, which occur mainly in subgenotype A1, affect HBeAg 
expression at the translational level and reduce HBeAg synthesis (Ahn et al., 2003).  
 
1.1.8.2  Mutations at the complete S region 
The preS1 and preS2 regions have the highest heterogeneity in the HBV genome. Mutations 
and deletions at the preS regions have been identified from HBV isolated from chronic HBV 
patients (Günther et al., 1999). Deletions and mutations at the preS2 start codon prevent 
preS2 protein synthesis, indicating that the expression of preS2 protein is not essential for 
viral replication, virion morphogenesis, and secretion (Yokosuka and Arai, 2006, Santantonio 
et al., 1992). 
The surface gene has a vital role in the life cycle of HBV and infectivity of the virus. HBsAg 
contains the ‗a‘ determinant, which is the initial target of the anti-HBs immune response 
(Carman et al., 1990). Mutations of the surface gene at the ‗a‘ determinant region lead to 
variations in the antigenicity and immunogenicity of the HBsAg, which may result in the 
impaired detection of the virus by the immune system (Torresi, 2002).  The most frequently 
described mutations are the immune/vaccine escape mutants, which can occur following 
vaccination, and the treatment of liver transplantation recipients with HBV immunoglobulin 
(Carman et al., 1990). The most common mutation is G to R at 145 in the S gene (sG145R), 
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which minimizes the binding of antibodies raised against S protein, to virions and subviral 
particles, and thus results in breakthrough infections (Cooreman et al., 1999, Tong et al., 
2013). Another mutation at the same position  sG145A, leads to diagnostic failure (Cooreman 
et al., 1999, Tong et al., 2013). Mutations sP120L, sT123N, sT126N, sQ129R, sM133L, 
sM133T and sD144A also have been reported to lead to vaccine escape (Carman et al., 1990, 
Yokosuka and Arai, 2006).  Therefore, there is a potential risk of false negative HBsAg 
results because commercially available monoclonal or polyclonal antibody may not  detect 
the mutant HBV strains (Yokosuka and Arai, 2006). 
 
1.1.8.3  Drug resistance mutations  
Immunomodulatory agents and nucleoside/nucleotide analogue  (NA)  antiviral agents have 
been used for the treatment of chronic HBV infection (Ching-Lung Lai, 2002).  Long-term 
use of NAs is associated with the evolution of viral resistance mutations in the HBV 
polymerase gene, resulting in treatment failure (Ching-Lung Lai, 2002). The most common 
mutation, which confers lamivudine resistance and occurs in the RT domain, is the rtM204V/I 
at the YMDD motif.  This mutation can occur together with mutations: rtV173L or rtL180M. 
Mutations associated with adefovir resistance are rtA181V/T and rtN236T (Tong et al., 
2013). Entecavir has a higher genetic barrier to resistance because three mutations are needed 
to generate resistance (Tong et al., 2013, Gish et al., 2012). After 5 years of therapy with the 
NAs, resistance to lamivudine is 80%, 29% to adefovir and only 1.2% to entecavir (Zoulim 
and Locarnini, 2009).  Moreover, because the polymerase ORF overlaps the ORF coding for  
HBsAg, amino acid changes in the HBsAg selected by NAs can alter its antigenicity (Torresi, 
2002). The HBsAg silent mutations overlapping polymerase region mutations selected by 
NAs include the mutants sE164D and sM198I (Torresi, 2002). 
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1.2 Epidemiology, Transmission and Natural History of HBV infection 
1.2.1 Epidemiology  
According to the most recent data from the World Health Organization, two billion people 
have evidence of past or present HBV infection and there are over 240 million chronic 
carriers of HBV globally (WHO, 2012).   At least 600 000 people die annually as a result of 
the clinical outcomes of HBV infection. The prevalence of HBV infection, which is measured 
by HBsAg-positivity, varies geographically. Areas of high endemicity (>8% HBV carriers) 
include South-east Asia, China, sub-Saharan and Southern Africa and the Amazon Basin 
(Hou et al., 2005, Burnett et al., 2005, Kramvis and Kew, 2007). Approximately 45% of the 
world‘s population lives in these regions (Kew, 2010). Areas of intermediate endemicity (2-
8%) include North Africa, southern and eastern Europe, Middle East and part of South 
America (Kramvis and Kew, 2007, Burnett et al., 2005, Hou et al., 2005). Low endemicity 
areas (<2%) encompass the developed countries: North America, western Europe and 
Australia. Recently Japan has been classified as a low endemicity region following the 
implementation of a successful vaccination program (Figure 1.7) (Andre, 2000). 
In Africa, 65 million people are infected with the virus and approximately 250 000 die every 
year because of  HBV infection (Kramvis and Kew, 2007).  Most of the African countries fall 
within the high endemicity regions and 70-95% of the population have been exposed to the 
virus at some stage of their lives. Exposure to HBV, measured by the prevalence of anti-HBc, 
ranges from 1.8% to 98%. This  varies between the different regions in Africa, with western 
Africa having a higher exposure of 85% and eastern parts of Africa showing 65-85% 
(Kramvis and Kew, 2007). 
  
30 
 
Figure 1.7: Geographic distribution of chronic Hepatitis B virus infection. Source: 
http://virology-online.com/viruses/HepatitisB.htm. Accessed on July 19, 2013 
 
1.2.2 Transmission  
Blood is the main carrier for HBV infection, although other body fluids, like semen and 
saliva, may also play a role in transmission. There is no evidence that HBV can be 
transmitted by airborne means or through the oral faecal route (Bancroft et al., 1977, Scott et 
al., 1980, Hou et al., 2005). HBV transmission routes can be divided into two types: 
(i) Perinatal transmission: when the infection passes from the mother to the child, 
through percutaneous and per mucosal exposure to the mother‘s blood from 28 
weeks of gestation up to 7 days after birth (Beasley and Hwang, 1983, Jonas, 2009, 
Burnett et al., 2012). This type of transmission is also called vertical infection.  
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Usually it occurs in HBeAg positive mothers and leads to chronic infection in the 
infant. This type of transmission has been observed mainly in China and southeast 
Asia (Kramvis and Kew, 2007, Hou et al., 2005).  
(ii)  Horizontal transmission occurs when HBV is passed from person to person or 
from person to surface to person. This route can be divided into four routes: 
a) Sexual, and especially homosexual activity, can transmit HBV, and this mode 
of transmission occurs in all areas of the world but is very common in regions 
of low endemicity (Alter, 2003, Wasmuth, 2009). 
b) Transmission between toddlers has been found to be the major route of 
infection in Africa, where there is a high prevalence of HBV. Infection during 
childhood can lead to chronic HBV infection and once these individuals 
become sexually active, sexual transmission becomes the dominant route of 
infection (Burnett et al., 2012). 
c) Worldwide percutaneous/parenteral transmission is an important mode of 
transmission. Infection, following unsafe injection drug use occurs mainly in 
developed countries. In developing countries, health care professionals and 
their patients are at risk of getting HBV infection when good clinical practice 
for blood transfusions and organ transplants is not followed.  Cultural customs 
like tattooing and scarification can also lead to the transmission of HBV.   
d) Transmission via HBV contaminated blood products in patients. 
  
1.2.3 Natural History of HBV infection   
The incubation period, which is the time from exposure to HBV to the onset of jaundice, 
ranges from 60 to 150 days, with an average of 90 days (Shepard et al., 2006). There is a 
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wide spectrum of clinical presentation of HBV infection, ranging from subclinical or 
asymptomatic carriage to acute self-limiting hepatitis or fulminant hepatitis to chronic 
hepatitis, which can lead to cirrhosis and/or HCC. Viral factors and the host immune response 
have been implicated in the pathogenesis and the clinical outcome of the infection. The age of 
the patient at the time of infection is also critical factor in determining the clinical outcome of 
HBV infection. The majority of perinatal or childhood infections are asymptomatic and 
usually progress to chronicity. While infections in adults are usually acute and self resolving 
(Figure 1.8) (McMahon et al., 1985, de Franchis et al., 2003). 
Figure 1.8: Natural history of Hepatitis B virus infection. Adapted from (Feitelson, 
1992) 
 
1.2.3.1  Acute hepatitis  
An acute HBV infection appears within 6 months after exposure to the virus. The clinical 
symptoms include nausea, vomiting, abdominal pain, fever, dark urine, change in the colour 
of the stool and hepatomegaly (Shepard et al., 2006).  HBsAg and anti-HBc-IgM are the first 
markers to appear in acute infections and alanine transaminase (ALT) levels are usually high, 
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while HBV DNA can be detected in one to two weeks after exposure. Fulminant hepatitis 
with liver injury is a complication of acute infection. Progression to chronic infection or the  
resolution of  the acute infection is dependent on the host‘s immune response to the virus 
(Shepard et al., 2006). 
  
1.2.3.2  Chronic hepatitis 
Chronic HBV infection is the persistence of HBsAg for more than 6 months in the serum of 
an infected person, with no anti-HBc-IgM (Shepard et al., 2006). The progression of chronic 
infection from acute or subclinical infection is dependent on host factors, mainly the age of 
the patient.  Ninety percent of infants infected develop chronic infection, while only 5% of 
adults will develop chronicity (Yim and Lok, 2006, de Franchis et al., 2003, Huang et al., 
2006). Patients chronically infected with HBV and lacking the anti-HBs, develop HBeAg, 
which is a marker of HBV replication and correlates with greater infectivity.  Seroconversion 
to anti-HBe is usually associated with resolution of the infection and/or the development of 
BCP/PC mutations in the virus (Shepard et al., 2006, McMahon et al., 2001).    
Chronic HBV infection can be divided into four phases:   
(i)  The immune tolerance phase, during which infected individuals have high HBV DNA 
levels and HBeAg positivity (Villeneuve, 2005), normal ALT levels and no liver 
inflammation. This phase usually occurs in infants who were infected at birth or early 
childhood, and it can last for up to four decades (Yim and Lok, 2006, de Franchis et 
al., 2003).  
(ii)  The immune clearance phase, in which there is seroconversion from HBeAg-
positivity to anti-HBe, followed by inflammation of the hepatocytes and increased 
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ALT levels (Yim and Lok, 2006, de Franchis et al., 2003, Villeneuve, 2005, Yim et 
al., 2006).  
(iii) The inactive or asymptomatic carrier state, where ALT levels become normal, HBV 
DNA is undetectable, there is no liver inflammation and anti-HBe persists.  This 
phase can last a lifetime. 
(iv)  The reactivation phase, which is characterized by elevated ALT levels and the 
presence of HBV DNA, with the possibility of further liver damage, leading to 
fibrosis and cirrhosis (Yim et al., 2006). 
 
1.2.3.3  Cirrhosis   
Patients chronically infected with HBV can develop cirrhosis. The aetiology of cirrhosis 
established alcohol consumption or viral hepatitis as culprits, with chronic HBV infection 
being the most common cause (Schuppan and Afdhal, 2008). Cirrhosis can be defined as an 
advanced stage of liver fibrosis that is accompanied by distortion of the hepatic vasculature 
leading to portal hypertension, liver function impairment and HCC (Wanless et al., 2000, 
Desmet and Roskams, 2004, Schuppan and Afdhal, 2008). During fibrosis, collagen replaces 
the infected, injured liver tissue (Sherlock and Dooley, 2008, Schuppan and Afdhal, 2008). 
Although, the prevalence of cirrhosis worldwide is not known, in the USA alone, more than 
25,000 deaths are as a result of cirrhosis. This number is probably more where there is a high 
prevalence of HBV infection (in areas such as Asia and Africa) (Schuppan and Afdhal, 2008). 
Unless clinical symptoms appear, cirrhosis remains undetected without a liver biopsy for 
histological examination and/or bioimaging by ultrasonography (Epstein et al., 1979, 
Schuppan and Afdhal, 2008).  Therefore, patients chronically infected with HBV should be 
checked regularly (Epstein et al., 1979, Schuppan and Afdhal, 2008).   
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1.2.3.4    Hepatocellular Carcinoma (HCC) 
HCC is one of the main malignant diseases, and one of the main causes of death worldwide 
(Parkin et al., 2008). HBV-associated cirrhosis is one of main risk factors for the 
development of HCC, although it has been reported that HCC can occur with or without 
cirrhosis (Bréchot et al., 2000).  The global distribution of chronic HBV infection and HCC 
incidence correspond. The incidence of HCC is particularly high in East and South East Asia 
and sub-Saharan Africa, where HBV carrier rates are between 10-15%. The incidence of 
HCC is intermediate in areas such as western Asia, Central America, eastern and southern 
Europe with carrier rates between 2-7%. The remaining countries have low carrier rates 
(<2%) and low prevalence of HCC (Parkin et al., 1999, Parkin, 2001).  Current American 
Association for the Study of Liver Diseases (AASLD) and European Association for the 
Study of Liver diseases (EASL) guidelines, recommend at least one annual screening for 
HCC using imaging techniques, in patients with cirrhosis (Schuppan and Afdhal, 2008). 
 
1.2.3.5  Occult Hepatitis B infection (OBI) 
According to the Taormina expert meeting in 2008, OBI is defined as ‗the presence of HBV 
DNA in the liver (with detectable or undetectable HBV DNA in the serum) of individuals 
testing HBsAg negative by currently available assays. When detectable, the amount of HBV 
DNA in the serum is usually very low (<200IU/ml)‘ (Raimondo et al., 2008). It has been 
suggested that the molecular basis of OBI is related to the long term persistence of viral 
cccDNA in the nuclei of hepatocytes (Raimondo et al., 2007). Individuals, who are HBsAg-
negative, with serum HBV DNA levels < 200 IU/ml, are considered to have ―true‖ OBI. 
Samples in which serum HBV DNA levels are similar to HBsAg positive overt infection, but 
are HBsAg-negative, have been termed ―false‖ OBI (Raimondo et al., 2008), or HBsAg-
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covert infection  (Bell et al., 2012).   
 
OBI can be classified into: seronegative (negative for all serological markers), which 
accounts for approximately 20% of all OBI cases, and seropositive (anti-HBs and anti-HBc-
positive), which accounts for 80% of OBI cases (Hollinger and Sood, 2010, Torbenson and 
Thomas, 2002, Raimondo et al., 2008).  Detection of OBI involves amplifying HBV DNA 
from liver and/or blood samples, using real time PCR, with a detection limit of < 10 copies of 
HBV DNA per reaction or nested PCR for three different, highly conserved regions of the 
HBV genome. Samples which yield amplicons from at least two different genomic regions, 
are considered to be representative of occult infections (Raimondo et al., 2007).    
The occurrence of OBI is worldwide and the distribution of OBI may reflect the general 
prevalence of HBV (Raimondo et al., 2007). OBI is found in HCV-infected individuals, 
cryptogenetic liver disease, dialysis patients, HIV-infected patients, blood donors and the 
general population (Gutiérrez-García et al., 2011).  
Essentially,  OBI is found in four clinical contexts: (i) recovery from acute infection leading 
to seroconversion from HBsAg to anti-HBs, (ii) chronic HBV infection with mutant strains 
that have a mutation in the S region and this could result in diagnostic failure of HBsAg by 
routinely used assays, (iii) chronic infection without any marker except HBV DNA, (iv) 
chronic infection with HBsAg levels too low to be detected by serological assays the most 
common type occurring  in endemic areas (Allain, 2004), (v) OBI in HIV-infected 
individuals.  OBI has many impacts on different clinical aspects, including the possible 
transmission of infection, risk of reactivation and enhancing liver disease progression that can 
lead to HCC (Raimondo et al., 2007).  The clinical importance of OBI remains controversial, 
which is the main reason for the growing interest in this topic (Raimondo et al., 2013). OBI 
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has been reported more commonly in HIV-positive individuals (Mphahlele et al., 2006, Bell 
et al., 2012). In resource-limited countries, the diagnosis of co-infection may be missed, 
because it is difficult to measure the HBV DNA viral loads, or use nucleic acid tests, as a 
result of the high cost, lack of human resources and infrastructure. If OBI is not treated, this 
infection may lead to a higher risk of cirrhosis and of hepatic-related deaths in HIV patients 
(Mphahlele et al., 2006, Firnhaber and Ive, 2009). 
 
1.3  HBV/ HIV co-infection 
HIV is a retrovirus, a member of family Retroviridae. It is an enveloped RNA virus and 
replicates by reverse transcription (Vogt, 1997). CD4
+
 T cells and macrophages of the 
immune system of infected individuals are specifically targeted and killed by HIV, resulting 
in host immunodeficiency (Carmichael et al., 1993). HBV and HIV share common routes of 
blood borne transmission, but they differ in efficiency by which certain types of exposures 
transmit them and in their prevalence by geographic region (Alter, 2006).  Worldwide, it has 
been estimated that 10% of the 34 million people infected with HIV, have chronic HBV 
infection (Alter, 2006).  It has been reported that HIV can negatively affect the natural 
history, physiology, diagnosis and therapeutic responses to HBV (Kottilil et al., 2005). As a 
result of  liver related diseases, patients co-infected with HIV and HBV have a high mortality 
rate, up to 19-fold higher than those infected with HBV alone, and are up to 6-fold more 
likely to develop chronic hepatitis B than are HIV-negative individuals (Thio, 2009).  In a 
study conducted in the USA, it was found that patients infected with both HBV and HIV are 
more likely to develop chronic HBV infection compared to those patients infected with HBV 
only (Bodsworth et al., 1991). In addition, HIV decreases the rate of seroconversion of 
HBeAg to anti-HBe and increases the level of HBV DNA replication (Krogsgaard et al., 
1987, Colin et al., 1999, Thio, 2009). Cirrhosis is one of the major complications of 
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HBV/HIV co-infection despite the decreased levels of ALT resulting from the HIV infection 
(di Martino et al., 2002, Thio, 2009). Moreover, anti-HBs-positive patients infected with HIV 
are at risk of losing this antibody, leading to the reactivation of the HBV infection (Thio, 
2009, Biggar et al., 1987, Laukamm-Josten et al., 1988). HIV infection can complicate the 
diagnosis of HBV because of reverse seroconversion of anti-HBs to HBsAg, especially if the 
CD4
+
T cell count is < 200 cells/mm
3
, which also leads to re-emergence of HBV replication. 
Therefore, if liver disease emerges in the presence of anti-HBs in HIV- infected individuals, 
it is  recommended that tests for HBV serological markers and HBV DNA be repeated (Thio, 
2009).  
 
1.3.1 HBV, HIV and HBV/HIV co-infection in Sudan 
Sudan, or officially the Republic of the Sudan is a country located in the north to east-central 
Africa. Before the southern Sudanese declared their independence and established South 
Sudan, Sudan was the biggest country in Africa. The collection of serum samples from 
patients for the present study was done prior to this separation, in July 2011.  
The majority of previous studies carried out in Sudan determined HBV infection using 
HBsAg as the marker by ELISA, although some of researchers used Immunochromatography 
tests (ICTs), followed by ELISA for confirmation.  For HIV infection, most of the studies 
followed the WHO recommendations for the diagnosis of HIV (WHO, 2006).  All the studies 
carried out between 1989 and 2012, to determine the prevalence of HBV, HIV and co-
infection in Sudan, are summarized in table 3.   
The prevalence of HBV infection ranges from 3.9% in Khartoum to 26% in patients seen in 
out-patient clinics in Juba in southern Sudan. The median HBV prevalence for all the studies 
reported in table 3 is 5.6%.  
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Detection of HBV DNA by PCR is not routinely done in Sudan because of financial and 
human resource constraints and only two studies describe the detection of HBV DNA. In the 
first study, when 404 HBsAg-negative serum samples from the Central Blood Bank were 
tested for anti-HBc, 36% (145/404) were found to be positive.  When these 145 were tested 
for HBsAg, 11% (16/145) were found to be overt infection i.e. HBsAg-positive, HBV DNA-
positive, and 10% (15/145) were HBsAg-negative, HBV DNA-positive i.e. OBI   (Mahgoub 
et al., 2011). Because only anti-HBc-positive samples were tested, this may not be a true 
reflection of the prevalence of either overt or occult infection in Sudanese blood donors. In 
addition to determining the prevalence of HBV infection in Sudanese asymptomatic blood 
donors, Maghoub et al., (2011) also determined the HBV genotypes:   57.5%   of blood 
donors were infected with genotype E, 40.5% with genotype D and 2% with subgenotype A2 
(Mahgoub et al., 2011). In the second study, when 100 serum samples from HBsAg-negative 
blood donors were tested, 42 were anti-HBc-positive.  Amplification for HBV DNA was only 
carried out for the 42 anti-HBc-positive sera and 38 of these were HBV DNA-positive 
(Mahmoud et al., 2013).  This translates to an OBI prevalence of 90% in the samples tested, 
which is rather high.  Therefore these results should be treated with caution for a number of 
reasons.  Firstly, the samples that were anti-HBc-negative were not tested. Secondly, 
amplification of S, C and X genes was carried out using SYBR green real-time PCR.  
Thirdly and paradoxically, an attempt to quantify the HBV DNA using the Taqman probe 
technique (Artus-Biotech, Germany), proved unsuccessful.
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Table 1.3 Prevalence of HBV, HIV and HBV/HIV co-infection in Sudan  
¶ NA: Not applicable,  
€
ND: Not measured  
 
Year Geographical area Participants 
Number of 
participants 
HBsAg  % Anti-HBc % Anti-HBs % HIV % HIV/HBV % References 
H
B
V
 s
tu
d
ie
s 
1989 Gezira- central Sudan Villagers 851 18.7 16.2 63.9 NA¶ NA (Hyams et al., 1989) 
1994 Juba- south Sudan Out patients 651 26 67 NM
€
 NA NA (McCarthy et al., 1994) 
2007 Omduman, central Sudan Pregnant women 728 5.6 NM NM NA NA (Elsheikh et al., 2007) 
2008 Shendi, north Sudan Blood donors 78 5.1 NM NM NA NA (Nail et al., 2008) 
2009 Darfur, western Sudan Blood donors 400 6.5 NM NM NA NA (Abou et al., 2009) 
2010 Gezira- central Sudan Out patients 404 6.9 47.5 47.5 NA NA (Mudawi et al., 2007) 
2011 Khartoum hospital staff 245 4.9 NM NM NA NA (Elduma and Saeed, 2011) 
2011 Khartoum Blood donors 404 3.9 36 50.4 NA NA (Mahgoub et al., 2011) 
2012 Khartoum Haemodialysis patients 353 4.5 NM NM NA NA (Gasim et al., 2011) 
H
IV
 s
tu
d
ie
s 
1995 Juba- south Sudan Out patients 401 NA NA NA 6.2 NA (McCarthy et al., 1995) 
1997 Khartoum Children 1118 NA NA NA 1.2 NA (Hashim et al., 1997) 
2006 Different sites TB  patients 1797 NA NA NA 4.0 NA (El-Sony, 2006) 
2006 Khartoum maternity hospital Pregnant women 305 NA NA NA 1 NA (Gassmelseed et al., 2006) 
2008 NA NA NA NA NA NA 1.4 NA {UNAIDS., 2008 #1267} 
2010 Khartoum Children 106 NA NA NA 5.7 NA (Abbas et al., 2010) 
2010 Khartoum maternity hospital Female sex workers 321 NA NA NA 0.9 NA (Abdelrahim, 2010) 
2011 Eastern Sudan pregnant women 430 NA NA NA 0.23 NA (Mohammed et al., 2011) 
H
B
V
/H
IV
 c
o
-
in
fe
ct
io
n
 s
tu
d
ie
s 
 
1989 
 
 
North east Sexually active heterosexuals 536 14 63 49 0 0 
 
 
(McCarthy et al., 1989a) 
1989 North east, east and south Soldiers 773 25 52 52 1.7 0.8 
 
(McCarthy et al., 1989b) 
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It is very difficult to surmise, from the data available and summarized in table 1.3, the true 
prevalence of HIV in Sudan because of the paucity of data and the wide time span over which 
these studies were performed.  HIV prevalence ranges from 0.23% in pregnant women from 
eastern Sudan to 6.2% in out-patient clinics in Juba in southern Sudan. The median 
prevalence for HIV infection is 1.3%.  In 2008, the estimated HIV prevalence in adults in 
Sudan was 1.4% {UNAIDS., 2008 #1267} and according to Sudan National AIDS control 
Programme (SNAP), this figure dropped to 052% in 2011 (SNAP, 2012).  
The only two studies, carried out on HBV/HIV co-infection in Sudan, were carried out 24 
years ago, using serological techniques.  The first study showed no HIV infection among 
sexually active heterosexuals in northeast Sudan and 14% had HBV infection (McCarthy et 
al., 1989a). The second study, among soldiers in different region of eastern Sudan, showed 
1.7% HIV infection and 25% HBsAg positivity, with only 0.8% being co-infected with HBV 
and HIV (McCarthy et al., 1989b). 
 
1.4 Nucleic acid sequencing techniques  
DNA is the molecule which encodes the genetic information used in the development and 
functioning of all known living organisms and many viruses. After the discovery of the 
genetic code by Watson and Crick in 1953 (Watson and Crick, 1953), it became increasingly 
apparent that the order in which nucleotides appeared within a sequence was critical. This 
ordering appeared to determine both the structure and function of proteins and other cellular 
processes. Moreover, the DNA was shown to code for regulatory elements that can control 
transcription and replication of DNA. Thus determining the order of nucleotides – termed 
DNA sequencing – became a vital biological research method. Sequencing of viral genomes, 
derived from clinical samples, may reveal the extent of viral genetic variation, response to 
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antiviral therapies and enhance the understanding of the course of infection (Ahmadian et al., 
2006). Below follows a  review on the evolution of sequencing technologies, which 
comprises two categories, termed first generation and second (next) generation sequencing 
(Zhou et al., 2010). 
 
1.4.1 First generation sequencing technologies: 
1.4.1.1  Maxam and Gilbert method: 
In 1977, Maxam and Gilbert invented a sequencing technique based on sequencing by 
chemical cleavage. DNA fragments are generated by digestion of the sequencing template 
using restriction enzymes, with the ends of the fragments being radioactively labelled  
(Maxam and Gilbert, 1977). This method allows breaking an end-labelled DNA strand at 
specific bases using chemical reagents. The labelled fragments are separated using 
electrophoresis in a polyacrylamide gel and are then detected by autoradiography. This 
process was not used extensively because it was technically complex and required hazardous 
chemicals, including radioactivity. 
 
1.4.1.2  Sanger technology  
In 1977, Frederick Sanger and colleagues developed a sequencing technique based on 
sequencing by chain-termination. Briefly, this method involves a single strand DNA template, 
DNA polymerase, DNA primer, normal deoxynucleotide triphosphates (dNTPs) and modified 
dideoxynucleotide triphosphates (ddNTPs) that terminate DNA elongation (Sanger et al., 
1977). The incorporation of a ddNTP terminates the extension of the new strand, because the 
modified nucleotide lacks a hydroxyl group, which is necessary for the formation of a 
phosphodiester bond. The ddNTPs, which are labelled with radioactive markers, are 
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visualized by autoradiography on a polyacrylamide gel after electrophoresis. Later, 
radioactive markers were replaced by colour fluorescent dyes  (Sanger et al., 1977). Sanger 
sequencing is the most frequently used method and is semi-automated, requiring machines 
such as the. ABI 3130XL (Ahmadian et al., 2006).  
Despite the fact that the Sanger sequencing method produces long sequence fragments, it is 
expensive, both in terms of monetary cost and time required per nucleotide. In addition 
Sanger sequencing is capable of detecting variation of only ≥20% of the entire population 
(Solmone et al., 2009). An alternative technique used to detect the quasispecies in the viral 
genome is cloning, which is a process that amplifies identical copies of DNA fragments. 
Previously, cloning followed by direct Sanger sequencing was the only method used to study 
the genetic diversity of a viral population (Ramírez et al., 2013) and as a reference technique 
to study viral quasispecies.  This technique,  however,  has a number of limitations, it is 
expensive time consuming and labour intensive, especially when a large  number of clones is 
required for a study (Ramírez et al., 2013). The continued improvement of sequencing 
technology lead to the development of next generation technologies, which are capable of 
sequencing many thousands of nucleotides faster and at a lower cost per nucleotide.   
 
1.4.2 Second (next) generation sequencing technologies (NGS): 
Next generation sequencing (NGS) technologies comprise a number of advanced methods, 
which have been invented recently. These technologies are able to produce a very high 
throughput of data and allow for the detection of mutations, even when present at very low 
levels in the quasispecies population (Hoffmann et al., 2007, Ijaz et al., 2008). Furthermore, 
the moderate cost per base, and the rapid turnaround time, has made this technology popular. 
Three phases of sample preparation are required when using NGS technologies:  
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(i) DNA library preparation, which involves DNA fragmentation, addition of adapters to each 
end of the fragments, denaturation and the immobilization of the resulting single stranded 
DNA on a solid surface, such as supporting beads; (ii) DNA clonal amplification by emulsion 
PCR or bridge PCR, and (iii) sequence reads by optical events produced from a cyclic chain 
extension using an enzyme, such as polymerase. Optical events are recorded by a Cooled 
Charge-Coupled Device camera (CCD) camera and analyzed using a computer algorithm   
(Metzker, 2010, Zhou et al., 2010). The three most commonly used NGS platforms are: 
 
1.4.2.1  GS FLX and GS Junior platforms:  
The GS FLX and GS Junior platforms use pyrosequencing technology (Figure 1.9). 
Pyrosequencing is a ―sequence-by-synthesis approach‖, in which beads covered with DNA 
primers are mixed with single-stranded templates from the DNA library. A relative number of 
beads and DNA single stranded fragments are mixed to ensure that each bead carries only one 
single-strand DNA molecule. This solution is mixed with oil to form an emulsion for the 
emulsion PCR. Thereafter, the beads are deposited onto a picotiter plate. When a new 
nucleotide is incorporated into the sequence, a pyrophosphate molecule is released, which is 
converted to ATP by ATP sulfurylase. The ATP drives the conversion of luciferin to 
oxyluciferin, releasing light energy, which is captured by a camera (Ronaghi, 2001, Metzker, 
2010, Zhou et al., 2010). The GS Junior machine and GS FLX machine from 454 Roche 
Diagnostics can generate reads of up to 400 bases in length, to a maximum depth of 0.035 
gigabases and up to 1000 bases in length at a maximum depth of 0.7 gigabases. (Capobianchi 
et al., 2013, Zhou et al., 2010).   
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Figure 1.9: Overview of the 454 sequencing system. Source: www.roche-applied-
science.com. Accessed on August 17, 2013 
 
1.4.2.2   Hi Seq 2000 (Illumina):  
The second platform is the Hi Seq 2000 from Illumina. This platform is based on bridge 
amplification. The reaction is carried out on the surface of a flow cell covered with 
oligonucleotides corresponding to the sequences of the adapters ligated during the sample 
preparation step.   The single-stranded DNA fragments from the DNA library are ligated with 
adapters and deposited on the surface of flow cell. Then, PCR of the DNA fragments is 
carried out, using bridge amplification. After several cycles of PCR, DNA copies accumulate 
on the surface. Fluorescently labelled nucleotides and polymerase are added, a fluorescence 
image is captured and the base unique fluorescence reveals the identity of newly incorporated 
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nucleotides, which are detected by the camera. The Illumina genome analyzer produces 
sequences of approximately 100 bases in length and a maximum depth of 600 gigabases of 
data per run (Capobianchi et al., 2013, Zhou et al., 2010, Illumina, 2013).  
 
1.4.2.3  SOLiD platform:  
This platform from Applied Biosystems is similar to the 454 Roche systems, in that it uses 
emulsion PCR for DNA amplification with beads.  The difference, however, is that the 
SOLiD platform uses a ligase enzyme instead of polymerase, and the method is called 
―sequencing by ligation‖. This technology produces reads of only 75 bases in length. 
However, up to 100 gigabases of data per run is possible (Capobianchi et al., 2013, Mardis, 
2008, Technologies, 2013).  
Although NGS technology has been used extensively in HIV studies, the ability of NGS 
technology to detect mutations at very low percentages is only now beginning to be 
implemented and applied for HBV research.   
 In 2004, Lindstrom et al., used pyrosequencing to detect lamivudine resistance in clinical 
samples from HBV-infected individuals (Lindström et al., 2004). The authors showed that 
pyrosequencing has a number of advantages compared to the Sanger sequencing method. 
Firstly, pyrosequencing is faster compared to Sanger sequencing. Ten years ago it was shown 
that ABI3100 machine, which utilizes  Sanger sequencing could process  16  samples per 
hour, whereas pyrosequencing can process 96 samples in 10 minutes (Lindström et al., 2004).   
Secondly, the sample preparation step in pyrosequencing was less complicated and quicker 
when compared to the preparation needed in Sanger sequencing method and lastly the 
dispensation order can be designed according to the variation expected in the genome  
(Lindström et al., 2004). The limitation of the technology at the time meant that reads were 
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only 40 bases in length. A major improvement in NGS occurred when the ultra deep 
pyrosequencing (UDPS) methods were developed.  The advantage of using UDPS is that it 
can produce  about 200 base pair reads compared to only 40 base pairs by earlier methods  
(Solmone et al., 2009).   UDPS have been used extensively in HIV research and specifically 
to study HIV drug resistance.  Very few studies have used UDPS to characterize the HBV 
drug resistance  (Solmone et al., 2009).  A study conducted in 2009, used UDPS for the first 
time to analyze the HBV drug resistance mutations in the RT domain of the polymerase 
region.  The results showed that  HBV strains from patients on NAs treatment have higher 
variability in the RT region, compared to strains from drug-naïve patients (Solmone et al., 
2009). Both previously described and novel drug resistance mutations were identified in this 
study, which were also found in HBV isolated from drug-naïve patients, thus confirming the 
findings of previous studies (Solmone et al., 2009).  More recently, Homs et al., confirmed 
that pyrosequencing is able to detect minor populations of the lamivudine resistance rtM240V 
mutation at the YMDD motif in drug-naïve HBV patients, even when occurring at 
significantly low levels.    Other YMDD variants were also detected (Homs et al., 2011). In 
the same study, the authors found that mutations in the polymerase region that, lead to drug 
resistance, occur together with the precore mutations in the same genome, in anti-HBe 
patients. This finding suggested that mutations in the precore region and YMDD polymerase 
motif are common in HBV quasispecies in chronic HBV patients (Homs et al., 2011). 
Furthermore, these authors have shown that two isolates from HBeAg-positive cases have a 
high percentage of stop codon mutations in the precore region, while isolates from HBeAg 
negative  carriers also have a low percentage of strains wild-type  at codon 28 (Homs et al., 
2011). In 2013, Rodriguez et al., used UDPS to detect variants with amino acid substitutions 
at rtA181and rtN236 as a minor population in treatment-naive patients, who later developed 
adefovir resistance (Rodriguez et al., 2013).  Recently, it has been shown that pyrosequencing 
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can detect quasispecies in the main core immunodominant motifs of the core gene of HBV 
(Homs et al., 2012). 
 
1.5 Aims and Objectives  
The objectives of this study were:  
(i) to carry out an in-depth analysis of the relationship of the subgenotypes of genotype D 
using complete genome sequence data, nucleotide divergence calculations, 
phylogenetic analysis and bioinformatics to detect amino acid signature motifs for 
each subgenotype and to redefine their geographical distribution. 
(ii) To molecularly characterize HBV in HBsAg-positive Sudanese liver disease patients 
and asymptomatic carriers of the virus, by genotyping as well as sub-genomic and full 
genomic sequence analysis of HBV isolates. 
(iii)  To molecularly characterize HBV infection in HBV/HIV co-infected Sudanese 
individuals with either overt or OBI. 
(iv) To develop and test bioinformatics tools to explore UDPS HBV sequence data and to 
compare UDPS results with those obtained from cloning based sequencing (CBS). 
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Aim: The aim of the present study was to systematically and
comparatively analyze the subgenotypes of genotype D of
hepatitis B virus.
Methods: In total, 304 complete genomes of all genotype D
subgenotypes were downloaded from the public databases.
The sequences were analyzed using nucleotide divergence
calculations, phylogenetic analysis and bioinformatics to
detect amino acids signature motifs for each subgenotype
and to define their geographical distribution.
Results: Intragroup divergence ranged from 0.8 1 0.5
(% 1 standard deviation) for subgenotype D6 to 3.0 1 0.3 for
D8. Inter-subgenotype divergencemostly ranged 4–7.5%. Phy-
logenetic analysis of genotype D showed separation into six
distinct clusters (subgenotypes D1, D2, D3/D6, D4, D5 and
D7/D8) with good bootstrap support. The mean intergroup
divergence between D3 and D6 was the lowest and fell below
the threshold of 4%, which is required to define a subgeno-
type, suggesting that subgenotypes D3 and D6 belong to one
subgenotype. “D8” is a genotype D/E recombinant, which
clusters with D7. A number of signature amino acids were
found in all four open reading frames that could differentiate
the subgenotypes, which also showed distinct geographical
distribution.
Conclusion: There are six and not eight subgenotypes of D,
D1–D6, which can be differentiated by distinct clustering with
high bootstrap support and signature amino acids. Subgeno-
types D3 and “D6” should be reclassified as a single subgeno-
type D3 and it would be more correct to classify “D8” as a
genotype D/E recombinant rather than a subgenotype.
Key words: bioinformatics, genotype, phylogenetic
analysis, serotype, signature amino acids, subgenotype
INTRODUCTION
HEPATITIS B VIRUS (HBV), the prototype memberof the family Hepadnaviridae, is hepatotropic and
replicates by reverse transcription. HBV is responsible
for chronic infection of approximately 350 million
people worldwide1 and causes both acute and chronic
liver disease. The majority of acute HBV infections are
self-limiting, whereas chronic HBV infection usually has
a lifelong course that may lead to the development of
liver cirrhosis and hepatocellular carcinoma (HCC; liver
cancer).2,3
Hepatitis B virus has a partially double-stranded
genome composed of approximately 3.2 kb, with four
overlapping open reading frames (ORF: preS/S, prec/
core, X and polymerase).4–6 As a result of its unusual
mechanism of replication by reverse transcription and
the lack of proofreading ability of its reverse tran-
scriptase,7 HBV displays sequence heterogeneity. To
date, nine genotypes, A–I, defined by a intergroup diver-
gence of at least 7.5% over the entire genome and
approximately 39 subgenotypes, with intergroup diver-
gence of 4–7.5%, have been identified.8–10 A 10th geno-
type J has been proposed.11 Most genotypes and some
subgenotypes have a distinct geographical distribu-
tion.6,9 HBV genotypes and, in some cases, subgenotypes
have been shown to play an important role in the clini-
cal consequences of the infection as well as in the
response to antiviral treatment.12,13
Compared to the other genotypes, genotype D has the
shortest genome of 3182 nucleotides in length and is
characterized by a 33 nucleotide deletion at the begin-
ning of the pre-S1 region.6 Genotype D has been classi-
fied into eight subgenotypes, D1–D8, showing distinct
geographical distributions.8,14–18
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The aim of this study was to carry out an in-depth
analysis of the relationship of the subgenotypes of geno-
type D using complete genomes, nucleotide divergence
calculations, phylogenetic analysis and bioinformatics
to detect amino acids signature motifs for each subgeno-
type and to redefine their geographical distribution.
METHODS
HBV nucleotide sequence selection
IN TOTAL, 301 complete genome sequences of 3182nucleotides in length of subgenotypes D1–D7 of HBV
and three sequences of subgenotype D8 (3212 nucle-
otides in length) were downloaded from the public
databases (GeneBank/The European Molecular Biology
Laboratory [EMBL]/DNA Databank of Japan [DDBJ]) as
follows: subgenotypes D1 (153), D2 (64), D3 (30), D4
(six), D5 (12), D6 (six), D7 (30) and D8 (three), up to
15 March 2012.
Phylogenetic analysis
The complete genome sequences were aligned using
Gendoc,19 and neighbor-joining phylogenetic trees with
a bootstrap of 1000 replicates were constructed using
Molecular Evolutionary Genetic Analysis MEGA ver. 5
(http:/megasoftware.net) software program based on
Kimura two-parameter distance estimation.
Nucleotide divergence calculations
Nucleotide divergence calculations were carried out
using DAMBE,20 and the means and standard deviation
(SD) were calculated to classify the subgenotypes.
Analysis for intergenotypic recombination
SimPlot ver. 3.5.1, an interactive 32-bit software
program that plots distances (or similarity) versus posi-
tion,21 was used to show recombination in isolates
FN594769–FN594771, previously classified as subgeno-
type D8.15 The window size of 200 bp and step sizes
of 20 bp were used. The putative recombinants were
compared to representative sequences belonging to
genotypes A–I, with outgroup genotype F.
The SimPlot ver. 3.5.1 program was used to find infor-
mative sites.22,23 Informative sites are sites at which two
sequences have a nucleotide in common and the other
two sequences share another one. Each informative site
supports one of three possible phylogenetic relation-
ships among the four taxa. Bootscanning24 and cluster
analysis maximizing the c2 were used to identify the
breakpoints in the intergenotypic recombinants.21,25
P-values for the subsequent division of the sequence
into genotypes were calculated using Fisher’s exact test.
Identification of amino acids signatures
All nucleotide sequences were translated using Gen-
Doc19 and individual subgenotypes were searched for
signature amino acids in the different ORFs of the HBV
genome.
RESULTS AND DISCUSSION
UNTIL 2008, GENOTYPE D of HBV was classifiedinto four subgenotypes (D1–D4).8,16 However,
since then, an additional four subgenotypes of D have
been identified, D5 in 2006,18 D6 in 2009,17 D7 in
200914 and D8 in 2010.15 These subgenotypes were pro-
posed using an intergroup divergence of 4–7.5% and
significant bootstrap support in the phylogenetic tree.8,16
Divergence calculations and
phylogenetic analysis
Table 1 summarizes the intragroup and intergroup
nucleotide divergences (% 1 SD) of 304 complete HBV
genome sequences belonging to subgenotypes D1–D8.
The intragroup divergences ranged from 0.8 1 0.5
(% 1 SD) for subgenotype D6 to 3.0 1 0.3 (% 1 SD) for
subgenotype D8. The intergroup divergence between the
subgenotypes ranged between 4% and 7.5% with some
exceptions, which are shown in bold in Table 1. The
mean intergroup nucleotide divergence was the lowest
between subgenotype D3 and subgenotype D6 at
2.6 1 0.6%.
The phylogenetic tree comparing the 304 complete
HBV genomes, belonging to genotype D, showed sepa-
ration into six clusters, subgenotypes D1, D2, D3/D6,
D4, D5 and D7/D8, supported by high bootstrap values
(Fig. 1). Using the algorithm described by Purdy in
2007,26 the serological subtypes or serotypes were deter-
mined. The subgenotypes of D show different frequen-
cies of serological subtypes: 94% of subgenotype D1
strains were classified as ayw2; 91% of subgenotype D2
as ayw3; 57% of subgenotype D3 as ayw2, 40% ayw3 and
3% ayw4; and 92% of subgenotype D5 was classified as
ayw3. All the strains belonging to subgenotypes D4, D6,
D7 and D8 were classified as ayw2 (Fig. 1). We con-
firmed the significant association of ayw2 with D1 and
ayw3 with D2, as previously shown.8 In the present
study, we demonstrate that ayw2 has a statistically sig-
nificant association with D4, D6, D7 and D8, while
ayw3 is associated with D5 (P < 0.05) (Fig. 1).
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The separation of subgenotype D6, from Papua, from
subgenotype D3, was not statistically supported whereas
its clustering with subgenotype D3 was well supported
(bootstrap = 99%), consistent with the fact that the
mean intergroup divergence between subgenotypes
D3 and D6 was the lowest (Table 1). Using six new
sequences, subgenotype D6 was identified by Utsumi
and colleagues as a separate subgenotype to D3, with
3.3–4.7% intergroup divergence and 88% bootstrap
support in the phylogenetic tree.17 However, by using 30
sequences of subgenotype D3 and the six sequences of
D6, we found a lower intergroup divergence of 2.6 1 0.6
(% 1 SD), with lower bootstrap support of 56% for
separate clustering of D3 and D6 and a significantly
high bootstrap support of 99% for the co-clustering
of D3 and D6. This new analysis suggests that D6 is
not a separate subgenotype but rather a clade of sub-
genotype D3.
Although the previous analysis showed a 100%
bootstrap support for the separation of subgenotypes
D7 and D815, our present analysis does not support
this separation but supports the co-clustering of D7
with D8 at 75%. Moreover, using SimPlot analysis
we corroborated the previous findings that the three
strains FN594769–FN594771, proposed to belong to
subgenotype D8,15 are a recombinant of genotype D
and E. The fourth isolate, FN594768, classified as sub-
genotype D8,15 was excluded from the present analyses
because it contained an insertion. As demonstrated for
FN594769 in Figure 2, by mapping the informative
sites we estimated the positions of transition between
genotypes D and E. The recombination profile deter-
mined for the three strains did not differ significantly
from that determined in the earlier analysis of Abdou
Chekaraou et al., who showed that FN594769–
FN594771 clustered with genotype E within the
regions ~1640–2430, and ~2830–3128 from the EcoR1
site15 After removing these genotype E regions from all
sequences compared, the remaining region showed a
decreased mean intergroup divergence of subgenotype
D8 with D7 being 3.4 1 0.3 (% 1 SD) instead of
4.8 1 1.6 (% 1 SD) when the complete sequence was
compared (Table 1). Furthermore, the length of the
subgenotype D8 of 3212 nucleotides is longer than the
characteristic length for genotype D of 3182 nucle-
otides6,16 and it also has the three nucleotide deletion
in the pre-S1, which is characteristic of genotype E.
Therefore, we propose that subgenotype D8 should be
considered as a genotype D/E recombinant rather than
a subgenotype of D as has been done for the C/D
recombinant circulating in Tibet.27
Even though, in agreement with others,9,28 we found
the intergroup divergence between subgenotypes D1
and D2 to be 3.1 1 0.5 (% 1 SD) (Table 1), below the
threshold of 4%, which is used to separate subgeno-
types, the separation into subgenotypes is justified. First,
the separate clustering of D1 and D2 is well supported
with significant bootstraps of 87% and 94% for D1 and
D2, respectively; second, they express different serologi-
cal subtypes, D1 ayw2 and D2 ayw3; and third, they
show distinct geographical distribution, with D1 found
mainly in the Middle East and D2 in Europe (Fig. 1).
Table 1 Mean intragroup and intergroup divergence of the subgenotypes of genotype D determined using 304 sequences down-
loaded from public databases
D1 D2 D3 D4 D5 D6 D7 D8
No. of sequences 153 64 30 6 12 6 30 3
D1 2.6 1 0.5†
D2 3.1 1 0.5 2.1 1 0.8
D3 3.8 1 0.6 3.9 1 0.6 2.2 1 0.7
D4 4.6 1 0.6 4.5 1 0.7 4.5 1 0.7 2.2 1 1.0
D5 5.0 1 0.6 5.0 1 0.5 4.9 1 0.6 5.0 1 0.6 1.7 1 0.7
D6 3.7 1 0.5 3.6 1 0.5 2.6 1 0.6 4.4 1 0.6 5.0 1 0.4 0.8 1 0.5
D7 4.7 1 0.4 4.7 1 0.4 4.7 1 0.6 4.0 1 0.5 5.4 1 0.4 4.8 1 0.4 2.8 1 0.6
D8 5.2 1 0.5 5.2 1 0.4 5.2 1 0.5 4.5 1 0.6 5.8 1 0.4 5.3 1 0.4 4.8 1 1.6 3.0 1 0.3
D8–E‡ 5.0 1 0.4 5.2 1 0.4 5.4 1 0.5 4.2 1 0.4 5.8 1 0.2 5.6 1 0.3 3.4 1 0.3 2.9 1 0.5
†The intragroup divergence shaded in grey and the intergroup divergence of less than 4% are shown in bold.
‡Mean intergroup and intragroup divergence determined after removing sequences at positions 1640–2430 and 2830–3128 from the
EcoR1 site, which represent the region of recombination between genotype D and E in subgenotype D8.
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Comparison of amino acids sequences of
the subgenotypes of D
Table 2 summarizes the comparison of amino acids of
the 304 HBV complete genomes belonging to the sub-
genotypes of genotype D. The amino acids that were
found predominantly in the individual subgenotypes
are shaded in grey, whereas those that were specific to an
individual subgenotype and found only in that sub-
genotype are encircled.
Although signature amino acids in the S region of
subgenotypes D1–D4 were previously compared,16 this
is the first study to compare amino acids signatures in all
the ORF of the subgenotypes D1 to “D8”. Some sub-
genotypes had specific signature amino acids that can
differentiate them from the other subgenotypes of D.
D5 had ps1:28R in the pre-S1, sp:88S in the spacer of the
polymerase region, while D4 had tp:161V in the termi-
nal protein and rh:107P in RNAse H in the polymerase
region. Moreover, there are a number of amino acids
Figure 1 A rooted phylogenetic tree of 304 complete genomes sequences of hepatitis B virus of the “eight” subgenotypes of
genotype D using neighbor-joining analysis. Bootstrap statistical analysis was performed using 1000 datasets, indicated as
percentages on the nodes. The sequences are labeled by their accession numbers and their country of origin: AUS, Australia; CAN,
Canada; CHN, China; EGP, Egypt; EST, Estonia; FR, France; GER, Germany; HAI, Haiti; IND, India; IRN, Iran; ITA, Italia; JAP, Japan;
KAZ, Kazakhstan; LEB, Lebanon; MLY, Malaysia; NIG, Niger; PAK, Pakistan; PAP, Papua New Guinea/Indonesia; PLD, Poland; RUS,
Russia; SRB, Serbia; SA, South Africa; SPN, Spain; SDW, Sweden; TAJ, Tajikistan; TUN, Tunisia; TUR, Turkey; UZK, Uzbekistan. The
size of the pie charts indicate the relative sample size of the sequences analyzed. The letter D followed by the numbers represent
the subgenotypes of D.
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that are predominately found in certain subgenotypes.
Amino acids ps1:85A, ps2:43L and ps2:54P in pre-S2
x:36S; x:102T and x:110Q in X region; and tp:45T,
sp:100T, sp:115D, sp:122S, sp:139N and rt:336M in the
reverse transcriptase were found predominantly in sub-
genotype D5. Subgenotype D4 could be differentiated
by tp:90N, sp: 95T and rt:122I. Subgenotypes D3/“D6”
had the same signature amino acids in all regions,
ps2:42L, sp:59F, sp:80F, sp:153L, rt:21S, rt:122L and
rt:130P, further supporting our proposal that these are
not separate subgenotypes of D. Subgenotype “D7”
could be distinguished by rh:138V and subgenotype
“D8” by sp:153S, which is also found in genotype E.
Subgenotype “D7” and “D8” share the signature amino
acid at rt:237T. Subgenotype D1 could be differentiated
by ps2:139V and sp:100S, while D2 was differentiated
by sp:128G and rt:126R. No signature amino acids were
found in the hepatitis B surface antigen and preC/C
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Figure 3 Mutation distribution graphs, for the basic core promoter/precore region (1742–1901 from the EcoR1 site), showing the
percentage of mutant residues relative to the reference motif found at the 10 loci of interest (1762, 1764, 1809–1812, 1858, 1862,
1896 and 1899). Eight datasets, one for each subgenotype of D, were submitted to the Mutation Reporter Tool to produce the graphs
(153 sequences for D1, 64 for D2, 30 for D3, six for D4, 12 for D5, six for D6, 30 for D7 and three for D8). The reference motif used
was AGGCACTGGG. This is also shown by the letter preceding each locus on the X-axis. To facilitate direct comparisons between the
graphs, conserved loci were not suppressed and the Y-axis was scaled to 100% by selecting the appropriate controls on the input page
of the Mutation Reporter Tool (Bell TG and Kramvis A, unpublished data). Residue A ( ), C ( ), G ( ), R ( ), T ( ).
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hepatitis B e-antigen (HBeAg) precursor proteins of the
different subgenotypes of D.
Mutations in the basal core promoter (BCP)
and precore (PC) regions
Using our team’s Mutation Reporter Tool (Bell TG and
Kramvis A, unpublished data) for the analysis of 10 loci
in the BCP and PC (1742–1899 from the EcoR1 site),
described previously,8 certain correlations were found
between the frequency of the mutations in these loci
and the subgenotypes of D. The frequency of the muta-
tions in the different subgenotypes are illustrated in
Figure 3. The BCP A1762T/G1764A occurred in all sub-
genotypes, except for subgenotypes D4 and D5, but this
may be as a result of the relatively low numbers of
sequences available for these subgenotypes and this pos-
sibility can only be precluded once additional sequences
become available. The mutation G1896A, which abol-
ishes the translation of HBeAg,29 was found in signifi-
cantly higher frequency in subgenotypes D1 and “D7”,
at 74% and 83%, respectively (P < 0.05) (Fig. 3).
G1899A, which often occurs together with G1896A,
occurred in 67% of subgenotype “D7”, at a significantly
higher frequency than in the other subgenotypes
(P < 0.05). 1858C occurred in 10% of subgenotype
“D7” strains, also at a statistically higher frequency than
in the other subgenotypes (P < 0.05). The 1858C is posi-
tively associated with genotype A whereas it is negatively
associated with genotype D.8 In order to exclude the
possibility that the subgenotype “D7” sequences with
1858C were genotype A/D recombinants in the PC
region, we carried out Simplot analysis,21 which did not
Figure 4 Global distribution of the “eight” subgenotypes of genotype D. The size of the pie charts indicates the relative sample size
of the number of sequences analyzed. The geographical distribution of the subgenotypes of D was updated using 304 complete
genomes (Fig. 1) and 488 subgenomic sequences from which the subgenotype could be determined (accession numbers available
upon request). According to the present analysis “D6” is reclassified as D3, “D7” becomes D6 and “D8” is more correctly classified
as a D/E recombinant.
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reveal any recombination between genotype A and sub-
genotype “D7” (data not shown).
Drug resistance and immune
escape mutations
Long-term antiviral treatment directed against HBV can
lead to the development of drug resistance as well as
immune and vaccine escape mutations.30,31 Although a
number of clinically relevant mutations were found to
occur (Tables S1 and S2), there was no correlation
between these mutations and the subgenotypes of D.
Geographical distribution of subgenotypes
of genotype D
Figure 4 updates the geographical distribution of the
subgenotypes of D using the 304 complete genomes
sequences and 488 partial subgenomic sequences. Sub-
genotype D1 was found mainly in the Middle East, sub-
genotype D2 in Europe and Asia, subgenotype D3 in
South Africa, Northern America and Europe, subgeno-
type D4 in Northern and Central Americas and Austra-
lia, subgenotype D5 only in India, subgenotype “D6”
reclassified as D3 from Papua New Guinea /Indonesia,
subgenotype “D7”, which becomes subgenotype D6
after the present analyses, in the Maghreb (Morocco,
Algeria and Tunisia) and subgenotype “D8”, the geno-
type D/E recombinant from Niger.
To conclude, these comprehensive analyses of the
subgenotypes of genotype D clearly demonstrate that
there are six rather than eight subgenotypes of D,
D1–D6, which can be differentiated by distinct cluster-
ing with high bootstrap support and signature amino
acids. Subgenotypes D3 and “D6” should be reclassified
as a single subgenotype, D3, and it would be more
correct to classify the previously named subgenotype
“D8” as a genotype D/E recombinant rather than a sepa-
rate subgenotype of genotype D.
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SUPPORTING INFORMATION
ADDITIONAL SUPPORTING INFORMATION maybe found in the online version of this article at the
publisher’s website:
Table S1 Genotype D strains with mutations in the
reverse transcriptase domain that may lead to drug
resistance.
Table S2 Genotype D strains with mutations in the
HBsAg that may lead to vaccine, detection and/or
immune escape.
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Table S1: Genotype D strains with mutations in the reverse transcriptase domain that may lead to drug resistance 
      HBV reverse transcriptase domain 
Codon     173 180 181 184 191 194 202 204 207 213 214 215 233 236 
      V  L  A  T  V  A  S  M  V  S  V  Q /P/H I  N 
Subgenotype Accession numbers Country                             
D1 
GU456682 
Iran 
. . . . . V  . . . . . S  . . 
GU456646 . . . . . . . . . . . . V  . 
GU456638 M  . . . . . . . . . . . . . 
GU456647 . . . . . . . . . . . S  . . 
GU456645 . . . . . . . . . . . S  . . 
GU456639 . . . . . . . . M  . E  . . . 
GU456637 . . . . . . . . . T  . . . . 
JF754633 
Turkey 
. . . . . . . . . T  . . . . 
JF754631 . . . . . . . . . . . S  . . 
JF754629 . . . . . . . . . . A  S  . . 
JF754623 . . . . . . . . . T  . . . . 
JF754619 . . . . . . . . . . . S  . . 
JF754599 . . . . . . . . . T  . . . . 
JF754614 . . . . . . . . . T  . . . . 
JF754598 . . . . . . . . . T  . . . . 
FJ904431  
Tunisia 
. . . . . . . . . . . S  . . 
FJ904446 . . . . . . . . . T  . . . . 
JN642155 
Lebanon 
. . . . I  . . . . . . . . . 
JN642153 . . . . . . . . . . . S  . . 
JN642149 . . . . . . . . . T  . . . . 
JN642145 . . . . . . . . . . . S  . . 
JN642137 . . . . . . . . . . E  . . . 
JN642129 . . . . . . . . . . E  . . . 
JN642158 . . . . . . . . M  . . . . . 
JN642154 . . . . . . . . . T  . . . . 
JN642150 . . . . . . . . . . . S  . . 
JN642140 . . . . . . . . . . G  . . . 
AF121242 Sweden . . . . . . . . . T  . . . . 
D2 
GQ477453 Poland M  . . . . . . . . . . . . . 
EU594398 Russia . . . . . . . . . . . S  . . 
JN642163 Lebanon . . . . . T  . . . T  . . . . 
AF043594 Germany . . . . . . . . . . . S  . . 
AB109478 Japan . . . . . . . . . T  . . . . 
X80925 UK . . . . . . T  . . . . . . . 
D4 GQ922003 Canada . . . . . . . . . . . . V  . 
D7 
FJ904441 
Tunisia 
. . . . . . . . . . E  . . . 
FJ904433 . . . . . . . . . . I  . . . 
FJ904395 . . . . . . . . . . A  . . . 
FJ904430 . . . . . . . . . . E  . . . 
FJ904414 . . . . . . . . . . .  S  . . 
FJ904404 . . . . . . . . . T  D  . . . 
D6 
AB493848 
Papua 
. . . . . . . . . . . S  . . 
AB493845 . . . . . . . . . . . S  . . 
AB554024 . . . A . . . . . . . . . . 
D8 FN594769 Niger . . . . . T . . . . . . . . 
Dots indicate amino acids identity and the mutations are highlighted in grey.  Only sequences, which had mutations, are shown. All other sequences were wild-type.   
 
 
 
 
 
 
 
Table S2: Genotype D strains with mutations in the HBsAg that may lead to vaccine, detection and/or immune escape 
Subgenotype Accession numbers Country 
HBsAg 
120 133 144 145 153 158 
P  M  D  G  P  F 
D1 
GU456682 Iran . . . . . L 
FJ904427 Tunisia . . E  R  . . 
JN642133 
Lebanon 
. S  . . . . 
JN642166  S  . . . . . 
JN642134 T  . . . . . 
AF151735 Germany . . E  . . . 
AY945307 India . . . . . L 
D2 EU594433 Russia T  . . . . . 
D5 
GQ205389 
India 
. . . E  . . 
GQ205385 . . . E  . . 
D8 FN594770 Niger . T  . . . . 
Dots indicate amino acids identity and the mutations are highlighted in grey.  Only sequences, which had mutations, are shown. All other sequences were wild-type.   
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Molecular characterization of hepatitis B virus in
liver disease patients and asymptomatic carriers
of the virus in Sudan
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Abstract
Background: Hepatitis B virus is hyperendemic in Sudan. Our aim was to molecularly characterize hepatitis B virus
from Sudanese individuals, with and without liver disease, because genotypes play an important role in clinical
manifestation and treatment management.
Methods: Ninety-nine patients - 30 asymptomatic, 42 cirrhotic, 15 with hepatocellular carcinoma, 7 with acute
hepatitis and 5 with chronic hepatitis- were enrolled. Sequencing of surface and basic core promoter/precore
regions and complete genome were performed.
Results: The mean ± standard deviation, age was 45.7±14.8 years and the male to female ratio 77:22. The median
(interquartile range) of hepatitis B virus DNA and alanine aminotransferase levels were 2.8 (2.2-4.2) log IU/ml and 30
(19–49) IU/L, respectively. Using three genotyping methods, 81/99 (82%) could be genotyped. Forty eight percent of
the 99 patients were infected with genotype D and 24% with genotype E, 2% with putative D/E recombinants and 7%
with genotype A. Patients infected with genotype E had higher frequency of hepatitis B e antigen-positivity and higher
viral loads compared to patients infected with genotype D. Basic core promoter/precore region mutations, including
the G1896A in 37% of HBeAg-negative individuals, could account for hepatitis B e antigen-negativity. Pre-S deletion
mutants were found in genotypes D and E. Three isolates had the vaccine escape mutant sM133T.
Conclusion: Sudanese hepatitis B virus carriers were mainly infected with genotypes D or E, with patients infected
with genotype E having higher HBeAg-positivity and higher viral loads. This is the first study to molecularly characterize
hepatitis B virus from liver disease patients in Sudan.
Keywords: Bioinformatics, Genotype, Serotype, Sudan, Subgenotype, Africa, Phylogenetics
Background
Hepatitis B virus (HBV), the prototype member of the
family Hepadnaviridae is responsible for chronic infec-
tion of more than 240 million people worldwide [1], of
which 65 million reside in Africa [2].
Sudan is an African country with high HBV seropreva-
lence of greater than 8% HBsAg-positivity, ranging from
6.8% in central Sudan to 26% in southern Sudan [3-5].
HBV infection occurs in early childhood in southern
Sudan, with the infection increasing with age in northern
Sudan [3,6]. HBV was shown to cause 22% of fulminant
hepatitis cases in Sudan [7] and 18.5% of Sudanese blood
donors were exposed to the virus and 4% were infected at
the time of donation [8]. Nine genotypes of HBV, A–I,
with a distinct geographic distribution have been recog-
nized [9-11]. A tenth genotype, J, has been proposed but
was found only in one person [12]. Genotype A, D and E
circulate in Africa [2]. Genotype A prevails in southern,
eastern and central Africa. Genotype D is the dominant
genotype in northern Africa, whereas in western Africa
genotype E predominates. Subgenotypes have also been
identified within genotypes A and D [9,10].
Considering Sudan’s unique position and the flux of
people across its borders, it is important that the HBV
genotypes prevailing in this country are determined. In a
single study, in Sudanese asymptomatic blood donors, it
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was found that 57.5% were infected with genotype E,
40.5% with genotype D and 2% with subgenotype A2 [8].
Moreover, a diversity of genotypes are distributed in
neighbouring countries [2]: genotype D in Egypt to the
north [13], genotype E in the Democratic Republic of
Congo to the west [14] and genotype A in Kenya [15,16]
and Uganda [17] to the south. Knowledge of the genotypes
prevailing in Sudanese, with and without liver disease, is
important in treatment management, as well as disease
prognosis because genotypes play a role in both of these
aspects [18,19].
The Regional committee for the World Health
Organization (WHO) Eastern Mediterranean Region
(EMR), to which Sudan belongs, urged member states
to:
“Improve the epidemiological surveillance systems,
develop a hepatitis registry and implement serosurveys
in order to produced reliable data to guide prevention
and control measures and monitor impact of
preventive strategies” [20].
Thus our objective was to molecularly characterize
HBV from HBsAg-positive persons with known clinical
status.
Methods
Serum samples
A cross-sectional, laboratory based study was conducted.
Ninety-nine sera were collected from HBsAg-positive
patients referred to the hepatology and general medical
clinics at IbnSina Hospital, Soba University Hospital and
Khartoum Teaching Hospital in Khartoum State be-
tween August 2008 and March 2009. The clinical report
forms (CRFs) were completed by qualified practitioners.
Informed consent was obtained from each patient in-
cluded in the study and the study protocol conforms to
the ethical guidelines of the 1975 Declaration of Helsinki
as reflected in a priori approval by the Human Ethics
Committees of the University of the Witwatersrand and
the University of Khartoum and the Ministry of Health
of Sudan. Alanine amino transferase (ALT) levels were
determined (reference range 5–40 IU/L) [21] and sam-
ples stored at -20°C. Chronic carriers were infected for
longer than six months and were classified as asymp-
tomatic carriers (ASCs) if they had normal ALT or
chronic hepatitis (CH) patients if they had abnormal
ALT. Acute hepatitis (AH) cases were diagnosed based
on clinical presentation (symptoms and clinical presence
of jaundice) plus high ALT and the presence of hepatitis
B core IgM antibody (HBcAbIgM). Clinical and ultra-
sonographic evidence were used to diagnose cirrhotic
(CR) and hepatocellular carcinoma (HCC) cases.
HBV serology
HBsAg was assayed using Monolisa™ HBsAg ULTRA and
HBeAg using Monolisa™ HBeAg-Ab PLUS kit (Bio-rad,
Hercules, CA). Anti-HBe and anti-HBc antibodies were
determined using HBeAg/Anti-HBe ELISA and Anti-HBc
Total ELISA, respectively (DIAsource ImmunoAssays S.A,
Nivelles, Belgium). Anti-HBc IgM was determined using
the ARCHITECTW kit (Abbott Diagnostics, Wiesbaden,
Germany).
DNA extraction
DNA was extracted from 200 μL of serum using QIAamp
DNA mini blood kit (QIAGEN GmbH, Germany),
according to manufacturer’s instructions, and eluted in
100 μL of buffer.
Real-time PCR quantification of HBV DNA
PCR primers, HBV-Taq1 and HBV-Taq2 covering a region
of the S gene (321 to 401 from the EcoRI site) with a
FAM/TAMRA labelled TaqMan BS-1 probe [22] were
used to quantify HBV DNA in an ABI 7500 Real Time
PCR System (Applied Biosystems, Foster City, Ca, USA).
A serial dilution of cloned plasmid DNA containing a sin-
gle genome of HBV DNA, with concentrations ranging
from 2 × 101 to 2 × 1011 IU/ ml, was used as template to
generate the standard curve. The second WHO Inter-
national Standard for HBV Nucleic Acid Amplification
Techniques (product code 97/750 National Institute for
Biological Standards and Controls (NIBSC); Hertfordshire,
UK), which has a final concentration of 106 IU/ml was
used as the internal standard. The standard curve, blank,
positive and negative controls, and samples were all tested
in duplicate. The measured IU/ml for each reaction was
calculated using the Ct (cycle threshold) value of each
PCR interpolated against the linear regression of the
standard curve. The lower detection limit of our assay
is ~20 IU/ ml. The conversion formula of IU =copies/4.7
was used [23-25].
Polymerase chain reaction (PCR) and restriction fragment
polymorphism assay (RFLP)
The basic core promoter/precore (BCP/PC) region and
complete S open reading frame (ORF) were amplified in a
MyCycler™ thermocycler (Bio-Rad, Hercules, Ca, USA)
using Promega Taq DNA polymerase (Promega, Madison,
WI). The BCP/PC PCR was amplified using a slight modi-
fication of the method described by Takahashi and col-
leagues [26] primers 1606 (+) (1606–1625 from EcoRI
site) and 1974 (−) (1974–1955 from EcoRI site) were used
for the first round (denaturation 94°C for 1 min, annealing
55°C for 1 min, extension 72°C for 2 min, 40 cycles) and
1653(+) (1653–1672 from EcoRI site) and 1959(−) (1959–
1940 from EcoRI site) for the second round, with the iden-
tical cycling conditions as the first-round PCR [25,27]. A
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nested PCR was carried out to amplify the complete S
ORF : primers 2410(+) (2410–2439 from EcoRI site) and
1314(−) (1314–1291 from EcoRI site) were used for the
first round (denaturation 94°C for 1 min, annealing 66°C
for 1 min, extension 72°C for 3 min, 40 cycles) and 2451
(+) (2451–2482 from EcoRI site) and 1280 (−) (1280–1254
from EcoRI site) for the second round (denaturation 94°C
for 1 min, annealing 65°C for 1 min, extension 72°C for 3
min, 40 cycles) [27]. Another nested PCR reaction was
carried out to amplify a short region of the S (459–710
from EcoRI site) to determine the genotype: primers 255
(+) (253–275 from EcoRI site) and 759 (−) (759–739 from
EcoRI site) were used for the first round (denaturation 94°C
for 30 sec, annealing 56°C for 40 sec, extension 72°C for 1
min, 40 cycles) and [459(+) (460–480 from EcoRI site)] and
[710(−) (711–691 from EcoRI site)] for the second round
(denaturation 94°C for 30 sec, annealing 56°C for 40 sec,
extension 72°C for 50 sec, 40 cycles) [28]. When the
complete S ORF and the short S could not be amplified, a
RFLP assay was used to determine the genotype of the
HBV isolates. Primers P7 (256–278 from EcoRI site) and P8
(796–776 from EcoRI site) were used to amplify nucleotides
256–796 of the S region. The amplicon was then cleaved
using restriction enzymes HinfI and Tsp509I, in separate re-
actions, to give the characteristic RFLP patterns for the dif-
ferent genotypes [29]. The complete genome was amplified
using a single amplification method with primers P1
(1821–1841 from EcoRI site) and P2 (1825–1806 from
EcoRI site), with modifications in the cycling conditions
[30]. Initial denaturation at 98°C for 1 min, 80°C for 30 sec
followed by adding the polymerase mix, 98°C for 1 min,
then 35 cycles of: 98°C for 10 sec, 57°C for 30 sec and 72°C
for 1 min.
Sequencing
The BigDye Terminator v3.0 Cycle Sequencing Ready Re-
action Kit (Applied Biosystems., Foster City, USA) was
used and sequencing performed using the ABI 3130XL
Genetic analyzer (Applied Biosystems, Foster City, CA). In
addition to sequencing primers: 2497F (2497–2516),
3188F (3188–3206) and 591F (591–611) used previously
[27,31], four new primers: 1069F (1069–1088) (5′- TGT
ATT CAA TCT AAG CAG GC-3′), Post-Bgl III (2000–
2017) (5′-CCG ATA CAG AGC TGA GGC-3′), 2022F
(2022–2041) (5′-CCT TAG AGT CTC CTG AGC AT-3
′), 2480R (2461–2480) (5′-CAC CTT ATG AGT CCA
AGG AA-3′), were used to sequence the complete gen-
ome. All positions are numbered from the EcoRI site of
genotype A (AY233286). The three overlapping fragments
of the complete S, and the 7 fragments of the complete
genome thus obtained, were assembled using the Frag-
ment Merger Tool [32]. Sequences were deposited in
GenBank, accession numbers KF170739-KF170812.
Phylogenetic analysis
Neighbour-joining using MEGA5 [33] or PHYLIP (Phyl-
ogeny inference package version 3.69) or DNADIST con-
secutively with NEIGHBOR were used to generate
dendrograms [34].
Analysis for intergenotypic recombination
SimPlot 3.5.1©, an interactive 32-bit software program,
that plots distances (or similarity) versus position [35] was
used to show recombination in isolate SDAC031 [33].
Results
HBV serology and viral loads
Of the 99 patients, 77 were males and 22 were females.
Mean age ± standard deviation (SD) was [45.7±14.8] years.
All sera were HBsAg- and anti-HBc-positive; 12 were
HBeAg-positive/anti-HBe-negative, 75 were HBeAg-
negative/anti-HBe-positive, and 12 had neither HBeAg
nor anti-HBe. All patients were HBV DNA-positive, with
a median (interquartile range) (IQR) viral load of [2.8
(2.2–4.2)] log IU/ml and ALT median (IQR) level was [30
(19–49)] IU/L (reference range 5–40 IU/L) [21].
Clinical and demographic characteristics
The 99 cases were classified into five clinical groups:
HCC (n=15), CR ( n=42), ASCs (n=30), AH ( n=7) and
CH ( n=5). The HCC patients were significantly older
than patients in the other groups (p <0.05) and the AH
patients were significantly younger (p <0.05). The ALT
levels were the highest in the AH (p <0.05) (Table 1).
The median viral load of HBeAg-positive patients [6.99
(5.63–7.57) log IU/ml] was significantly higher than in
HBeAg-negative patients [2.55 (2.09–3.42) log IU/ml]
(p<0.05). The viral loads and frequency of HBeAg-
positivity did not differ between clinical groups.
HBV genotyping and phylogenetic analysis
In order to maximize the number of isolates genotyped,
three methods were used sequencially (Figure 1).
81 HBV isolates were thus successfully genotyped
Firstly, 53 of 99 were genotyped using amplification and
sequencing of the complete S (2848–835 from EcoRI),
followed by phylogenetic analysis (Figure 2), secondly,17
of 46 were genotyped by amplification and sequencing of
a short S fragment (520–704 from EcoRI), followed by
phylogenetic analysis (trees not shown) and thirdly,11 of
29 by RFLP analysis.
The relatively longer amplicon of the S region of 2.1
kb in length, compared to the shorter regions used for
the short S and RFLP amplifications, meant that not all
samples could be amplified in the longer region success-
fully. 18.2% (18/99) could not be genotyped using any of
the three methods. No sequences could be obtained for
10 of these isolates and for the remaining 8 only the
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BCP/PC region was sequenced, which is not sufficient to
differentiate between genotypes D and E.
The genotype distribution in the 81 samples was 59%
genotype D: 30% genotype E: 8.5% genotype A: 2.5% pu-
tative D/E recombinant. If we include the 18 samples
that could not be genotyped, 48.5% (48/99) were infected
with genotype D, 24.2% (24/99) with genotype E, 7.1%
(7/99) with genotype A and 2% (2/99) were infected with
a putative D/E recombinant.
Phylogenetic analysis of the complete S region allowed
for further classification into subgenotypes (Figure 2). Based
on the recently suggested classification system [33], 23 of
31 genotype D isolates belonged to subgenotype D1 (74%),
3 to D2 (10%), 1 to D3 (3%) and 4 to D6 (13%). One geno-
type A isolate belonged to subgenotype A1 (Figure 2).
The complete genome of four isolates was amplified,
two (SDAC024 and SDAC031) belonged to genotype D
and two (SDAC047 and SDAC125) to genotype E.
Table 1 Demographic and clinical characteristics of 99 patients
Clinical status
HCC (15) ASC (30) CR (42) AH (7) CH (5)
Male: Female 13:02 22:08 37:05:00 02:05 03:02
Age mean ±SD 57.3±13.8a 42.8±15.1 46.5±12.9 32.1±12.4a 37.6±41.0
ALT median IU/L (IQR) 40 (24–50) 22 (18–33) 27 (18–45) 461 (312–834)a 38 (29–47)
HBeAg positive (%) 2 (13.3) 2 (6.7) 7 (16.7) 1 (14.3) 0
Log viral loads 3.8 2.5 2.8 3 2.1
IU/ml median (IQR) (2.4-4.7) (2.2–3.3) (2.2-5.3) (2.2-3.8) (2.0-3.6)
HCC Hepatocellular carcinoma, ASC Asymptomatic carriers, CR Cirrhosis, AH Acute hepatitis, CH Chronic hepatitis.
aSignificant difference with other groups.
Figure 1 Algorithm summarizing protocol and results of the molecular characterization of BCP/PC region and genotyping of HBV.
a Three isolates showed genotype D based on S region and genotype A based on BCP/PC region.
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Although the genotypes determined using the complete
genome agreed with that determined using the S ORF,
there was a discrepancy in the subgenotype classification
of SDAC031. Using phylogenetic analysis of the complete
S, it clustered as an outlier of subgenotype D4, whereas fol-
lowing complete genome phylogenetic analysis it clustered
with D6 (Figure 2). Simplot analysis showed SDAC031 to
be a recombinant of D6 and D4. By mapping the inform-
ative sites, we estimated the transition positions between
D6 and D4 (Figure 3). The genotype E isolates (SDAC047
and SDAC125) clustered together when the complete S
was compared, whereas they separated into different clades
in the complete genome analysis (data not shown).
Although the majority of subgenotype D isolates showed
the respective distinct subgenotype amino acids signatures
[33], there were exceptions. SDAC031 (D6) showed
preS2I42T, spV59F and rtT237P. SDAC085 (D6) had
spV59S. SDAC107 (D6) had preS2I42T and rtT237P. All
17 genotype E isolates had genotype E signature amino
acid motifs.
Comparison of patients infected with genotypes D and E
Because the majority were infected with either genotype D
or E, further analyses compared the patients’ clinical and
virological features infected with these genotypes. No sig-
nificant difference was observed in gender, age, ALT and
Figure 2 A rooted phylogenetic tree of 53 complete S sequences of HBV obtained from Sudanese liver disease patients (shaded in
box) with 104 reference HBV sequences, using neighbour-joining. Bootstrap statistical analysis was performed using 1000 datasets, indicated as
percentages on the nodes. The sequences are labeled by their accession numbers and country. [AUS, Australia; CMR, Cameron; CAN, Canada; CAR,
Central African Republic; CHN, China; COV, Côte d’Ivoire; DRC, Democratic Republic of Congo; EGP, Egypt; EST, Estonia; FR, France; GHN, Ghana; GER,
Germany; HAI, Haiti; IND, India; IRN, Iran; ITA, Italia; JAP, Japan; KAZ, Kazakhstan; LEB, Lebanon; MAD, Madagascar; MLY, Malaysia; MLW, Malawi; NAM,
Namibia; NIG, Niger; PAK, Pakistan; PAP, Papua New Guinea/Indonesia; POL, Poland; RUS, Russia; RWD, Rwanda; SRB, Serbia; SOM, Somalia; SA, South
Africa; SPN, Spain; SDW, Sweden; TNZ, Tanzania; TAJ, Tajikistan; TUN, Tunisia; TUR, Turkey; UGN, Uganda; UK, United Kingdom; USA, United States; UZK,
Uzbekistan ]. The letters, A, D and E, represent the genotypes and the numbers the subgenotypes. A rooted phylogenetic tree of the complete
genome of SDAC 031 (shaded) relative to 17 reference HBV sequences, using neighbour-joining is shown in the left hand box. When the complete
genome was analyzed SDAC031 clustered with D6 whereas when the S region alone was analyzed it clustered with D4.
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clinical groups of patients infected with either genotype.
Patients infected with genotype E, showed a significantly
higher frequency of HBeAg-positivity compared to pa-
tients infected with genotype D (p <0.05) and HBV DNA
levels in patients infected with genotype E were signifi-
cantly higher (p <0.05) (Table 2).
Molecular characterization of HBV isolates
Analysis of basic core promoter/precore (BCP/PC) region
Of the 70 isolates amplified and sequenced in the BCP/PC
region, 62 amplfied in the S region and thus had genotype
assignments. 57 isolates belonged to either genotype D or
E, and 5 to genotype A. Seven of 8 genotype D or E isolates
Figure 3 Graphs show bootscanning values of query sequence SDAC031 to representative sequences of subgenotypes D1 to D6 and
outgroup, genotype F. Graphs were generated using Simplot version 3.5.1© with window size: 200 bp, step size 20 bp, gap-strip off, 100
bootstrap replicates, Kimura transition/transversion ratio:2 and NEIGHBOR. Dashed vertical lines indicate breakpoints. The numbers of informative
sites, which are shared by the isolate with subgenotype D4 are shown above and with subgenotype D6, below, on the right hand side of the
four-member trees representing these sites. The genomic regions belonging to subgenotype D4 are shaded in grey.
Table 2 Clinical and demographic characteristics of 81 patients, for which HBV was genotyped
Clinical status Demographic Biochemical and virological
characteristics characteristics
HCC (13) ASC (24) CR (33) AH (7) CH (4) Male: Female Age
mean ±SD
ALT median
IU/L (IQR)
HBeAg
positive (%)
Viral loads log
median IU/ml (IQR)
Genotype D (%) 4(30.7) 14(58.3) 23(69.7) 4(57.1) 3(75) 38:10 44.6 ±15.1 29 (19–57) 4 (8.3) 2.8 (2.0-3.9)
Genotype E (%) 6(46.2) 6(25) 8(24.3) 3(42.9) 1(25) 17:07 49.3 ±14.3 29 (18–65) 7 (29.2)a 4 (2.6-5.7)a
Genotype D/E (%) 1(7.7) 0 1(3) 0 0 2:0 56.5 ±7.0 NA 0 2.4 (2.3-2.41)
Genotype A (%) 2(15.4) 4(16.7) 1(3) 0 0 5:2 38.14 ±14.51 33 (28–54) 1 (14.3) 2.6 (2.3-3.9)
HCC, Hepatocellular carcinoma; ASC, Asymptomatic carriers; CR, Cirrhosis; AH, Acute hepatitis, CH, Chronic hepatitis.
aSignificant difference between patients infected with genotype D or E.
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from HBeAg-positive patients had wild-type BCP/PC, and
one (SDAC118) had G1764T. The mutations found in
genotype D or E isolates from HBeAg-negative individuals
are shown in Figure 4: 15/49 genotype D or E isolates from
HBeAg-negative sera, had wild-type BCP/PC region. In
22/49 HBeAg-negative sera, the absence of HBeAg was as
a result of missense mutations affecting the translation of
the HBeAg precursor: 18 had the classical stop codon mu-
tation G1896A (p< 0.05, when comparing isolates from
HBeAg-negative and –positive sera) and 4 had initiation
codon mutations, 2 A1814T and 2 T1815C. A1762T/
G1764A was found in 11 G1896A mutants and in one
T1815C mutant. Six isolates from HBeAg-negative sera had
A1762T/G1764A alone. The Kozak sequence was GCAC
at 1809–1812 in 45 isolates, GTAC in isolate SDAC 121
and TCAT with 1858C and 1888A in isolates SDAC018,
SDAC090 and SDAC091. SDAC050 had 1858C with
1888A alone.
Although generally the BCP/PC region cannot be used
to determine specific genotypes, genotype A and its
subgenotypes can be differentiated from genotypes D or
E because of specific sequence characteristics. One
genotype A isolate from a HBeAg-positive patient,
(SDAC108) had A1762T/G1764A. From the BCP/PC se-
quences it was deduced that this isolate belonged to
subgenotype A2, because it had GCAC at 1809–1812,
1858C and 1888G. The other four genotype A isolates
were from HBeAg-negative individuals. These isolates,
SDAC062, SDAC073 SDAC100 and SDAC113, belonged
to subgenotype A1 because they had TCAT at 1809–
1812, 1858C and 1888A. One isolate had wild-type BCP/
PC region, two had A1762T/G1764A, one with G1862T
and the fourth isolate had G1862T alone. No significant
association was found between the BCP/PC mutations
and genotypes or clinical groups.
Analysis of the pre-S1, pre-S2, Surface and Polymerase regions
The complete S region was sequenced for 53 isolates and
pre-S mutations were detected in 14 (26%). Four muta-
tional patterns were identified: pre-S1 deletions (2/14;
14%), pre-S2 start codon mutation (4/14; 29%), pre-S2
start codon mutation with pre-S2 deletion (1/14; 7%) and
pre-S2 deletion alone (7/14; 50%) (Table 3). Transcription
regulatory box domain substitutions [CCAAT→CTAAT]
(803–807 from EcoRI site), were found in two isolates
(SDAC095 genotype E and SDAC098 genotype D). Three
cis-acting elements mutations were found: C1092T in the
Enhancer I in one isolate, C1155T in the Enhancer I in 6
isolates and T3109G S2 promoter in 2 isolates. PreS2F22L
was found in 6 genotype E and three genotype D isolates.
The vaccine escape mutation, sM133T, was observed in
genotype E isolates, SDAC022, SDAC067 and SDAC088.
In the reverse transcriptase domain of the polymerase, the
following mutations were detected: rtA194T in SDAC049
(genotype D), rtV207M in SDAC020 (genotype D), rtS213T
in SDAC063 and SDAC098 (genotype D), SDAC002,
SDAC121 and SDAC004 (genotype E), rtV214A in
SDAC059 (genotype E) and rtS215Q in SDAC049 and
SDAC090 (genotype D).
Discussion
In Sudan, where HBV is hyperendemic, little is known
about the genotypes and mutants of HBV in liver disease
patients. Thus HBV, from 99 patients, belonging to five
clinical groups, were studied. Of the 81 samples that were
successfully genotyped, close to 60% belonged to genotype
D whereas the opposite was true in Sudanese blood do-
nors, where genotype E prevailed (57%) [8]. HCC patients
in this study, who were infected with either genotype D or
E, were significantly older than ASC, CH, AH, CR patients,
with the AH patients being significantly younger (Table 1).
Figure 4 Mutation distribution in the basic core promoter/precore region, at 11 loci of interest (1762, 1764, 1809–1812, 1814, 1815,
1858, 1888 and 1896), of 49 genotype D or E HBV isolates from HBeAg-negative patients. Boxed motif represents the wild- type of
genotypes D or E. Data were obtained using the Mutation Reporter Tool [36]. Mutations are shaded in grey. The frequency of the mutational
patterns did not differ between genotype D and E.
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This differs from HCC patients, infected with genotype A,
who develop cancer at a significantly younger age [28]. In
agreement with others [37,38], the HCC group had the
highest median viral load. High viral loads have been im-
plicated as a risk factor for HCC development [39].
In agreement with the study in Sudanese blood donors
[8], the predominant subgenotype of D was D1. Further-
more, following phylogenetic analysis of the complete S
region, two isolates, which lacked the 33 nucleotide dele-
tion, characteristic of genotype D, were genotype D/E
recombinants [8,33,40]. Following phylogenetic analysis
of the complete S, one isolate belonged to subgenotype
A1, and from the BCP/PC sequence, a further four were
deduced to belong to subgenotype A1 [41]. This is the
first time that subgenotype A1 has been identified in
Sudan whereas a previously sequenced genotype A iso-
late from Sudan belonged to A2 [8]. Subgenotype A1
circulates in southern and eastern Africa and Southern
Asia and A2 is found in Northern and Central Europe
and North America [42].
Discrepant results were obtained in the subgenotype as-
signment of SDAC031 when the complete S and complete
genome were analyzed. The complete S clustered as an
outlier of D4 whereas the complete genome clustered
with D6. D4 and D6 are phylogenetically closely related
(Figure 2). Further analysis using Simplot, showed that it
was a D6/D4 recombinant (Figure 3) and the majority of
signature amino acids were of D6, with the exception of a
number of amino acids, which were of D4 [33]. Geograph-
ically, D6 is distributed in theMaghreb and Madagascar,
whereas D4 in the Americas and Australia. It is possible
that D4 originated in Africa but has subsequently been re-
placed by other subgenotypes of D and the recombinant is
a remnant of the original strain/s.
The HBV genotypes show a distinct geographical dis-
tribution in Africa, with genotype D predominating in
the North, genotype E in the West and genotype A in
the South-East [9]. This is the first study to describe the
co-circulation of genotypes D and E in liver disease pa-
tients and to allow the comparison of patients infected
with these two genotypes. In agreement with a study
carried out in Sudanese blood donors [8], viral loads
were significantly higher in genotype E-infected patients
compared to genotype D-infected, with patients infected
with genotype E, showed a significantly higher frequency
of HBeAg-positivity. The small size of HBeAg allows it
to traverse the placenta and elicit HBe/HBcAg-specific T
helper cell tolerance in utero [43]. Thus babies born to
HBeAg-positive mothers have high chronicity rates than
those born to HBeAg-negative mothers [43]. The high
frequency of HBeAg-positivity in mothers infected with
genotype E, would lead to its vertical transmission and
Table 3 Pre-S region mutations and deletions
Clinical group Genotype Pre-S2 S tart codon Deletions
Region Nucleotides Amino acids Region and functions affected
ID Size Position Size position
SDAC024 CR D ATG Pre-S2 21 35-55a 7 16-22a
SDAC048 CR D ATG Pre-S1 72 2998-3069 24 51-74 S promoter, Transactivator domain
SDAC083 CR D ATG Pre-S2 21 35-55 7 16-22
SDAC097 CR D GTGb Pre-S 2 9 45- 53 3 19-21
SDAC098 CH D ATG Pre-S1 18 3129-3146 6 94-99 Hsc70 binding site, CCAAT binding factor (CBF)
binding site, Cytosolic anchorage determinant (CAD)
SDAC112 ASC D ATG Pre-S2 6 49-54 2 20-21
SDAC118 CR D ATG Pre-S2 54 4-57 18 5 to 22 pHSA binding site, Viral secretion
SDAC107 CR D ATA - - - - - -
SDAC090 CR D ATA - - - - - -
SDAC058 CR E ATG Pre-S2 9 58-66c 3 20-22c Transactivator domain
SDAC059 HCC E GTG Pre-S2 12 52-63 4 18-21 Transactivator domain
SDAC088 HCC E ATG Pre-S2 12 52-63 4 18-21 Transactivator domain
SDAC095 HCC E ATG Pre-S2 15 52-66 5 18-22 Transactivator domain
SDAC067 ASC E GTG - - - - - -
SDAC113 ASC A ACA - - - - - -
a nucleotide or amino acid position relative to genotype D (GU456684).
b mutant pre-S2 start codon italicized.
c nucleotide or amino acid position relative to genotype E (AB205191).
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explain the high prevalence and geographical restriction
of this genotype in Africa and to African emigrants to
other regions [14]. The higher HBeAg-positivity seen in
individuals infected with genotype E, could confer toler-
ance and less serious clinical manifestations than geno-
type D, where HBeAg-positivity was lower. This could
explain why genotype E prevails in the Sudanese blood
donors [8], whereas genotype D prevailed in the liver
disease patients in the present study.
The majority of the HBeAg-negativity was as a result of
the classical G1896A, which abolishes HBeAg expression
[44] and occurs in genotype D or E but not A because the
encapsidation signal secondary structure precludes this
mutation in genotype A [45,46]. Other mutations includ-
ing transcriptional A1762T/G1764A and translation initi-
ation mutations were responsible of HBeAg-negativity in a
number of patients. Three isolates had TCAT instead of
GCAC in the Kozak sequence preceding the precore
initation codon and can affect HBeAg expression at the
translational level [47]. This Kozak mutation occurred to-
gether with 1858C and 1888A (pattern 5, Figure 4), which
are characteristics of subgenotype A1 [41]. One isolate has
1858C and 1888A alone. However, following phylogenetic
analysis of the complete S region, these four isolates were
found to belong to genotype D. It is possible that these pa-
tients were co-infected with genotypes D and A or with D/
A recombinants. These possibilities can only be discrimi-
nated by complete genome cloning and sequencing.
Four different pre-S mutational patterns were identified
(Table 3). In genotype E, pre-S2 deletions were found
mainly in HCC patients, whereas in genotype D, the dele-
tion mutants were from non-HCC patients. However, the
numbers were small to reach any firm conclusions. Pre-S
deletion mutants were found in genotype E isolates
from ASCs from Guinea [48] and Sudan [8]. Pre-S
deletion/mutations affect the progression to serious
liver disease in patients infected with either genotype
B or C [49].
Six genotype E and three genotype D isolates had
preS2F22L, which is a risk factor for HCC [50,51]. Inter-
estingly, three genotype E isolates had the sM133T mu-
tation, which could possibly compromise antibody
neutralization and may represent potential vaccine
escape mutants [52]. However, because these individuals
were not vaccinated for HBV, this mutation may have
emerged as a result of host immune pressure. The
reverse transcriptase mutations rtA194T, rtV207M,
rtS213T, rtV214A and rtS215Q detected in the present
study are neither primary resistance mutations, nor
have they ever been seen in overt resistance during ther-
apy [53]. When mutations rtA194T, rtV207M rtS213T
rtV214A and rtQ215S were tested in our sensitive and
reliable in vitro resistance test system, the mutants
showed no resistance to lamivudine (LMV), entecavir
(ETV), adenofovir (ADF) and tenofovir (TDF). (Glebe
et al., unpublished observations).
Conclusion
This is the first study to molecularly characterize HBV from
Sudanese liver disease patients, who were predominantly
infected with genotypes D and E, allowing comparison of
the effect of these genotypes on clinical manifestation in
the same ethnic group.
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This paper is a follow up of the paper submitted for publication together with our Sudanese 
collaborators, which has been included in Appendix A (Mudawi et al).  In order to facilitate 
the comprehension of this section, a summary of the major findings of the Mudawi et al paper 
is provided by way of introduction.   
 
 Human Immunodeficiency (HIV) is a serious health problem in sub-Saharan Africa. HIV 
infection is complicated by co-infection with other pathogens including hepatitis B and C 
viruses (HBV and HCV) that share similar routes of infection. Co-infection with HBV or 
HCV and HIV is characterized by more rapid progression of liver disease including 
accelerated fibrosis, cirrhosis and hepatocellular carcinoma. No clear knowledge about HBV 
in the setting of HIV infection is available in Sudan, and it was important to determine this in 
order to select appropriate antiretroviral therapy. Moreover, no studies have been carried out 
to determine the presence of HBV DNA, in the absence of HBsAg, in HIV-positive Sudanese. 
Thus the aims of the study were to determine the prevalence of HBV and HCV infection and 
the prevalence of occult hepatitis B infection (OBI) among adult Sudanese HIV individuals. 
A total of 358 HIV- infected patients were enrolled in the study with a mean age + standard 
deviation (SD) of 35.2 + 9.3 years, with male: female ratio of 1.3:1.0. Mean alanine 
aminotransferase + SD (ALT) levels of the study population was 10.9+ 18.0 U/L. All 
participants tested positive to HIV antibodies using indirect ELISA. 
Of the 358 patients, 225 (62.8%) were anti- HBc IgG-positive indicating previous exposure 
to HBV infection. The mean + SD, age and ALT levels of this subpopulation were 35.3 + 9.4 
years and 11.0 + 20.9 U/L, respectively, and these values did not differ from those of the 
population as a whole. Forty two patients (11.7%) were HBsAg-positive. Mean + SD, age 
and ALT levels of the group was 34.7+ 8.7 years and 9.8 + 7.2 U/L respectively and these 
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for both HBeAg and anti-HBe. HBV DNA was detected by PCR in 96 patients (26.8%); all 
were anti-HBc IgG–positive. Forty two patients (11.7%) were HBsAg-positive and 54 
patients (15.1%) were HBsAg -negative indicating occult infection. Overall median 
[interquartile range (IQR)] viral load was 2.9[1.7-4.1] log10 IU/ml, with HBsAg-positive 
individuals having significantly higher viral loads compared to HBsAg-negative patients. 
Eight HBsAg-positive, HBeAg-positive, anti-HBe-negative patients had viral loads of 5.6 
log10 IU/ml, 24 HBsAg-positive, HBeAg-negative, anti-HBeAg-positive patients had viral 
loads of 3.8 log10 IU/ml and 10 HBsAg-positive, HBeAg/anti-HBeAg-negative had viral 
loads of 3.9 log10 IU/ml. Thirty five (9.8%) HBsAg-negative patients had a viral load < 2.3 
log10 IU/ml (< 200 IU/ml) (true OBI) and nineteen (5.3%) had viral loads >2.3 log10 IU/ml 
(>200 IU/ml) (false OBI or HBsAg-covert). One patient was reactive in both anti-HBc IgG 
and anti-HBc IgM, the patient was HBsAg-negative with normal ALT and had detectable 
HBV DNA on PCR indicating a recent HBV infection or a HBV reactivation in a patient with 
OBI. 
In conclusion in Sudan, HBsAg-negative HBV infection was detected in 15.1% of patients. 
Prevention of HBV and HIV through education and vaccination against HBV is essential in 
our setting. All HIV infected patients should be carefully screened for HBV infection, with 
HBsAg and anti-HBc Ig G antibodies prior to starting ART. Although PCR testing would 
detect OBI, which would be missed by serological testing alone, it is too expensive to include 
as a routine screening test in Sudan 
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Objectives: Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) share 
common routes of blood borne transmission. In HBV mono-infected Sudanese individuals, 
genotypes D, E and A circulate.  The objective of this study was to molecularly characterize 
HBV from HBV/HIV co-infected individuals. Methods: From 32 HBsAg-positive and 18 
HBsAg-negative sera, the polymerase overlapping the S region and the basic core promoter 
(BCP/PC) of HBV were amplified and sequenced. Results: HBV from 37 samples was 
successfully genotyped and the genotype distribution was 46% D, 21.6% E, 18.9% A and 
13.5% D/E recombinant. Compared to mono-infected individuals, the frequency of the D/E 
recombinant and genotype A was higher in HBV/HIV co-infected patients, as was the 
intragroup divergence of genotype E.  BCP/PC mutations affecting HBeAg expression at the 
transcriptional and translational levels were detected. Two HBsAg-positive individuals had 
preS deletion mutants. In the S region, the following mutations could account for the HBsAg-
negativity: sM133T, sE164G, sV168G and sS174N.  No primary drug resistance mutations 
were found.  Conclusion: In HBV/HIV co-infected Sudanese, the ratio of genotype A to non-
A was higher than that in mono-infected patients. The genotype E intragroup divergence in 
HBV/HIV co-infected individuals was significantly higher than that in HBV mono-infected 
patients.   
 
Key words: occult HBV infection, genetic diversity, deletion mutants, subgenotypes 
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INTRODUCTION  
Hepatitis B virus (HBV), the smallest DNA virus that infects humans, is a member of family 
Hepadnaviridae and it causes acute and chronic liver disease.  Human  immunodeficiency 
virus (HIV) is an enveloped RNA virus that replicates by reverse transcription 
1
. HBV and 
HIV share common routes of blood borne  transmission, but they differ in efficiency of 
transmission and in their geographic distribution 
2
.  Worldwide, it has been estimated that 
10% of the 34 million people infected with HIV, have chronic hepatitis B infection 
2
.   
In Sudan, the prevalence of HBV infection ranges from 3.9% in blood donors in Khartoum 
3
 
to 26% in patients seen in out-patient clinics in Juba in southern Sudan 
4
. It has been 
estimated that  HIV prevalence in adults in Sudan was 1.4% 
5
 and according to Sudan 
National AIDS control Programme (SNAP), this figure has decreased  to 0.52% in 2011 
6
. It 
is very difficult to surmise, from the data available, the true prevalence of HBV/HIV co-
infection in Sudan because of the paucity of data and the wide time span between studies.  
Using serological techniques, two studies carried out 24 years ago determined the prevalence 
of HBV/HIV co-infection in Sudan.  The first study showed 14% HBV infection among HIV-
negative individuals who were sexually active heterosexuals in northeast Sudan 
7
. The second 
study, among soldiers in eastern Sudan, showed 1.7% HIV infection and 25% HBsAg 
positivity, with only 0.8% being co-infected with HBV and HIV 
8
.  In a recently completed 
study, our group has shown of the 358 HIV-infected individuals from Khartoum, 225 (62.8%) 
had at least one HBV serological marker, with 129 (36%) being HBV DNA negative and 96 
(26.8%) being HBV DNA-positive by real-time polymerase chain reaction (Rt-PCR) 
9
  HBV 
DNA was detected together with HBsAg in 42 (11.7%) and without HBsAg in 54 (15.1%) of 
the participants  
9
.  Of these, 35 (9.8%) had a viral load < 200 IU/ml [< 2.3 log10 IU/ml] and 
 4 
 
therefore true occult hepatitis B infection (OBI) 
10
 and 19 (5.3%) had  viral loads >200 IU/ml 
[> 2.3 log10 IU/ml] and were therefore HBsAg-covert 
11
. 
As a result of the lack of proofreading activity of the viral polymerase, HBV displays 
considerable sequence heterogeneity, leading to its classification into at least 9 genotypes 
12-
20
, which are defined by the inter-genotypic differences of more than 7.5% in the complete 
HBV genome 
12, 21, 22
. It is considered that genotypes play an important role in treatment 
management and disease prognosis 
23-25
. In Sudan, close to 60% of liver disease patients were 
infected with genotype D (predominantly subgenotype D1), 30% infected with genotype E, 
8.5% infected with genotype A and 2.5% infected with D/E recombinant 
26
. On the other 
hand,  in Sudanese blood donors, genotype E prevails (55%), followed by genotype D (39%), 
D/E recombinant (4%)  and genotype A (2%)  
3
.  No information exists about the distribution 
of HBV genotypes in HIV-infected individuals in Sudan.   The objectives of this study were 
to genotype and molecularly characterize HBV and to determine possible virological 
characteristics that could differentiate isolates from HBsAg-positive and HBsAg- negative 
HIV-infected Sudanese. 
PATIENTS AND METHODS 
Ethical considerations: 
The study is the continuation of our previous study on HBV/HIV co-infection among adult 
Sudanese HIV patients
9.   The study was originally approved by the ethics committee of the 
Faculty of Medicine, University of  Khartoum and the National Ethics Committee at the 
Federal Ministry of Health.   All patients signed informed consent and the clinical report 
forms were completed by qualified practitioners. The study was approved by the Human 
Ethics Committee of the University of the Witwatersrand.   
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Serum samples: 
Serum samples collected from 358 HIV-positive treatment naïve patients and  96  were 
positive HBV DNA using realtime PCR
9
.  Fifty of these 96 were randomly selected for 
downstream genotyping and molecular analysis of the HBV.   
 
DNA Extraction 
DNA was extracted from 200 µL of serum using QIAamp DNA mini blood kit (QIAGEN 
GmbH, Germany), according to manufacturer‟s instructions, and eluted in 100 µL of elution 
buffer. 
Polymerase Chain Reaction (PCR) 
Two regions of the HBV genome  were  amplified: the basic core promoter/ precore 
(BCP/PC) region (1742-1900 from EcoR1) was amplified using a minor modifications of the 
method described by Takahashi and colleagues 
27
, primers 1606 (+) (1606–1625 from EcoR1 
site) and 1974 (−) (1974–1955 from EcoR1 site) were used for the first round and 1653(+) 
(1653–1672 from EcoR1 site) and 1959(−) (1959–1940 from EcoR1 site) for the second 
round.   The region 2624 – 1240 from EcoR1, covering part of the  polymerase region and 
overlapping complete S (2848 to 835 from the EcoR1 site) (P/S) region  was amplified using 
primers 2410(+) (2410–2439 from EcoR1 site) and 1314(−) (1314–1291 from EcoR1 site) for 
the first round and 2451 (+) (2451–2482 from EcoR1site) and 1280 (−) (1280–1254 from 
EcoR1 site) for the second round 
28
.  
Sequencing 
The BigDye Terminator v3.0 Cycle Sequencing Ready Reaction Kit (Applied Biosystems., 
Foster City, USA) was used and sequencing was performed using the ABI 3130XL Genetic 
analyzer (Applied Biosystems, Foster City, CA). The three overlapping fragments of the 
 6 
 
region 2624 – 1240 from EcoR1, obtained were assembled using the Fragment Merger Tool 
29
.  Sequences were deposited in GenBank, accession numbers XXXXXXXX – 
XXXXXXXX.. 
Phylogenetic analysis 
Neighbor-joining phylogenetic tree with a bootstrap of 1000 replicates was constructed  using 
MEGA5 
30
 or PHYLIP (Phylogeny inference package version 3.69). DNADIST 
consecutively with NEIGHBOR (neighbor joining) were used to generate dendrograms and 
viewed in TreeView 
31, 32
.  
RESULTS 
HBV serology, amplification and quantification of HBV DNA  
Of the 50 HBV DNA-positive patients randomly selected, 28 were males. Mean age ± 
standard deviation (SD) was 35 ± 8.1 years. ALT median [interquartile range (IQR)] was 
[6.15 (3.3-11.8)] IU/L (reference range 5–40 IU/L) 33  and the median of HBV DNA viral 
load (IQR) was [4.2 (3.56-6.67)]  log IU/ml. Thirty-two (64%) were HBsAg-positive and 18 
(36%) were HBsAg-negative. Only 6 were HBeAg-positive.   No difference in the age, 
gender, HBsAg prevalence and ALT levels was observed between 50 samples (randomly 
selected for further analyses), and the original 96 HBV DNA-positive samples 
9
.   Of the 18 
HBsAg-negative patients, 10 had viral loads < 200 IU/ml [< 2.3 log10 IU/ml], and thus 
according to the Taormina definition, were true OBI 
10
 .  The remaining 8 had viral loads > 
200 IU/ml [> 2.3 log10 IU/ml] and therefore  HBsAg-covert  infections 
11
, (Table 1). No 
difference in the age, gender and ALT levels was observed between the true OBI and 
HBsAg- covert.       
HBV genotyping and phylogenetic analysis 
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From the 50 samples, sequences were obtained from 46: 27 samples in both the BCP/PC and 
the P/S region, 12 in the BCP/PC alone and 7 in the P/S region only.  For three samples, 
however, the sequences of of the S region were not of good quality and therefore could not be 
used for genotyping.   
In total, 37 HBV isolates were successfully genotyped using one of two methods: 
1. 31 out of 37 were genotyped using phylogenetic analysis of the P/S region   (Figure 
1). 
2. The BCP/PC region sequences could be used to differentiate between genotype A and 
non-A.  Six out of 37 had 1858C characteristic of genotype A and all belonged to 
subgenotype A1 because they had 1809-1812 TCAT and 1888A.    Six samples had 
1858T characteristic of non-A genotypes but this region cannot differentiate between 
genotype D and E and thus these samples could not be genotyped.   
The genotype distribution of the 37 isolates was:  17 (46%) genotype D, 8 (21.6%) genotype 
E, 7 (18.9%) genotype A and 5 (13.5%) putative D/E recombinant. If we include the 13 
(26%)  samples that could not be genotyped, the distribution in the 50 samples was 34% 
(17/50) infected with genotype D, 16% (8/50) with genotype E, 14% (7/50) with genotype A 
and 10% (5/50) were infected with a putative D/E recombinant.  The genotype distribution 
did not differ between HBsAg-positive and HBsAg-negative sera nor between HBsAg-covert 
and OBI patients. Comparing the genotype distribution of HBV isolates in the Sudanese 
HBV/HIV co-infected individuals to mono-infected liver disease patients 
26
, the frequency of 
genotype A  and the  D/E recombinant was higher in  HIV co-infected patients (p<0.05)  
(Figure 2). 
Using the following criteria:  phylogenetic analysis of the P/S region, inter-group divergence, 
signature amino acids and geographical distribution, the HBV genotypes were further 
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classified into subgenotypes 
20
.   Ten of 17 genotype D isolates belonged to subgenotype D1 
(58.8%), 2 to D2 (11.7%), and 5 to D6 (29.5%) and the one genotype A isolate belonged to 
subgenotype A1 (Figure 1).   SDH042-OBI was an outlier of the cluster containing 
subgenotypes of D1- D3 and D5.  However, when the analysis was repeated using only the 
complete S region (2848 to 835 from the EcoR1 site) SDH042-OBI clustered with 
subgenotype D1 (Figure 1A).   
Genetic diversity of Sudanese strains 
The intra-group divergence of the HBV isolated from the HBV/HIV-co-infected individuals 
in the present study were compared to those isolated from HBV mono-infected liver disease 
patients 
26
 (Figure 3).  The intra-group divergence of genotype E from HBV mono-infected 
liver disease patients was lower than the intra-group divergence of genotype D from HBV 
mono- infected liver disease patients (p<0.05), whereas in HBV/HIV co-infected individuals 
this difference was not observed (Figure 3).  Moreover, only the intra-group divergence of 
genotype E from HBV/HIV co-infected individuals was higher than intra-group divergence 
of genotype E from HBV mono-infected liver disease patients (p<0.05).  The intra-group 
divergence of the HBV/HIV co-infected individuals was 83% higher than that in HBV mono-
infected liver disease patients for genotype E, whereas it was only 3.7% higher for genotype 
D.   
 Analysis of BCP/PC region 
BCP/PC mutations can down regulate or abolish the expression of the HBeAg at the 
transcriptional, translational or post-translational levels 
34
.   Of the 6 isolates from HBeAg-
positive sera, two had mutations at the BCP: [SDH052 (HBsAg-positive- genotype D] had 
A1762G and [SDH084 (HBsAg-positive- genotype E)] had A1762T/G1764A. The remaining 
4 isolates, from HBeAg-positive patients, had wild type BCP/PC. Thirty of the 44 isolates 
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from HBeAg-negative individuals (17 HBsAg-positive: 13 HBsAg-negative) were 
successfully amplified and sequenced in the BCP/PC region. Twenty-five isolates had 
genotype assignments: 11 belonged to genotype D, 5 to genotype E, 6 to genotype A and 3 
were D/E recombinants.  The mutations found in the isolates from HBeAg-negative patients 
are shown in Table 2.  Three isolates had A1762T alone and 3 isolates had start codon 
mutations at 1814-1816.  Ten of the 26 isolates had G1896A. Even though 1858T is found in 
both genotypes D and E and allows for G1896A to occur, G1896A was found more 
frequently in genotype E and the D/E recombinant compared to genotype D (p<0.05).  
Moreover, G1896A occurred more frequently in isolates from HBsAg-positive compared to 
HBsAg-negative individuals (p< 0.05).  G1896A occurred together with A1762T/G1764A in 
two genotype E isolates.   The mutation C1766T was found in 5 genotype A isolates only 
(p<0.05).   
Analysis of the pre-S1, pre-S2, Surface and polymerase regions 
The sequence of the P/S region (2624- 1240 from EcoR1 site) was obtained for 31 HBV 
isolates from HBV/HIV co-infected individuals. Of the 31 isolates, 20 from HBsAg-positive 
and 11 from HBsAg-negative. PreS deletions were found in two genotype E isolates: 
SDH084-HBsAg-positive had a 93 nucleotide deletion in the preS1 and preS2 regions, from 
3178 to 58 from EcoR1 site, which lead to an 8 amino acid deletion from position 111 to 118 
in the preS1 and 23 amino acids, were deleted from position 1 to 23, in the preS2.  SDH120- 
HBsAg-positive had a 36 nucleotide deletion in the preS2 starting from nucleotide 5 to 40 
from EcoR1 site, which results in a 12 amino acid deletion from position 6 to 17.  Table 3 
shows the various mutations in the polymerase and overlapping S regions.   
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DISCUSSION 
In our recently completed study of 358 HIV-positive participants, 225 (62.8%) had 
serological evidence of past or current HBV infection.  HBV DNA was detected in 96 
(26.8%):   42 (11.7%) with overt HBsAg-positive infection and 54 (15.1%) with HBsAg-
negative and anti-HBc as a marker of past HBV infection 
9
.  Fifty of the 96 HBV DNA-
positively samples were randomly selected for molecular characterization of the HBV.   
The distribution ratio  of  HBV genotypes D and E, found in HBV/HIV co-infected 
individuals (Figure 2),  did not differ from that  found in HBV mono-infected liver disease 
patients and there was no difference in their clustering in the phylogenetic tree (Figure 1) 
26
.  
However, genotype A and the putative D/E recombinant were found in a higher frequency in 
HBV/HIV co-infected individuals compared to HBV mono-infected liver disease patients 
(genotype A: 18.4% versus 8.6%, and D/E: 13.2% versus 2.5%) (p < 0.05).  Genotypes D, E, 
A and D/E recombinant were found in Sudanese blood donors, with genotype E 
predominating 
3
.  
With regard to the subgenotype distribution, in agreement with the previous studies of HBV 
in Sudan 
3, 26
, subgenotype D1 was found to predominate in the HBV/HIV co-infected 
individuals (Figure 1). Thus the predominant subgenotype of D found in Sudan is D1.  This is 
the subgenotype of D that prevails in the Mediterranean, Arabian subcontinent and in China 
30 
. Subgenotype A1 was found circulating in in HBV/HIV-co-infected individuals and the 
liver disease patients 
26
, whereas  subgenotype A2 was found in blood donors  
3
.  
Subgenotype A1 predominates in eastern and southern Africa  and subgenotype A2 is the 
subgenotype of A  predominating outside Africa 
35
  .   
Following the calculation of the intra-group divergence of the  genotype D and E isolates 
from HBV mono-infected liver disease patients and HBV/HIV co-infected individuals, it was 
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found that genotype E from HBV mono-infected liver disease patients had a  low diversity  of 
1.8% compared to 2.7%  for genotype D from HBV mono-infected liver disease patients 
(p<0.05) (Figure 4). Genotype E has been characterized to have a low diversity compared to 
other genotypes and subgenotypes of HBV.  Using more than 400 sequences of HBV isolated 
from west African countries, the genetic diversity of genotype E was found to be 0.73% for 
the S gene and 1.7% for the complete genome 
36
. Complete genomes of genotype E isolates 
from Namibia, Angola and Madagascar differed from each other by only 1.2% 
37
. Genotype 
D has been shown  to be the most divergent genotype after genotype C 
38
.   The significant 
difference in the intragroup divergence of  genotypes D and E seen in mono-infected 
individuals, however, was not seen in HBV/HIV co-infected individuals and the intra-group 
divergence of genotype E in HBV/HIV co-infected individuals was significantly higher than 
that in HBV mono-infected liver disease patients (Figure 4).  It appears that in HBV mono-
infected liver disease patients, who are immune competent, the genetic diversity of genotype 
E is constrained whereas in HBV/HIV co-infected individuals there is an expansion of the 
quasispecies.  HIV infection and its associated immune suppression might alter the 
heterogeneity of the virus and increase the genetic variability of HBV 
39
, which may be as a 
result of the reactivation of occult HBV that can survive in the presence of immune selection.   
The 81% prevalence of HBeAg-negativity in HBV/HIV co-infected patients 
9 was lower than 
in HIV- negative patients, where 88 % were HBeAg
 –negative 26. When comparing the 
mutation distribution in BCP/PC, at 10 loci that can affect HBeAg-expression  (1762, 1764, 
1809 –1812, 1814–1816 and 1896), we found that mutations at 1762 and 1764 occurred less 
frequently in isolates from HBV/HIV co-infected individuals compared to those from mono-
infected liver disease patients (p<0.05).  Mutations at 1762 1764 can reduce the transcription 
of precore mRNA, resulting in lower expression of HBeAg 
40
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Two genotype E HBV isolates from HBsAg-positive HBV/HIV co-infected individuals had 
deletions in the preS1 and preS2 regions. No deletions were detected in genotype D isolates.  
The 12 amino acid deletion mutant was found in the pre-S2 whereas the 31 amino acid 
deletion covered the 3‟ pre-S1 and 5‟pre-S2.  Similar deletion mutants were found in 
genotype D and E isolates from Sudanese HBV mono-infected liver disease patients 
26
 but 
only in genotype E isolates from blood donors in Sudan 
3
 and Guinea 
41
.   The deletion 
mutants in HBV genotype E isolates from HBV mono-infected liver disease  patients were 
mainly in hepatoceullar carcinoma patients whereas this was not the case for genotype D 
isolates 
26
.  Deletion mutants  in the pre-S have been implicated in the progression of liver 
diseases in genotypes B and C 
42
 and the development of hepatoceullar carcinoma in 
genotype A 
43
.  The presence of deletion mutants in HBV from HBV/HIV co-infected 
individuals has been described in genotype A, both subgenotype A1 
44
 and subgenotype A2 
45
.  PreS2F22L was found in four isolates from HBsAg-positive HBV/HIV co-infected 
individuals and was found to be significantly associated with G1896A.   PreS2F22L has been 
significantly associated with  cirrhosis 
46
 and has been shown to be a s risk factor for 
development of HCC in Chinese patients infected with genotype C 
47
 and in Indian patients 
infected with genotype D 
46, 48
.   HIV infection has been intimated to increase the 
hepatocarcinogenic potential of HBV 
49
.   
In agreement with other studies in HIV-infected individuals, HBsAg-negativity was frequent 
44, 50
.  The HBsAg-negativety resulted in both OBI (viral loads < 200 IU/ml[< 2.3 log10 
IU/ml]) 
10
 and HBsAg-covert infection (viral loads > 200 IU/ml [> 2.3 log10 IU/ml]) 
11
.  In 
the case of OBI, the inability to detect HBsAg could be as a result of its presence at very low 
concentrations, below the detection limits of the assay.  In the case of the HBsAg-covert 
infection, the HBsAg-negativity may be the result of the presence of detection escape 
mutations in the „a‟ determinant.  Although we found no mutational pattern that could 
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differentiate the HBV isolated from HBsAg-negative individuals from those isolated from 
HBsAg-positive ones, there were a number of mutations that could account for the HBsAg-
negativity (Table 3).   These mutations include ps2R48T, sM133T, sE164G, sV168G and 
sS174N and have also been found in strains circulating in HBsAg-negative HIV infected 
individuals infected with subgenotype A1 of HBV 
44
.  Of particular interest is S174N that has 
only been detected in HBV from HBsAg-negative HBV/HIV co-infected individuals 
44, 51
 and 
has been described as a reactivation marker in a single patient infected with subgenotype A2 
51
.  No primary drug resistance mutations were detected in the present study.  This is not 
unexpected because all patients recruited in this study were treatment naïve.   
 The distribution of genotypes D and E of HBV found in HBV/HIV co-infected individuals 
did not differ from those found in HBV mono-infected liver disease patients.  However, the 
ratio of genotype A to non-A in HIV co-infected individuals was found to be higher than that 
found in mono-infected patients.  A predominance of genotype A of HBV in HIV co-infected 
individuals has also been reported by others 
44, 45, 52
. Subgenotype A1 is the predominant 
strain circulating in countries neighbouring Sudan, including Kenya 
53
 and Uganda 
54
.  In a 
previous study, it was shown that the only factor that differentiated HBV-positive HIV-
infected individuals from those who were HBV-negative was the number of lifetime sexual 
contacts 
11
, thus implicating sexual transmission of this subgenotype 
44
   Furthermore, the 
intragroup divergence of genotype E in HBV/HIV co-infected individuals was significantly 
higher than that in HBV mono-infected patients.  We detected preS deletions, mutations 
associated with severe liver disease, detection-escape mutations as well as reactivation 
markers in the HBV isolated from HIV co-infected individuals.  These alterations can have 
important implications in exacerbating the clinical manifestations of HBV infection, its 
detection and clinical management.   
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Table 1: Characteristics of HBV isolated from HIV-positive individuals 
 
    Patient characteristics Viral characteristics HBV Infection 
HBsAg 
status 
isolate Gender Age ALT IU/L Genotype Subgenotype Viral load IU/ml log 
 
Positive 
SDH001 Male 50 24 D D1 6.82 Overt Infection 
SDH020 Female 26 19.9 E  NA 4.25 Overt Infection 
SDH025 Female 23 7.6 D D2 6.86 Overt Infection 
SDH028 Male 31 10.6 - - 4.74 Overt Infection 
SDH043 Female 34 4.6  - - 3.46 Overt Infection 
SDH049 Male 45 11.8 D D1 5.65 Overt Infection 
SDH050 Male 48 0.4 D D1 9.16 Overt Infection 
SDH052 Male 38 16.1 D D6 7.28 Overt Infection 
SDH065 Male 32 18.2 D D1 8.19 Overt Infection 
SDH071 Male 35 1.2 D/E NA 4.56 Overt Infection 
SDH075 Female 32 5.5 D D1 3.73 Overt Infection 
SDH078 Male 25 7.6  - - 4.08 Overt Infection 
SDH079 Male 25 11.7  - - 3.34 Overt Infection 
SDH084 Male 25 8.9 E NA 6.23 Overt Infection 
SDH097 Female 23 6.4 D/E NA 4.53 Overt Infection 
SDH111 Female 36 7.6  - - 3.67 Overt Infection 
SDH113 Female 42 27.5 D/E NA 3.37 Overt Infection 
SDH116 Male 23 5.5 E NA 4.19 Overt Infection 
SDH120 Male 27 17.8 E NA 7.83 Overt Infection 
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Positive 
SDH122 Female 38 8.4  - - 4.00 Overt Infection 
SDH123 Female 35 15.2 D D1 7.20 Overt Infection 
SDH146 Female 33 8  - - 4.17 Overt Infection 
SDH153 Female 28 5.9 D D1 4.16 Overt Infection 
SDH184 Female 30 5.9 A A1 7.00 Overt Infection 
SDH188 Male 28 4.2 E NA 4.95 Overt Infection 
SDH189 Female 30 0.8  -  - 3.42 Overt Infection 
SDH193 Male 45 5.9 E  - 8.16 Overt Infection 
SDH194 Female 37 0.8 D D6 3.14 Overt Infection 
SDH195 Male 38 3.3 A A1 3.59 Overt Infection 
SDH196 Male 38 13.1  - - 3.13 Overt Infection 
SDH199 Female 35 3.8 A A1 3.08 Overt Infection 
SDH200 Male 45 5.6 A A1 7.12 Overt Infection 
Negative 
SDH005 Female 45 12.3 D D1 <2.3 OBI 
SDH007 Female 30 14 D D2 3.55 HBsAg- covert 
SDH022 Male 27 7.2 D D1 <2.3 OBI 
SDH036 Female 30 5.9  - - <2.3 OBI 
SDH042 Male 41 0.8 D D1 <2.3 OBI 
SDH058 Male 42 8.4 D D6 2.33 HBsAg- covert 
SDH061 Male 50 1.4 D D6 <2.3 OBI 
SDH087 Male 22 11.8 D D2 <2.3 OBI 
SDH119 Female 35 11.8 D/E NA <2.3 OBI 
SDH126 Male 45 2.9 A A1 <2.3 OBI 
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Negative 
SDH130 Male 37 2.2  - - 3.92 HBsAg- covert 
SDH147 Female 23 4.6  - - 5.45 HBsAg- covert 
SDH152 Female 38 2.1 E NA 4.62 HBsAg- covert 
SDH160 Male 37 1.2  - - 4.01 HBsAg- covert 
SDH172 Female 35 3.8 A A1 <2.3 OBI 
SDH174 Male 40 3.3 E NA 4.38 HBsAg- covert 
SDH192 Male 54 7.9 D/E NA 2.78 HBsAg- covert 
SDH197 Male 40 2.5 A A1 <2.3 OBI 
 
(-): No genotype assignment, NA: not applicable, OBI: occult hepatitis B infection, HBsAg-covert: HBsAg-negative with viral loads >200 IU/ml 
[> 2.3 log10 IU/ml] 
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Table 2: Molecular characteristics of the BCP/PC region  of HBV isolated from HBeAg-negative HIV co-infected individuals 
HBsAg Isolate Genotype Subgenotype 
viral load 
IU/ 
ml log 
1753 
1762-
1764 
1766 1768 
1809-
1812 
1814-
1816 
1817 1850 1858 1862 1888 1896 1899 
Positive 
SDH025 D D2 6.86 T  AG  C  T  GCAC  ATG  C  T  T  G  G  A  G 
SDH049 D D1 5.65 T  AG  C  T  GCAC  ATT  C  T  T  G  G  G  A 
SDH065 D D1 8.19 T  AG  G  T  GCAC  ATG  C  T  T  G  G  A  G 
SDH071 D/E  NA 4.56 T  AG  C  T  GCAC  ATG  C  T  T  G  G  A  G 
SDH075 D D1 3.73 T  AG  C  T  GCAC  ATG  C  T  T  G  G  G  C 
SDH097 D/E  NA 4.53 T  AG  C  T  GCAC  ATG  C  T  T  G  G  A  A 
SDH116 E  NA 4.19 T  AG  C  T  GCAC  ATG  C  T  T  G  G  A  A 
SDH120 E  NA 7.83 T  AG  G  T  GCAC  ATG  C  T  T  G  G  A  G 
SDH123 D D1 7.2 G  TG  T  A  GCAC  ATG  C  T  T  G  G  G  G 
SDH153 D D1 4.16 T  AG  C  T  GCAC  ATG  C  T  T  G  G  A  G 
SDH188 E  NA 4.95 T  TA  C  T  GCAC  ATG  C  T  T  G  G  A  G 
SDH194 D D6 3.14 G  AG  C  T  GCAC  ATG  C  T  T  G  G  G  G 
SDH195 A A1 3.59 T  AG  T  T  TCAT  ATG  C  A  C  G  A  G  G 
SDH199 A A1 3.08 T  AG  C  T  TCAT  ATG  C  A  C  G  A  G  G 
SDH200 A A1 7.12 T  GT  T  T  TCAT  ATG  C  A  C  G  A  G  G 
Negative 
SDH007 D D2 3.55 T  AG  C  T  GCAC  AAG  C  T  T  G  G  G  G 
SDH042 D D1 <2.3 T  AG  C  T  GCAC  ATG  C  T  T  G  G  G  G 
SDH058 D D6 2.33 G  TG  C  T  GCAC  ATG  C  T  T  G  G  G  G 
SDH061 D D6 <2.3 G  TG  C  T  GCAC  ATG  C  T  T  G  G  G  G 
SDH126 A A1 <2.3 T  AG  T  T  TCAT  ATG  C  A  C  G  A  G  G 
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Negative 
SDH152 E  NA 4.62 T  AG  C  T  GCAC  ATT  C  T  T  G  G  G  G 
SDH172 A A1 <2.3 T  AG  T  T  TCAT  ATG  C  A  C  T  A  G  G 
SDH174 E  NA 4.38 T  AG  C  T  GCAC  ATG  C  T  T  G  G  G  G 
SDH192 D/E  NA 2.78 T  AG  C  T  GCAC  ATG  C  T  T  G  G  A  A 
SDH197 A A1 <2.3 T  AG  T  T  TCAT  ATG  C  A  C  G  A  G  G 
S: S region, RT/POL: reverse transcriptase/ Polymerase, P: positive, N: Negative.  
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Table 3:S and polymerase mutations found in  HBV isolated from HBV/HIV co-infected individuals.  
Type of mutation HBV region Mutation Genotype HBsAg-status 
Vaccine and immune escape 
PreS1 I48E A Positive 
PreS2 
Q10R D/E Positive 
R48T 
E Positive 
D Positive 
D Positive 
D Negative 
PreS2F22 mutation PreS2 
F22S 
E Positive 
D Positive 
F22L 
D/E Positive 
E Positive 
E Positive 
D/E Positive 
a' determinant mutation S 
P120T E Positive 
M133T D Negative 
G145R E Positive 
E164G 
D/E Negative 
E Negative 
HBV “Reactivation” marker S V168G 
E Positive 
A Positive 
D/E Negative 
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HBV “Reactivation” marker S S174N* 
D Negative 
D/E Negative 
D/E Negative 
Overlapping polymerase drug resistant mutations RT/POL 
A181 D/E Negative 
Q215S 
D Positive 
D positive 
I233 E positive 
NA: not applicable, * Significant association 
 29 
 
Figure 1  
 A rooted phylogenetic tree of 31 HBV isolates from HBV/HIV co-infected individuals of the 
region 2624 – 1240 from EcoR1, covering the polymerase region and overlapping complete S 
(2848 to 835 from the EcoR1 site). The 30  isolates sequenced in the present study have the 
prefix SDH and are shown in bold, followed by the clinical status (HBsAg-positive, HBsAg-
covert and OBI).  These were compared using neighbour-joining with 30 HBV sequences 
from  Sudanese liver disease patients
26 
 in italic and 55 reference  sequences, labelled by their 
accession numbers and country of origin. Bootstrap statistical analysis was performed using 
1000 datasets and the percentages are indicated on the nodes. Box A illustrates the clustering 
of SDH042-OBI  relative to the subgenotypes of D when only the complete S (2848 to 835 
from EcoR1 site) was analyzed.   The different subgenotypes are represented by different 
shapes: Subgenotype D1 (square), D2 (triangle), D3 (inverted triangle) and D5 (circle).    
Figure 2 
The ratio of the distribution of genotypes in HBV in mono-infected liver disease patients 
26
 
compared to  HBV/HIV co-infected individuals.   
Figure 3 
Comparison of the genetic diversity of genotype D and E HBV isolated from HBV mono-
infected  liver disease patients and HBV/HIV co-infected individuals. 
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Abstract
Aims: The aims of this study were to develop bioinformatics tools to explore ultra-deep pyrosequencing (UDPS) data, to test
these tools, and to use them to determine the optimum error threshold, and to compare results from UDPS and cloning
based sequencing (CBS).
Methods: Four serum samples, infected with either genotype D or E, from HBeAg-positive and HBeAg-negative patients
were randomly selected. UDPS and CBS were used to sequence the basic core promoter/precore region of HBV. Two online
bioinformatics tools, the ‘‘Deep Threshold Tool’’ and the ‘‘Rosetta Tool’’ (http://hvdr.bioinf.wits.ac.za/tools/), were built to
test and analyze the generated data.
Results: A total of 10952 reads were generated by UDPS on the 454 GS Junior platform. In the four samples, substitutions,
detected at 0.5% threshold or above, were identified at 39 unique positions, 25 of which were non-synonymous mutations.
Sample #2 (HBeAg-negative, genotype D) had substitutions in 26 positions, followed by sample #1 (HBeAg-negative,
genotype E) in 12 positions, sample #3 (HBeAg-positive, genotype D) in 7 positions and sample #4 (HBeAg-positive,
genotype E) in only four positions. The ratio of nucleotide substitutions between isolates from HBeAg-negative and HBeAg-
positive patients was 3.5:1. Compared to genotype E isolates, genotype D isolates showed greater variation in the X, basic
core promoter/precore and core regions. Only 18 of the 39 positions identified by UDPS were detected by CBS, which
detected 14 of the 25 non-synonymous mutations detected by UDPS.
Conclusion: UDPS data should be approached with caution. Appropriate curation of read data is required prior to analysis,
in order to clean the data and eliminate artefacts. CBS detected fewer than 50% of the substitutions detected by UDPS.
Furthermore it is important that the appropriate consensus (reference) sequence is used in order to identify variants
correctly.
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Introduction
The continued improvement of DNA sequencing technologies
has led to the development of next generation sequencing (NGS)
methods, including ultra-deep pyrosequencing (UDPS), which are
capable of sequencing many thousands of nucleotides, quickly and
at a low cost per nucleotide. These technologies have overcome
the disadvantages of the traditional dye-terminating DNA
sequencing technology developed by Frederick Sanger [1]. These
disadvantages include the relatively high cost per nucleotide, in
terms of money and time, and the fact that Sanger sequencing is
only capable of detecting sequence variants, which are present in
20% or more of a quasispecies population [2,3]. Moreover, NGS
methods also overcome several of the drawbacks of cloning based
sequencing (CBS), such as the time, money and expertise required
to prepare samples, especially when a large number of clones is
required [4]. NGS methods are used primarily for de novo or ‘‘shot-
gun’’ sequencing of new or known genomes. This produces a very
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large number of short reads, which are then assembled to produce
a complete sequence. Several algorithms and tools exist to process
these short reads [5]. In addition to producing short reads, the
pyrosequencing platform can be used for amplicon re-sequencing
(UDPS). These longer reads are typically an amplicon covering a
genomic region of interest. At present, the GS Titanium UDPS
chemistry produces reads of approximately 400 bases in length.
Few bioinformatic tools, which are affordable and accessible to
resource-constrained environments, are currently available to
assist with the processing and analysis of amplicon re-sequencing
data. The Roche AVA software (http://www.454.com/products/
analysis-software/#amplicon-tabbing), although free of charge,
can only be installed on a computer running a particular GNU/
Linux distribution, and a number of commercial software
packages cost several thousand US dollars for a single license.
Alignment and visualization tools, which are used routinely for
smaller datasets, are not suitable for datasets containing hundreds
or thousands of reads. Additionally, many of these software
solutions require a level of technical expertise, which many
biological researchers may not possess.
Pyrosequencing is an error-prone technique [6]. Distinguishing
between a true biological variant and an error (artefact) is a vital
step in analysing pyrosequencing data. Although a number of
studies discuss error correction in pyrosequencing data [6,7], there
is currently no consensus regarding the error threshold, which
should be applied. Knowledge of well-characterized regions of a
genome is important in order to develop tools to examine
pyrosequencing data and to distinguish between artefacts and true
variations.
Hepatitis B virus (HBV) displays remarkable sequence hetero-
geneity, with 9 genotypes (named A to I) currently recognized
[8,9]. The precore/core (PC/C) open reading frame (ORF) of
HBV encodes for both the hepatitis B e antigen (HBeAg) and the
core protein (HBcAg). This region is preceded by the basic core
promoter (BCP) region, which controls transcription of both the
PC/C mRNA and the pregenomic RNA (pgRNA) during the
replication cycle [10]. The BCP/PC ORF overlaps the X ORF.
HBeAg is a soluble, non-particulate protein that is secreted in the
serum or expressed on the surface of the hepatocyte [11,12].
Conventionally, HBeAg expression is an indicator of active HBV
infection and on-going viral replication [12]. However, HBeAg
expression may be reduced or completely suppressed by various
viral mutations, even in the presence of viral replication.
Mutations in two regions may affect HBeAg expression: precore
mutations (for example, G1896A) [13] and BCP mutations (for
example, A1762T/G1764A) [14]. The viral capsid is composed of
HBcAg [15]. Mutations may occur more frequently in N-terminal
or central region of the core protein, which does not overlap other
reading frames [16].
Using a segment of this well-characterized BCP/PC/C region
of HBV as a model, the objectives of this study were to:
N develop bioinformatics tools to explore UDPS data,
N test and use them to determine the optimum error threshold,
and
N compare results between UDPS and CBS using HBeAg-
positive and –negative sera infected, with either genotype D or
E.
Materials and Methods
Sample Selection
Written informed consent was obtained from all participants
and the consent was approved by the Sudanese Ministry of Health,
who gave permission for the sera to be used for research purposes.
The Human Ethics Committees of the University of the
Witwatersrand and the University of Khartoum approved the
study. Four serum samples were selected from our previous study
on HBV from monoinfected individuals, where the HBV genotype
was determined using phylogenetic analysis [17]. Sample #1 was
HBeAg-negative and infected with genotype E of HBV (GenBank,
KF170783), sample #2 was HBeAg-negative, genotype D
(KF170739), sample #3 was HBeAg-positive, genotype D
(KF170740) and sample #4 was HBeAg-positive, genotype E
(KF170788).
Wet Laboratory Work
Ultra-Deep Pyrosequencing (UDPS). A region of the HBV
genome (1653–1959 from EcoR1 restriction site) was amplified
using a slight modification of a previously described method [18].
Primers 1606 (+) and 1974 (2) were used for the first round PCR,
and 1653 (+) and 1959 (2) for the second round PCR. The first
round PCR was followed by gel-purification using Zymoclean Gel
DNA Recovery Kit (Zymo Research Corp, Irvine, CA, USA). For
the second round PCR, modified primers, which were ligated to
adaptors and tags, were used (Table 1). Following second round
PCR, the amplicons were gel-purified and subjected to UDPS in
the forward direction on the Roche 454 GS Junior platform (454
Life Sciences, Roche Company, Switzerland), which provided
reads covering the region of interest (coordinates 1653–1959). The
UDPS sequencing data has been submitted to the GenBank SRA
database, as BioProject accession: PRJNA239442 and the
following are the BioSample accessions: SAMN02664575,
SAMN02664576, SAMN02664577, SAMN02664578.
Cloning Based Sequencing (CBS). After nested PCR, the
307 nucleotide amplicon (1653–1959 from EcoR1 site) was gel-
purified and cloned into pTZ57R/T vector (55 ng/ml) using
Instaclone PCR Cloning Kit (Fermentas, Waltham, MA, USA),
and transformed into TOP10 Escherichia coli (Invitrogen, Carlsbad,
CA, USA). The transformants were grown on Ampicillin plates.
Positive clones were identified by restriction fragment length
polymorphism (RFLP) assay. At least 20 clones per sample were
sequenced by direct sequencing, using a BigDye Terminator v3.0
Cycle Sequencing Ready Reaction Kit (Applied Biosystems.,
Foster City, USA) on an ABI 3130XL Genetic Analyzer (Applied
Biosystems). The sequencing primer used was M13 forward (59-
GTAAAACGACGGCCAGT-39). A phylogenetic tree was gen-
erated as described previously [17]. Clone sequences have been
deposited in GenBank: Genotype D: KJ496256-KJ496297,
Genotype E: KJ496206-KJ496255.
Dry Laboratory Work
Data pre-processing. UDPS data for three sequencing runs,
for each of the four samples, was processed and analyzed as shown
in the flow diagram (Figure 1). The data from each run, for each
sample, was processed individually. Separate binary standard
flowgram format (SFF) files were opened in the R statistical
programming language [19], using the ‘‘raw’’ clip-mode param-
eter (which does not perform any clipping or trimming) of the
‘‘rSFFreader’’ library [20]. Sequence data were searched for the
forward and reverse primer sequences and the adaptor sequence
for verification. Sequence lengths in each file were plotted and
examined statistically (data not shown).
Ultra-Deep Pyrosequencing of Hepatitis B Virus
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Figure 1. Flow diagram of the analysis procedure used for the UDPS data.
doi:10.1371/journal.pone.0095377.g001
Table 1. Sequences of HBV-specific primers, tags and adaptors used for ultra-deep pyrosequencing.
Position from EcoRI site HBV specific target sequence Tag sequences" Adaptor sequencesJ
PCR 1 1606 (+) [1606–1625] 59-GCATGGAGACCACCGTGAAC-39 No tag No adaptor
1974 (2) [1974–1955] 59GGAAAGAAGTCAGAAGGCAA-39 No tag No adaptor
PCR 2 1653 (+) [1653–1672] 59-CGTATCGCCTCCCTCGCGCCATCAG-39 ACACGACGACT1 CAT AAG AGG ACT CTT
GGA CT
ACACGTAGTAT2
ACACTACTCGT3
ACGACACGTAT4
1959 (2) [1959–1940] 59-CTATGCGCCTTGCCAGCCCGCTCAG-39 No tag GGC AAA AAC GAG
AGT AAC TC
"Short specific sequences used to label the different samples: 1: sample #1; 2: sample #2; 3: sample #3; 4: sample #4.
JShort specific sequence used to ligated onto the ends of the fragments. These adaptors provide priming sequences for both amplification and sequencing of the
sample-library fragments.
doi:10.1371/journal.pone.0095377.t001
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The distribution of all sequence lengths was examined and a
length range was selected, which excluded reads with very low
counts. Several Linux command-line BASH scripts and Python
programming language scripts (available on request) were written to
include only reads within a specified length range (between 330 to
360 nucleotides) for further processing. A genotype D reference
sequence (GU456684) was then added to each dataset, and the file
was aligned with the Muscle program [21]. Each alignment was
then processed by a Python script, which scanned the reference
sequence in the alignment and removed any reads from the
alignment with an insertion (a residue aligned with a gap in the
reference sequence). In the remaining alignment (excluding reads
with insertions), positions (columns), containing only gaps, were
collapsed and this alignment was ‘‘Dataset 1’’. The repeated runs
for all ‘‘Dataset 1’’ sequences for each sample were then combined
into one dataset, the final ‘‘Dataset 1’’. The file containing reads
with insertions was ‘‘Dataset 2’’ for each run and these were
processed individually because of variable read lengths, as a result
of insertions at different positions in the reads.
Development of deep threshold tool. For pyrosequencing
data of human immunodeficiency virus (HIV), a probability of
error, ranging from 0.5% to 1%, has been used [6]. In the present
study, using HBV data, a web-based tool (the ‘‘Deep Threshold
Tool’’) (http://hvdr.bioinf.wits.ac.za/tools/) was developed to
examine the number of errors in each position (column) in an
alignment, depending on the probability of error value. In order to
examine the number of errors, the tool requires an input
alignment in FASTA format, the lower and upper bounds of the
probability of error, and an increment value (Figure 2A). A
nucleotide mapping offset can be specified, so that the resulting
output coordinates reflect the correct position of the sequence in
the entire genome. Potentially untidy ends of reads (such as the
reverse primer region) can be excluded from the analysis by
specifying a length shorter than the sequence length.
Statistical calculation of the threshold. A nucleotide was
considered an ‘‘error’’ if its frequency in a column in the alignment
was less than the threshold, which was determined as follows. An
expected frequency of E=probability of error6read depth
(R) was used. A Pearson’s x2 test statistic was calculated as follows:
Figure 2. The input pages of the bioinformatics tools (A) ‘‘Deep Threshold Tool’’. The first field specifies the input FASTA file. Fields are
available for the user to specify the nucleotide offset mapping of the first position in the input file, the number of nucleotides (length) to process, the
starting and ending probabilities of error to examine, and the probability of error increment (step) to use. (B) ‘‘Rosetta Tool’’. The first field specifies
the input FASTA file. Fields are available for the user to specify the nucleotide offset mapping of the first position in the input file, the position of the
first in-frame nucleotide of the coding region of interest, the last in-frame nucleotide of the coding region of interest, the amino acid offset of the first
amino acid in the coding region of interest, and the probability of error to use.
doi:10.1371/journal.pone.0095377.g002
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with O being the observed value, starting at 1. If M was less than
the x2 distribution (with a= 0.05 and one degree of freedom), then
O was incremented by a value of one and the test was repeated.
The value for O at which the x2 distribution was exceeded, was
considered the threshold value (count). This threshold was
calculated for each position in the alignment. Any nucleotide
with a frequency below this threshold was considered an error or
artefact.
Development of rosetta tool. Amino acid data were
examined using the newly-developed ‘‘Rosetta Tool’’. This tool
requires the same input file as the ‘‘Deep Threshold Tool ‘‘. It also
requires a nucleotide offset mapping and the start and end
positions of a protein region. This does not have to include the
position of the start or stop codon; any region of a protein can be
processed, as long as the number of nucleotides specified by the
range is a multiple of three. The probability of error at which the
data must be analyzed is also required (Figure 2B).
Results
A total of 10952 reads were generated on the 454 GS Junior
platform for the three runs for all four samples. Of these, 9738
reads (88.9%) were included in the study (2002, 3049, 1955 and
2732 reads for samples 1, 2, 3 and 4, respectively) and 1214 reads
(11.1%), which were considered either too short or too long, were
excluded. These 9738 reads were split into Dataset 1 (8967 reads,
92.1%) and Dataset 2 (771 reads, 7.9%) (Figure 1). Ninety-two
clones were generated for all four samples: 23 clones for sample
#1, 22 for sample #2, 20 for sample #3 and 27 for sample #4.
Deep Threshold Tool Output
The output page generated by the Deep threshold Tool includes
a table for each increment of the probability of error (Figure 3),
which shows the distribution of nucleotides at all columns at which
at least one base can be considered an ‘‘error’’. Because a
nucleotide was considered an ‘‘error’’, if its frequency in a column
in the alignment was less than the threshold, any variation above
the threshold was considered a legitimate variant for that
probability of error (Figure 4). Figure 5 summarizes the results
graphically. This summary table was consulted and the lowest
probability of error, at which established, well-characterized
variants are still detected, was selected. In the present study, the
Figure 3. An example section of the output from the ‘‘Deep Threshold Tool’’, showing the two tables of output provided for each
probability of error examined. The ‘‘expected’’ and ‘‘threshold’’ counts are shown in the top table, as well as the number of interesting columns
(those columns containing at least one mutation at above-threshold frequency), and a list of the interesting columns. The bottom table provides
detailed output, showing the number of each residue occurring in each interesting column.
doi:10.1371/journal.pone.0095377.g003
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lowest probability of error at which substitutions at positions 1753,
1773 and 1896 are still evident was 0.5%, and this was taken to be
our probability of error value.
Rosetta Tool Output
Alignments generated from direct sequencing, UDPS or CBS
can also be submitted to the Rosetta Tool. This would typically be
done in order to make use of the nucleotide/amino acid alignment
viewer component of the tool. The tool produces a number of
output tables (Figures 6–8). Figure 6 is an alignment showing each
codon followed by the amino acid. Amino acids have been colour-
coded according six different categories: Aliphatic (Glycine,
Alanine, Valine, Leucine and Isoleucine), Hydroxyl (Serine,
Cysteine, Threonine and Methionine), Cyclic (Proline), Aromatic
(Phenylalanine, Tyrosine and Tryptophan), Basic (Histidine,
Lysine and Arginin) and Acidic (Aspartate, Glutamate, Asparagine
and Glutamine). The display of nucleotides or amino acids can be
toggled on or off for ease of reference. Figure 7 shows the
distribution of each residue at each position at which at least one
residue is considered an error. Such error residue counts are
highlighted with a black background for reference. Figure 8
contains separate tables for each codon at which at least one
residue is an ‘‘error’’, and shows the distribution of codons and
amino acids at this position. Synonymous and non-synonymous
mutations can be differentiated. Rows containing substitutions
occurring below the threshold, ‘‘error’’ nucleotides are highlighted
with a black background.
In order to analyze the data downstream, the Rosetta Tool
produces a ‘‘masked’’ data file, which is generated by replacing all
‘‘error’’ residues in the nucleotide alignment, with an ‘‘X’’
character. This alignment is then be translated into amino acids,
with an amino acid of ‘‘X’’ used whenever at least one ‘‘X’’
character per codon occurs. Both the nucleotide and amino acid
masked files can be downloaded in FASTA format.
Using the selected probability of error of 0.5%, masked files
were generated and the UDPS data were then analyzed using the
two newly developed tools and the Mutation Reporter Tool [22].
Analysis of Pyrosequencing Reads
Each sample in Dataset 1 was then analysed using the newly
developed ‘‘Deep Threshold Tool’’ and a probability of error of
0.5% was selected, because this was the lowest probability of error
at which all three well characterized mutations (T1753G/C,
T1773C and G1896A) were present. The resulting threshold
(count) value will differ depending on the number of reads (depth)
in each file, for a given probability of error. For each sample,
output of the ‘‘Deep Threshold Tool’’ lists the loci detected at
above threshold value and these were then analyzed using the
Mutation Reporter Tool, with a reference motif being the
corresponding consensus sequences for each genotype or sub-
genotype. The distribution of substitutions at the nucleotide level
in the BCP/PC/C region varied between samples, depending on
the HBV genotype and HBeAg status (Figure 9). At 0.5%
probability of error or above, substitutions were identified at 39
unique positions in the four samples:31 in the X region (1674 to
1838 from the EcoR1 site; 165 nucleotides), three in the PC region
(1814 to 1900; 87 nucleotides) and five in the core region (1901 to
1939; 39 nucleotides) (Figure 9). Ten of the 39 positions were
present in at least two samples.
Based on the fact that direct sequencing is capable of detecting
substitutions occuring in $20%, of the quasispecies population
substitutions were classified as high frequency ($20%) and low
frequency substitutions (,20%). High frequency substitutions
were found at 11 positions and low frequency at 28 positions.
Figure 4. The first of two summary output tables provided by the ‘‘Deep Threshold Tool’’. For each probability of error in the range
specified, the expected and threshold values are shown, the number of interesting columns (IC) and the list of these interesting columns. This table
provides a summary of the output provided in the previous tables (Figure 3 top).
doi:10.1371/journal.pone.0095377.g004
Figure 5. The second of two summary output tables provided by the ‘‘Deep Threshold Tool’’. For each probability of error in the range
specified (shown in reverse order in this table), a bullet is shown in the corresponding column of the table for each interesting column at which at
least one mutation occurred at above-threshold frequency. This table can be consulted to determine the probability of error, which should be used
on a given dataset. In this example, the well-characterized positions 1753, 1773 and 1896 are examined, and a probability of error of 0.005 selected, as
this is the highest probability of error at which above-threshold mutations at the three positions are detected.
doi:10.1371/journal.pone.0095377.g005
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A consensus of genotype E was used to identify substitutions in
genotype E (samples #1 and #4). The T1741C substitution was
detected in both samples at a high frequency, regardless of the
HBeAg status, while the following substitutions: A1757G,
A1762T, G1764A, G1896A, G1937A/T and A1938C, were
found at a high frequency in HBV from a HBeAg-negative patient
(sample #1) (Figure 9). Substitutions A1735G, G1742A, A1747C,
T1753C and T1909C were found at a low frequency in sample
#1, and T1707C was found at a low frequency in sample #4
(Figure 9).
Similarly, when the genotype D sequences (samples #2 and #3)
were compared to their corresponding consensus sequence, 1678T
was found in sample #2 and 1678C in sample #3. The consensus
of genotype D had 1678T. From phylogenetic analysis carried out
in our previous study, HBV from sample #2 belongs to
subgenotype D1 and from sample #3 to subgenotype D6 [17].
The consensus of subgenotype D1 has T at 1678 and that of
Figure 6. The first output table of the ‘‘Rosetta Tool’’, showing codon (triplets), followed by single-letter translated amino acids, for
each read in the input FASTA alignment. This alignment can be used to easily locate mutations of interest and to locate synonymous and non-
synonymous mutations. The visibility of the nucleotide and/or amino acids columns can be toggled on or off, as required.
doi:10.1371/journal.pone.0095377.g006
Figure 7. The second output table of the ‘‘Rosetta Tool’’ (truncated), showing the frequency of each possible codon (triplet) and
where it occurs in the alignment. Frequencies shown with a black background occurred at below-threshold levels and therefore can be
disregarded.
doi:10.1371/journal.pone.0095377.g007
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subgenotype D6 has C. Therefore, when sample #3 was
compared to the consensus of subgenotype D6, only low frequency
substitutions were detected (T1696C, G1733A, G1745A, G1748,
G1751A, G1756A and T1765C) (Figure 9). When the reference
sequence was changed from the D to D1, the mutation pattern of
sample #2 (subgenotype D1), changed (Figures 9). Using either
reference sequence D or D1, the following substitutions were
detected with high frequency: A1727G, C1730A, A1761C,
G1764A, A1775G and G1896A, whereas the frequency of
1773T and 1912T decreased when using D1 instead of D as the
reference sequence (Figure 9). The following substitutions relative
to D1, occurred in sample #2 at low frequency: T1678C,
A1680C, C1706T, T1724C, A1725C, G1728A, G1736A,
G1739C/T, T1741C, G1745A, G1748A, G1751, T1753G,
A1772T, T1773C, T1842C, T1909C, T1912C and C1913G.
Summarizing the above, in the four samples substitutions were
identified at 39 unique positions. Sample #2 (HBeAg-negative,
genotype D) had substitutions in 26 positions, followed by sample
#1 (HBeAg-negative, genotype E) in 12 positions, sample #3
(HBeAg-positive, genotype D) in 7 positions and sample #4
(HBeAg-positive, genotype E) in only four positions. The ratio of
nucleotide substitutions between isolates from HBeAg-negative
and HBeAg-positive patients was 3.5:1. Moreover, genotype D
isolates showed greater variation in the X, PC and core regions,
compared to genotype E isolates, with the two genotype D samples
having 33 substitutions compared to the 16 detected in the
genotype E samples.
The ‘‘Rosetta Tool’’, which was developed as part of this study,
was used to analyze sequence data at the amino acid level.
Substitutions identified at the nucleotide level were translated into
amino acids and classified as synonymous or non-synonymous.
Fourteen substitutions, 12 in the X region and 2 in the C region,
were synonymous. Twenty-five, 19 in the X region, three each in
the PC and C regions, were non-synonymous mutations. All non-
synonymous mutations occurred within single, non-overlapping
reading frames (1653 to 1814, and 1839 to 1939 from the EcoR1
restriction site), and the region between the start of the PC and the
end of the X (1814 to 1838) was completely conserved in all
ultradeep pyrosequences.
Most of the 21 insertions found in Dataset 2 occurred within
homopolymeric regions and were therefore considered to be PCR
or pyrosequencing artefacts [23].
Analysis of CBS and Comparison to UDPS
At least 20 clones were generated per sample. The BCP/PC
region sequenced is relatively short and does not differentiate
genotypes D and E following phylogetic analysis. Both identical
and multiple clones were generated, with HBV from HBeAg-
negative sera showing greater divergence (Figure 10).
CBS data was analyzed at the 39 loci, previously recognized by
UDPS, using the Mutation Reporter Tool and a consensus
sequence for each genotype/subgenotype as the reference
sequence. In the four samples, substitutions at 18 of the 39
positions (46.2%) were detected by CBS (Table 2) (Figure 11). CBS
detected all high frequency substitutions but only 25% (7/28) of
the low frequency substitutions (Table 2). Moreover, the following
nucleotide substitutions were detected in different samples by
either UDPS or CBS, at position:
1. 1707 by CBS in sample #2 and by UDPS in sample #4,
2. 1775 by CBS in sample #1 and by UDPS in sample #2 and
3. 1842 by CBS in sample #3 and by UDPS in sample #2.
For the four samples, CBS detected only 14 of the 25 non-
synonymous mutations, detected by UDPS (58.3%).
Discussion
The aims of this study were to build bioinformatics tools to assist
in determining the threshold at which pyrosequencing data should
be analyzed, and to compare quasispecies distributions obtained
using UDPS and CBS, and compare results between UDPS and
CBS using HBeAg-positive and –negative sera infected, with either
genotype D or E.
Direct (Sanger) sequencing produces a single ‘‘read’’ for each
sample. After curating the sequence and resolving ambiguous
bases, the sequence is ready for further downstream processing.
Whilst UDPS, which generates several thousand reads per sample,
is a powerful technology, the analysis of the read data before
downstream processing is critical. The depth of coverage provided
by UDPS is also one of its shortcomings, as the data needs to be
carefully curated for errors (artefacts), which may have been
introduced by the PCR amplification and/or the sequencing
process [2,23]. The increased sensitivity of the platform to detect
thousands of reads also means that it may generate such artefacts.
A probability of error of between 0.5% and 1% for UDPS has
been used previously for HIV samples [6]. Subsequent studies on
HBV sequence data have either used the same probability of error,
or have not reported details of this component of the analysis
[2,3,24]. The probability of error, which is used, will influence the
downstream detection of variants. As such, selecting an appropri-
ate probability of error is an essential step in the analysis. In
response to the lack of consensus in selecting a probability of error
and determining a threshold, we developed an online bioinfor-
matics tool to explore this aspect of the analysis. The ‘‘Deep
Threshold Tool’’ provides the researcher with detailed output of
variation at different probabilities of error. The analysis is
objective and repeatable, and the selected probability of error
can be reported and defended. Data for a project can be processed
by the tool, so that a probability of error can be selected for that
specific project, organism or assay. Using a fixed, predetermined
probability of error for the UDPS platform as a whole is overly-
broad and too general, as it is not possible to indicate how a
particular probability of error would be applicable to a different
organism, genomic region or investigation. Using the ‘‘Deep
Threshold Tool’’ developed in the present study, a probability of
Figure 8. Examples of the final series of tables output by the
‘‘Rosetta Tool’’, showing details of the codons (triplets) and
amino acids occurring at each position in the alignment. Cells
with black backgrounds indicate where at least one nucleotide in the
triplet occurred at below-threshold levels. These rows can be
disregarded. The ‘‘Below Threshold’’ column lists the residues, for each
position of the codon (indicated by the square brackets), which were
below the. threshold.
doi:10.1371/journal.pone.0095377.g008
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error of 0.5% was selected for the BCP/PC/C region of HBV,
which agrees with previous reports for HIV [6].
The output must be interpreted in light of existing biological
knowledge of the variation known to occur in the sequenced
region. The tool is objective and outputs results for different
probabilities of error ‘‘blindly’’. There is no ‘‘right answer’’ or
absolute correct threshold, as we cannot possess complete
knowledge of all the stochastic processes, from the sample to the
PCR to the sequencing platform to the sequence results. Variation
may be introduced at the various PCR stages, rather than by the
sequencing hardware itself [23]. What we can do, however, is to
interrogate these data at different probabilities of error, and make
an informed decision on which value to select. It is important that
the method used to process and curate the UDPS data, as well as
any numerical values used (such as probability of error or
threshold), be reported in all UDPS studies. Failure to provide this
level of detail makes it difficult to accurately assess and relate any
results reported.
The emergence of G1896A mutation in the PC region is known
to be associated with HBeAg seroconverion [13]. The presence of
wild-type (G) at 1896 in sample #1 and sample #2,which were
isolated from HBeAg-negative patients, confirms the ability of
UDPS to detect minor populations, which may not be detected by
Sanger sequencing [25,26]. Similar results have been reported in
Figure 9. Graphs showing mutation distribution of the UDPS data at the nucleotide level using either genotype E or D consensus
sequence as the reference. A star indicates a non-synonymous mutation. The graphs were built using the Mutation Reporter Tool [22].
doi:10.1371/journal.pone.0095377.g009
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more recent HBV studies. The HBV population from HBeAg-
positive sera showed a high percentage of stop codon mutations in
the precore region, while isolates from HBeAg-negative carriers
had a low percentage of wild-type residues at codon 28 [24].
Although the selection of genotype D samples was random, we
later discovered that sample #3 belonged to subgenotype D6,
while sample #2 belonged to subgenotype D1. As illustrated in
Figures 9 and 10, knowledge of the genotype and subgenotype of
HBV is important when determining the presence of mutations.
Depending on the reference or consensus sequence used, the
variant at a particular position, may either represent the signature
of a particular subgenotype or be a legitimate mutation.
Therefore, where possible, a consensus sequence of the genotype
or subgenotype should be used, to ensure that variants are
examined in the appropriate context.
Six mutations (A1757G, A1762T, G1764A G1896A, G1937A/
T and A1938C) were found in high frequency (.20%) in sample
#1, genotype E isolated from a HBeAg-negative patient. The
G1896A mutation is known to create the stop codon at amino acid
28 and to abrogate HBeAg expression [13], while the double
Figure 10. A rooted phylogenetic tree of 92 cloned BCP/PC sequences (position 1653 to 1939 from EcoRI site) from four serum
samples. Sample #1 was HBeAg-negative and infected with genotype E of HBV, sample #2 was HBeAg-negative, genotype D, sample #3 was
HBeAg-positive, genotype D and sample #4 was HBeAg-positive, genotype E. Bootstrap statistical analysis was performed using 1000 datasets,
indicated as percentages on the nodes. The letters, D and E, represent the genotypes.
doi:10.1371/journal.pone.0095377.g010
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mutation A1762T/G1764A is known to down-regulate the
transcription of precore mRNA that is translated into HBeAg
[14]. Although A1757G is a synonymous mutation and thus has
no effect on the protein sequence, it overlaps cis-regulatory
elements within the basic core promoter. In the present study,
1757G was found to be associated with A1762T/G1764A. This
association has also been shown by others, who found that chronic
hepatitis patients infected with HBV with 1757G/1762A1764A
had higher HBV DNA levels compared to patients infected with
the wild-type 1757A/1762T1764A [27]. Moreover, A1757G was
found to in HCC patients infected by genotype C [28]. Non-
synonymous mutations G1937A/T and T1938C within the core
region occurred at a high frequency (Figure 9). These mutations
are located within a T-cell epitope, which is an important
Figure 11. Graphs showing mutation distribution of the CBS data at the nucleotide level using either genotype E or D consensus
sequence as the reference. A star indicates a non-synonymous mutation. The graphs were built using the Mutation Reporter Tool [22].
doi:10.1371/journal.pone.0095377.g011
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component of the host’s immune response to HBV infection [29].
These two mutations have recently been reported in strains of
HBV genotype B isolated from Taiwanese patients [30]. Other
substitutions (T1707C, A1735G, A1747C and T1909C) were
found at low frequencies (,20%) and have not been reported in
previous studies.
In sample #2 (genotype D isolated from HBeAg-negative),
mutations A1727G, C1730A, A1761C, G1764A, A1775G and
G1896A were detected at high frequency. A1727G and C1730A
are located in the Enhancer II region and have been detected in
cirrhotic patients [28] and are associated with reduced HBcAg
expression and HBV DNA levels in the liver [31]. A1761C has
previously been detected within a mutational motif (1761–1766) in
isolates from patients with cirrhosis and chronic hepatitis [32]. The
A1775G is associated with loss of HBeAg in Taiwanese children
[33]. T1678C, G1753A and T1773C, which were found in the
minority of the quasispecies population, have previously been
associated with severity of HBV infection and progression to HCC
[28,34].
The following substitutions were found as minor populations
and have not previously been documented. In HBV from HBeAg-
negative samples: A1735G, G1742A, A1747C and T1909C in
genotype E and A1680C, C1706T, T1724C, A1725C, G1728A,
G1736A, G1739C/T, G1751A, A1772T, T1842, T1909C,
T1912C and C1913G in genotype D (Figure 9) and in HBeAg-
positive samples: T1696C, G1733A and G1751A in genotype D
and T1707C in genotype E. Mutations G1745A and G1748A
were found in both HBeAg-negative and HBeAg-positive geno-
type D samples. It is possible that these have not previously been
detected because direct (Sanger) sequencing can only detect
variation that occurs in 20% or more of the population. More
extensive studies may reveal the relevance of these minor variants.
The genotype E isolates were found to harbour fewer mutations
in the X, PC and core regions compared to genotype D, which is
in agreement with previous studies showing low genetic diversity of
genotype E [35,36]. Furthermore, a greater number of mutations
were found in HBeAg-negative samples of both genotype D and E
compared to HBeAg-positive samples. It was reported that the
frequency of HBV mutations is higher in HBeAg-negative
patients, this is as a result the immune response of the host
against the virus before the loss of HBeAg [37]. However, because
only four samples, belonging to the two genotypes from HBeAg-
positive and HBeAg-negative samples, were analyzed, additional
samples would be required before any firm conclusions can be
reached about the differences in nucleotide divergences between
these genotypes from HBeAg-positive and –negative sera.
In this study, where 9738 sequence reads were generated by
UDPS, 39 unique positions were detected by UDPS, while only 18
(46.2%) of these position were detected by CBS. High frequency
substitutions were found in 11 positions and were all detected by
CBS, whereas only 6/28 (25%) low frequency substitutions were
detected by CBS (p,0.05) (Figures 9 and 10).
Although the testing of the tools was done on a small sample set
and the findings cannot be generalized, it is evident that the data
generated by the increased read-depth provided by UDPS should
be approached with caution. Appropriate curation and examina-
tion of the reads are required to ensure that artefacts are not
interpreted as variants. Moreover, identification of variants must
be performed against a suitable reference or consensus sequence,
as a ‘‘mutation’’ of interest may simply be a known signature or
variant when examined in the correct genotypic or subgenotypic
context. UDPS detected a greater number of substitutions than
CBS. Relative to CBS, UDPS is cheaper to undertake, both in
terms of time and expense. However, without rigorous and careful
examination and interpretation of read data, the results generated
by UDPS may be misleading. As illlustrated in the present study, a
thorough knowledge of the genome of interest and its known
variants is essential in order to accurately and reliably interpret the
high resolution read data generated by UDPS.
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CHAPTER 6: GENERAL DISCUSSION AND CONCLUSION  
 
It is surprising perhaps, that Sudan, being a HBV hyperendemic African country (>8% 
HBsAg-positivity), had no published data on the HBV genotypes prevailing in Sudanese liver 
disease and HIV patients, prior to the initiation of this study. A diversity of HBV genotypes is 
found in countries neighbouring Sudan (Kramvis and Kew, 2007): genotype D in Egypt to the 
north (Saudy et al., 2003), genotype E in the Democratic Republic of Congo to the west 
(Mulders et al., 2004) and genotype A in Kenya (Mwangi et al., 2008, Ochwoto et al., 2013) 
and Uganda to the south (Usuda et al., 2000, Hannoun et al., 2005, Forbi et al., 2013). In 
view of Sudan‘s unique position and the movement of people across its borders, a description 
of the HBV genotypes prevailing in this country was important. HBV genotypes are relevant 
when considering both the clinical consequences of infection and response to antiviral 
treatment (Kramvis and Kew, 2005, Kao, 2002a). The first study describing HBV genotypes 
in Sudan, published after the initiation of the present study, was undertaken on blood donors, 
and reported that 57.5% were infected with genotype E, 40.5% with genotype D and 2% with 
subgenotype A2 (Mahgoub et al., 2011). Subsequently, results of the present study showed 
that Sudanese liver disease patients were mainly infected with HBV genotypes D and E, with 
genotype D predominating (Yousif et al., 2013).  
Genotype D, which prevails in the Mediterranean, is the only genotype with a worldwide 
distribution. It is the genotype of HBV with the shortest genome (3182 nucleotides) 
characterized by a 33 nucleotide deletion in the preS1 region. The availability of a large 
number of sequences in the public databases, with diverse geographical distribution and the 
description of nine subgenotypes of D with close phylogenetic relationships, motivated us to 
carry out an extensive analysis of the sequencing data and to update the classification of 
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genotype D (Paper I, Chapter 2).  This allowed for the accurate classification of the 
subgenotypes of D prevailing in Sudan.   
Subgenotypes D1 to D4 were described previously, following phylogenetic analysis and 
based on an intergroup divergence of 4–8% and high bootstrap support, subgenotypes D1 to 
D4 were described (Kramvis et al., 2008, Norder et al., 2004).  Later when the upper limit of 
intergroup divergence was lowered to 7.5% (Kramvis et al., 2008), an additional five 
subgenotypes of D (D5 to D9) were identified (Banerjee et al., 2006, Utsumi et al., 2009, 
Meldal et al., 2009, Abdou Chekaraou et al., 2010, Ghosh et al., 2012). However, our 
analysis of subgenotypes D1 to D8 (Paper I, Chapter 2) showed the separation of 
subgenotypes D6 (from Papua) and D3 to be uncertain. With the additional sequences 
analyzed, we found that the mean intergroup divergence +SD between these two 
subgenotypes was 2.6% + 0.6, whereas it was reported to be more than 4% in an earlier study, 
when fewer sequences were compared (Utsumi et al., 2009). The 2.6% nucleotide divergence 
is significantly lower than the 4% cut-off required for separation into subgenotypes (Kramvis 
et al., 2005a, Kramvis et al., 2008).  Moreover, the bootstrap value in our phylogenetic 
analysis was low (56%), while it was reported as 88% in the earlier study (Utsumi et al., 
2009). Subgenotype D3 and ―D6‖ were also found to share signature amino acids (Paper I, 
table 2). Therefore we reclassified subgenotype D6 as a clade of subgenotype D3, rather than 
a separate subgenotype. Although the intergroup divergence between subgenotypes D1 and 
D2 was only 3.1% + 0.5, we proposed that this separation be retained because it is supported 
by high bootstrap values and the two subgenotypes have different serological subtypes, ayw2 
in D1 and ayw3 in D2 and distinct geographical distributions (Paper I, figure 1).   
We confirmed that the three strains proposed, as belonging to subgenotype D8 (GenBank 
Accession Numbers FN594769–FN594771) (Abdou Chekaraou et al., 2010), are a 
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recombinant of genotypes D and E (Yousif and Kramvis, 2013).  The recombination profile 
determined for the three strains did not differ significantly from that reported initially: 
FN594769– FN594771 clustered with genotype E within the regions ~1640–2430 and 
~2830–3128, from the EcoR1 restriction site. We found that these isolates are a subgenotype 
D7/genotype E recombinant. Furthermore, subgenotype D8 has a three nucleotide deletion in 
the preS1, which is characteristic of genotype E. Therefore, we proposed that subgenotype 
―D8‖ should be renamed as a genotype D/E recombinant, rather than a subgenotype of D. 
Our updated analysis showed that there are in fact six and not eight subgenotypes.  
Subsequent to our analysis,  by using six complete HBV genomes sequences,  Gosh and col-
leagues (2010) identified subgenotype ―D9‖ from India, which is a genotype D/C recombi-
nant (Ghosh et al., 2012).  Recombination events have been described between HBV geno-
types that circulate in the same geographical region (Simmonds and Midgley, 2005). Geno-
types C/D in Tibet, (Zhou et al., 2011), E/A in Guinea (Garmiri et al., 2009), and B/C in Asia 
(Sugauchi et al., 2002).  Although a number of researchers have suggested that recombinant 
strains should not be classified as novel subgenotypes but reported separately, these sugges-
tions have not been followed widely (Shi et al., 2013, Kramvis et al., 2008, Pourkarim et al., 
2010a). Definition of subgenotypes should meet specific criteria (Kramvis et al., 2005a, 
Kramvis et al., 2008).  These criteria include nucleotide divergence of between ~4% and 
7.5%, monophyletic clustering and good bootstrap support to separate subgenotypes 
(Kramvis et al., 2008).  Distinct geographical separation  (D1 versus D2) and/or different se-
rological subtypes (D1 versus D2, and I1 versus I2),  monophyletic clustering and good boot-
strap support, can be used to separate subgenotypes, when the nucleotide divergence is less 
than 4% (Kramvis, 2014).  The establishment of a scientific committee for controlling the 
definition of new HBV genotypes/subgenotypes has been proposed (Kramvis et al., 2005a, 
Kurbanov et al., 2010).  
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Genotypes D and E were found in Sudanese liver disease (Paper II, Chapter 3) and HIV-
positive  patients  (Paper III, Chapter 4).  This is in contrast to the predominance of genotype 
E found in Sudanese blood donors (Mahgoub et al., 2011).  The circulation of either genotype 
D or E in liver disease patients belonging to the same ethnic group, allowed for the compari-
son of patients infected with these two genotypes (Paper II, Chapter 3). No significant differ-
ence was observed in gender, age, ALT and clinical groups of patients infected with  either 
genotype. When we compared the viral loads in the liver diseases patients infected with geno-
types D and E, we found that viral loads were significantly higher in genotype E-infected pa-
tients compared to genotype D-infected patients. Moreover, patients infected with genotype 
E, showed a significantly higher frequency of HBeAg-positivity. The same results were re-
ported by Mahgoub and colleagues (2011) in Sudanese blood donors (Mahgoub et al., 2011) 
and in a Ghanaian study (Candotti et al., 2006). The higher HBeAg-positivity seen in HBV 
genotype E mono-infected individuals with liver disease patients could confer tolerance re-
sulting in less serious clinical manifestation when compared to infection with genotype D 
where HBeAg-positivity is lower (Chen et al., 2005). This could explain why genotype E 
prevailed in the Sudanese blood donors (Mahgoub et al., 2011), and genotype D prevailed in 
the liver disease patients in the our study.  The genetic diversity of genotype E isolates was 
significantly lower than the genotype D isolates.  Genotype E has been characterized as hav-
ing a low diversity compared to other genotypes and subgenotypes of HBV (Kramvis and 
Paraskevis, 2012, Hübschen et al., 2009, Kramvis et al., 2005b). 
Subgenotype D1 was found to predominate in the liver disease mono-infected patients (Paper 
II, Chapter 3) and HBV/HIV co-infected individuals (Paper III, Chapter 4).  This is in 
agreement with the previous study of blood donors (Mahgoub et al., 2011, Yousif et al., 
2013). Therefore the predominant subgenotype of D found in Sudan is D1. This is the 
subgenotype of D that prevails in the Mediterranean, Arabian subcontinent and in China 
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(Yousif and Kramvis, 2013).  Moreover, our study is the first to report the presence of 
subgenotype A1 in Sudan.  Subgenotype A1 predominates in southern and eastern Africa, 
including Kenya (Ochwoto et al., 2013) and Uganda (Forbi et al., 2013), which border with 
Sudan.    
The Sudanese HCC patients infected with either genotype D or E were significantly older 
than asymptomatic carriers as well as the chronic, acute and cirrhotic hepatitis, with the acute 
hepatitis patients being significantly younger.  This differs from southern African HCC pa-
tients, infected with genotype A, in particular subgenotype A1, who develop cancer at a sig-
nificantly younger age (Kew et al., 2005).  Southern Indian HCC patients infected with sub-
genotype A1 have also been shown to be significantly younger than those infected with geno-
type D (Gopalakrishnan et al., 2013).  The Sudanese HCC group had the highest median viral 
load compared to the other disease groups.  High viral loads have been implicated as a risk 
factor for HCC development (Liu et al., 2008). 
HBV and  HIV share the same transmission route (Alter, 2006) and  the prevalence of HIV 
among Sudanese adult ranges from 0.9% to 1.4% (UNAIDS., 2010).  More than 60% of HIV 
patients were shown to have at least one marker of HBV infection, with over a quarter being 
HBV DNA positive, with ~12% overt infection and 15% OBI (Paper V, Appendix  A). HBV 
isolated from 50 patients randomly sampled from our study were used to molecularly 
characterize HBV from Sudanese HIV-infected patients.  Similar to HBV mono-infected 
patients, genotypes D and E were found in HBV/HIV co-infected individuals, with genotype 
D predominating (Paper III, Chapter 4). However, the frequency of genotypes A and D/E 
recombinant was relatively higher in HBV/HIV co-infected patients compared to HBV mono-
infected liver disease patients (genotype A: 18.4% versus 8.6%, and D/E: 13.2% versus 
2.5%).  Moreover, there were a number of differences between the HBV isolates from  mono-
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infected compared to HBV/HIV co-infected individuals.  Although the genotypes prevailing 
in the mono- and co-infected individuals did not differ significantly, a lower proportion of the 
mono-infected individuals were HBeAg-positive (12%) compared to the co-infected 
individuals (18%).  It is possible that HIV, by causing immunosuppression may delay or 
prevent seroconversion to the inactive carrier phase in patients with chronic HBV infection 
(Bodsworth et al., 1991). However, there is also the possibility that the HIV co-infected 
patients, who were significantly younger than the mono-infected liver disease patients, did 
not have enough time to seroconvert or were recently infected with HBV (Paper V, Appendix 
A).  In contrast to mono-infected patients, HBeAg-expression and the viral loads in co-
infected patients did not differ between those infected with genotype D and E.  Furthermore, 
the intra-group divergence of genotype E in HBV/HIV co-infected individuals was 
significantly higher than that in HBV mono-infected liver disease patients.  It is possible that 
the genetic diversity of genotype E is constrained in the immunocompetent mono-infected 
individuals but allowed to expand in HBV/HIVco-infected patients, who are 
immunocompromised.   
 
Using the Taormina definition of OBI (Raimondo et al., 2008), 36% of the 50 serum samples 
used in HBV/HIV study were HBsAg-negative, of which, 20% had viral loads of <200 IU/ml 
and therefore  OBI. The absence of HBsAg and the presence of HBV DNA in these OBI 
cases is probably as a result of low viral loads, which prevent the detection of HBsAg by the 
routine serological techniques.  Higher viral loads of >200 IU/ml HBV DNA, in the absence 
of HBsAg, were found in 16% of HBV/HIV co-infected individuals.  This infection has been 
defined as ―false occult‖ (Raimondo et al., 2008) or ―HBsAg-covert” (Bell et al., 2012).  A 
similar proportion of OBI and HBsAg-covert infection has also been found in southern 
African HBV/HIV co-infected individuals (Bell et al., 2012), infected with HBV 
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subgenotype A1 (Makondo et al., 2012).   In order to explain the HBsAg-negativity seen in 
the HBsAg-covert individuals the preS/S region was sequenced (Paper III, chapter 4).  Only 
one mutation, sS174N, was found that could differentiate between HBV isolated from 
HBsAg-negative and -positive individuals.   This is in agreement with two previous studies 
(Makondo et al., 2012, Henke-Gendo et al., 2008), where patients were infected with 
subgenotype A1 and A2, respectively.   sS174N has been described as a reactivation marker 
(Henke-Gendo et al., 2008).  Other mutations in the S region that could account for the 
HBsAg-negativity were also found in HBV isolated from  HBV/HIV co-infected individuals  
including  ps2R48T, sM133T, sE164G and sV168G, but these, in agreement with other 
studies in HBV/HIV co-infected individuals, could not differentiate between HBsAg-negative 
and  HBsAg-positive infection (Pourkarim et al., 2011b). 
 
Eleven isolates from HBV mono-infected patients (paper II, chapter 3) and two isolates from 
HBV/HIV co-infected patients (paper III, chapter 4) had deletions in the preS region. The 
deletion mutants in HBV genotype E isolates from HBV mono-infected liver disease patients 
were mainly from HCC patients whereas this was not the case for genotype D isolates.  The 
numbers, however, were too low to reach any firm conclusion.  Deletion mutants have been 
reported to occur more frequently in HCC patients (Kew et al., 2005) and HIV co-infected 
patients (Audsley et al., 2010). Deletion mutants in the preS have been reported to enhance 
the progression of liver disease in genotypes B and C (Chen et al., 2006). Similar deletion 
mutants were found in Sudanese and Guinean blood donors in genotype E (Mahgoub et al., 
2011, Garmiri et al., 2009) and in South African HIV patients infected with subgenotype A1 
(Makondo et al., 2012).  As noted previously, these deletion mutants may be a risk factor for 
the development of HCC in HBV/HIV co-infected individuals, if HBV infection is left 
untreated (Makondo et al., 2012). 
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The genotyping and molecular characterization of HBV isolated from HBV-mono- and 
HBV/HIV co-infected Sudanese patients was carried out using Sanger nucleic acid 
sequencing, which can only detect variation that occurs in at least 20% of a viral population.  
Because of its complex replication cycle, high replication and mutations rates, HBV exists in 
patients as a heterogeneous viral population, composed of closely related, non-identical 
genomes, known as quasispecies (Rodriguez-Frias et al., 2013). Traditionally, 
characterization of a viral quasispecies population has been carried out using amplification, 
cloning and sequencing (CBS: cloning based sequencing).  This method is labour intensive 
and expensive, both in terms of time and cost.  Recently developed next generation 
sequencing (NGS) produce a very high throughput of data and allow for the detection of 
mutations, even when present at very low levels in the quasispecies population (Hoffmann et 
al., 2007, Ijaz et al., 2008).   
 
Bioinformatic tools were developed  in order to analyze the data generated using UDPS and 
CBS of the BCP/PC region of four Sudanese serum samples, infected with either genotype D 
or E of HBV, from HBeAg-positive and HBeAg negative patients.  This allowed for the 
identification of nucleotide substitutions and variants in the BCP/PC region and comparison 
between genotypes and different stages of HBV infection, namely, HBeAg-positive and 
negative phases.  Using the newly developed ‗Deep Threshold Tool‘, the probability of error 
that could detect biologically important mutations in the BCP/PC region was found to be 
0.5%.  Previously, a probability of error of between 0.5% and 1% for UDPS has been used 
for HIV samples (Eriksson et al., 2008). Studies on HBV sequence data have either used the 
same probability of error, or have not reported details of this component of the analysis 
(Margeridon-Thermet et al., 2009, Homs et al., 2011, Solmone et al., 2009). In agreement 
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with previous studies (Homs et al., 2011), the presence of the wild type (G) at 1896 in sample 
#1 and sample #2, which were isolated from HBeAg-negative patients (Paper IV, Chapter 5), 
confirms the ability of UDPS to detect minor populations, which may not be detected by 
Sanger sequencing (Hoffmann et al., 2007, Ijaz et al., 2008).  As shown in figures 9 and 10 
(Paper IV, Chapter 5), the determination of mutation/variant depends on the reference used in 
the analysis.  Thus knowledge of the genotype and subgenotype of HBV is important when 
determining the presence of mutations. Therefore, where possible, a consensus sequence of 
the genotype or subgenotype should be used, to ensure that variants are examined in the 
appropriate context. 
 
UDPS was able to detect mutations that occurred both at high frequency (> 20%) and at low 
frequency (< 20%), with more mutations being detected in samples from HBeAg-negative 
samples and genotype D samples showing greater variability compare to genotype E.  HBV 
with mutations, previously shown to biologically important, including  G1896A (Carman et 
al., 1989) and A1762T/G1764A (Okamoto et al., 1994), were detected in both HBeAg-
positive and HBeAg-negative samples belonging to both genotypes.  Moreover, substitutions 
not previously described in the literature were detected using UDPS, which can detect minor 
population of the quasispecies. It is possible that these have not previously been detected 
because direct (Sanger) sequencing can only detect variation that occurs in 20% of the 
population in the quasispecies. However, until more extensive analysis is undertaken on a 
larger number of samples, it cannot be determined whether these are true mutations or 
artefacts.  Compared to CBS, UDPS identified 39 unique positions, of which only 18 (46.2%) 
were identified by CBS. As expected, CBS identified  all high frequency substitutions, 
because these mutations were present in >20% of the population of the quasispecies, while 
only 6/28  (25%) of the low frequency mutations (< 20%) were identified by CBS, 
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confirming  the limitations of the CBS.  
Summary  
Using the specific criteria, that have been suggested previously, to define 
genotypes/subgenotypes of HBV, we determined that genotype D has six and not eight 
subgenotypes. The importance of HBV genotypes in clinical consequences of infection and 
response to antiviral treatment has led us to characterize HBV genotypes circulating in 
Sudan. HBV mono-infected patients and HBV/HIV co-infected individuals, were mainly 
infected with genotype D or E.   HBV mono-infected patients, infected with genotype E, had 
higher HBeAg-positivity and higher viral loads than those infected with genotype D. The 
ratio of genotype A to non-A, as well as the genotype E intra-group divergence were higher in 
HBV/HIV co-infected individuals compared to HBV mono-infected individuals. OBI was 
found in 15.1% HBV/HIV co-infected patients and its clinical relevance remains to be 
determined.  In order to overcome the limitations of Sanger sequencing, which include its 
high cost and inability to detect minor populations in quasispecies, next generation 
sequencing techniques such as UDPS have been developed.  We demonstrated that correct 
analysis of UDPS data requires appropriate curation of read data, in order to clean the data 
and eliminate artefacts and that the appropriate consensus (reference) sequence should be 
used in order to identify variants correctly. CBS detected fewer than 50% of the substitutions 
detected by UDPS. This new technology may allow the detection of minor variants between 
the different genotypes of HBV and provide biomarkers for the prediction of clinical 
manifestation of HBV and response to antiviral therapy.   
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Abstract 
Objectives: Human immunodeficiency virus (HIV) in sub-Saharan Africa is complicated by co-
infection with hepatitis B and C viruses (HBV, HCV) that share similar transmission routes. Our aims 
were to determine the prevalence of HBsAg-positive and HBsAg –negative HBV, and HCV infection 
among HIV-infected patients.   Methods:A cross-sectional study was conducted among treatment-
naïve HIV-positive adults in Khartoum state.  HBV, HCV and HIV infection were detected using 
immune assays for HBsAg, anti-HBc, anti-HCV or anti-HIV, while real time polymerase chain 
reaction (PCR) was used to measure HBV DNA.   Results: The age (mean+standard deviation (SD)) of 
358 patients was  35.2+9.3 years, with a male: female ratio of 1.3:1.0 and mean+SD alanine 
aminotransferase (ALT) levels of 10.9+18.0 U/L. Evidence of current or past HBV infection was 
detected in 62.8% of the patients and HBV DNA in 96 patients (26.8%): 42 HBsAg-positive (11.7%) 
and 54 (15.1%) HBsAg-negative, indicating occult hepatitis B infection. Anti-HCV was detected in 
1.7%.  Conclusion: Evidence of HBV infection was detected in 26.8% of HIV patients  with HBsAg-
negative infection, with viremia, detected in 15.1% of  the patients..  All HIV-infected patients should 
be carefully screened for HBV, preferably using PCR, prior to initiation of antiretroviral therapy. 
 
 
Key words: polymerase chain reaction,  HBV detection,  HBsAg-negative, occult HBV infection, 
hepatitis C virus 
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INTRODUCTION 
Human Immunodeficiency (HIV) is a serious health problem in sub-Saharan Africa 
1
. HIV infection is 
complicated by co-infection with other pathogens including hepatitis B and C viruses (HBV and HCV) 
that share similar routes of infection. Worldwide, it is estimated that over 240 million people 
2 
and 150 
million people 
3
 have chronic HBV or HCV infection, respectively. Globally there are 34 million 
people infected with HIV, 69% of them reside in sub-Saharan Africa 
1
.   Although the introduction of 
antiretroviral therapy (ART) has decreased the death rate and the incidence of new acquired 
immunodeficiency syndrome (AIDS) defining diseases among HIV infected individuals, liver disease, 
mainly as a result of HBV or HCV co-infection has emerged as one of the leading causes of non-AIDS 
related mortality and morbidity 
4
. Co-infection with HBV or HCV and HIV is characterized by more 
rapid progression of liver disease including accelerated fibrosis, cirrhosis and hepatocellular 
carcinoma
5, 6
.    
 
Sudan, located in the north to east-central Africa is  endemic for HBV infection, with HBV exposure 
rates  from 47%
7
,  - 78%
8
, prevalence of HBsAg  6.9%
7
  - 18.7% 
9
 , prevalence of HCV antibodies 
2.2% 
10
- 4.8% 
11
 and prevalence of HIV among adult population  0.9-1.4% 
12
.
 
  However,  there is no 
clear knowledge about HBV in the setting of HIV infection, and it would be important to determine 
this and select appropriate ART, specially as HIV patients may also develop hepatic toxicity and lactic 
acidosis under ART, which is based on a combination of drugs which includes Lamivudine, Stavudine, 
Efavirenz and Nevirapine
13
.  
No studies have been carried out to determine the presence of HBV DNA, in the absence of HBsAg, in 
HIV-positive Sudanese.  Thus the aims of this study were to determine the prevalence of HBV and 
HCV infection and the prevalence of occult hepatitis B infection (OBI) among adult Sudanese HIV 
patients. 
4 
 
MATERIALS AND METHODS 
Patients  
A cross-sectional study was conducted during the period December 2010 to June 2012 in Khartoum, 
Sudan.   All treatment-naïve adults (18 years and over), who tested positive for HIV antibodies using 
indirect enzyme linked immunosorbent assay (ELISA),  attending Omdurman Medical AIDS care Unit 
(OMACU) and Bashair hospital HIV treatment center in Khartoum state, were included in the study. 
Children younger than 18 years and pregnant women were excluded. The study was approved by the 
Ethics committee of the Faculty of Medicine, University of Khartoum, the National Ethics committee, 
Federal Ministry of Health, Sudan and by the Human Ethics Committee of the University of the 
Witwatersrand, South Africa. Written consent was obtained from all participants before their 
enrollment. 
 
Data collection 
Data was collected using a specially designed questionnaire with basic demographic criteria including 
age, gender and potential risk factors for transmission of infection such as multiple sexual partners, 
intravenous drug use, previous history of jaundice and blood transfusion and history of hepatitis B 
vaccination. All patients were classified according to the WHO clinical staging 
14
.  All HIV-infected 
patients were classified according  to WHO clinical staging
15
 
 
Collection and storage of samples: 
Ten milliliters (10 ml) venous blood sample was collected from each patient and divided in two blood 
collection tubes: 7 ml in ethylenediaminetetraacetic acid  (EDTA)  tubes and 3 ml in plain tubes for 
serum separation. Separated plasma and serum samples were stored at -30°C for further analysis.   
5 
 
Immune assays 
Detection of anti-HIV was done using an indirect enzyme linked immunosorobet assay (ELISA) kit 
(Biorex, Antrium, United Kingdom). HBsAg, anti-HBc IgM and IgG, hepatitis B e antigen and 
antibodies (HBeAg, anti-HBe), and anti-HCV were detected using immune assays from  Diasource 
(Nivelles, Belgium); the immune assay for hepatitis D virus antibodies (anti-HDV)  came from 
Diagnostic Automation, Inc. (Calabasas, California).  In all tests the instructions of the suppliers were 
strictly followed. 
DNA extraction and quantitative real time-polymerase chain reaction (PCR) 
HBV DNA was extracted with the SACACE Ribo virus  kit  (HBV Real-TM Quant, Sacace 
Biotechnologies, Como, Italy) as recommended by the supplier. An internal control (HBV IC) with 
known viral concentration (specific for each lot) was used to monitor the amplification and exclude 
any loss of genomic DNA or PCR inhibition and to enable the precise calculation of the HBV viral 
load in the samples. The extracted DNA was immediately used for PCR. Real Time PCR was done 
using the HBV Real-TM Quant. ® Kit (Sacace Biotechnologies, Como, Italy). 12.5 μL of the extracted 
HBV DNA was added to an equal volume of the reaction mixture provided by the kit. With each run, 3 
standards known of the HBV DNA (QS1 HBV, QS2 HBV, and QS3 HBV) and the other three 
standards of the internal control (QS1 IC, QS2 IC, and QS3 IC) were used to calculate the viral copy 
numbers. Real Time PCR was done according to the manufacturer's instructions as follows: stage 1: 
95° C for 15 minutes and in stage 2: a two temperature cycle with 95° C for 20 seconds and 60° C for 
40 seconds which was repeated for 42 times. Cy3 dye was used for the sample and FAM for the 
internal control. The signals from these dyes were calculated and presented as numbers.  The 
sensitivity  of the assay is ~20 genome copies/ml, which is equivalent to 12 IU/ml (1.1 log10 IU/ml), 
conversion factor = 1,7.   
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Statistical analysis 
Statistical analysis was done using SPSS software program to calculate frequencies, Chi-squared (χ2) 
and t-values; significance was assumed at p-values < 0.05.  
RESULTS 
A total of 358 HIV- infected patients were enrolled in the study with a mean age + standard deviation 
(SD)  of 35.2 + 9.3 years, with male: female ratio of 1.3:1.0.  Mean alanine aminotransferase + SD 
(ALT) levels of the study population was 10.9+ 18.0 U/L. Demographic criteria of the study 
population and risk factors for acquiring HBV infection are shown (Table 1). All participants tested 
positive to HIV antibodies using indirect ELISA.  
HBV serology 
Of the 358 patients, 225 (62.8%)  were anti- HBc IgG-positive indicating previous exposure to HBV 
infection. The mean + SD,  age  and ALT levels of this subpopulation were 35.3 + 9.4 years and 11.0 + 
20.9 U/L, respectively,  and these values did not differ from those of the population as a whole (Table 
1).  Only 4 patients (1.1%) reported being vaccinated against HBV infection, however, anti- hepatitis 
B surface antibodies were not tested in this group of patients.  Male gender and intravenous drug use 
were found to be risk factors for positivity for HBV markers (p< 0.05).   
HBsAg-positive patients 
Forty two patients (11.7%) were HBsAg-positive.  Mean + SD, age and ALT levels of the group was 
34.7+ 8.7 years and 9.8 + 7.2 U/L respectively and these values did not differ from those of the 
population of 225 patients who were anti-HBc IgG-positive. History of jaundice was an indicator of 
being HBsAg-positive (p< 0.05) (Table 2).  Eight patients (19.0%) were HBeAg-positive and anti-
7 
 
HBe-negative, 24 patients (57.1%) were HBeAg negative and anti-HBe positive and 10 patients 
(23.8%) were negative for both HBeAg and anti-HBe. All patients were negative for anti-HDV.  
Viral loads 
HBV DNA was detected by PCR in 96 patients (26.8%); all were anti-HBc IgG–positive. Forty two 
patients (11.7%) were HBsAg-positive and 54 patients (15.1%) were HBsAg -negative indicating 
occult infection. Median viral loads, interquartile range (IQR) and demographic criteria of patients 
with detectable HBV DNA on PCR and risk factors are shown in tables 3, 4 and 5. Risk factors 
associated with HBV DNA-positivity included blood transfusion, previous dental procedures, history 
of jaundice and WHO clinical stages 3 and 4 (p < 0.05) (Table 3).  Overall median [IQR] viral load 
was 2.9[1.7-4.1] log10 IU/ml, with HBsAg-positive individuals having significantly higher viral loads 
compared to HBsAg-negative patients (Table 5).  Eight HBsAg-positive , HBeAg-positive, anti-HBe-
negative patients had viral loads of 5.6  log10 IU/ml, 24 HBsAg-positive, HBeAg-negative, anti-
HBeAg-positive patients had viral loads of 3.8 log10 IU/ml and 10 HBsAg-positive, HBeAg/anti-
HBeAg-negative had viral loads of 3.9 log10
 
IU/ml. Thirty five (9.8%) HBsAg-negative patients had a 
viral load < 2.3 log10 IU/ml (< 200 IU/ml) (true OBI) and nineteen (5.3%) had viral loads >2.3 log10 
IU/ml  (>200 IU/ml) (false OBI or HBsAg-covert).  One patient was reactive in both anti-HBc IgG and 
anti-HBc IgM, the patient was HBsAg-negative with normal ALT and had detectable HBV DNA on 
PCR indicating a recent HBV infection or a HBV reactivation in a patient with OBI. 
HCV infection  
Six patients (1.7%), of  which five were female,  tested positive for anti-HCV antibodies, mean age + 
SD was 34.3+ 12.9 and mean+ SD ALT level was 6.0 + 3.8U/L. None of them was an intravenous 
drug user and there were no significant risk factors for HCV infection. Five of these patients were anti-
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HBc IgG-positive, with two having detectable HBV DNA on PCR. One patient was HBsAg positive, 
while the second patient was HBsAg negative indicating occult HBV infection.  
DISCUSSION 
The 62.8% exposure rate to HBV infection and prevalence of HBsAg of 11.7% detected in the HIV-
positive Sudanese patients in the present study did not differ from HBV exposure rates found 
previously in HIV-negative patients where HBV exposure rates  ranged from 47%
7
,  - 78% 
8
 and 
prevalence of HBsAg  6.9%
7
 - 18.7%
9
  .    The prevalence of HCV antibodies of 1.7% was also similar 
to prevalence rates of HCV in HIV-negative patients of 2.2%
10
 - 4.8%
11
 from previous studies. Similar 
exposure rates to HBV and HCV among HIV-positive and HIV-negative individuals in sub-Saharan 
African countries have been reported 
16
.  In Ethiopia, in HIV-positive patients, the exposure to HBV 
and prevalence of HBsAg is 47.5% and 3.9%, respectively compared to 41.9% exposure to HBV  and 
5.4% HBsAg-positivity in HIV- negative patients 
17
. In Uganda exposure to HBV and prevalence of 
HBsAg is 59% and 8.3%, respectively in HIV- positive patients compared to 51.9 % and 10.4% in 
HIV- negative patients 
18
. A study in Mozambique in HIV-positive patients revealed exposure to HBV 
is 69.6%, HBsAg 10.6% and HCV antibodies 1.4%  compared to 62.5%, 9.0% and 1.5%, respectively 
in HIV- negative individuals 
19
. These findings  support the hypothesis that in regions with high 
endemicity to HBV infection such as in sub-Saharan Africa, most HBV infections occur in childhood 
either perinatally or more often through horizontal transmission such as close contact within 
households, medical procedures using non-sterile equipment and through traditional medical practices 
long before exposure to HIV 
20, 21
. This is in contrast to countries with low endemicity for HBV 
infection such as the United States, Europe and Australia.  Here,  although the HBV prevalence in 
HIV-positive patients  may be similar to that found in high endemicity regions (with Soriano et al 
22
 , 
for example, reporting a 7.1% HBsAg-positiviity), it is relatively  higher when compared to HIV-
negative patients. This is because both HBV and HIV are usually acquired in adulthood through sexual 
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transmission or intravenous drug use 
23
.  Studies have also shown that following acute HBV infection, 
HIV patients are more likely to develop chronic infection than non-HIV patients and this may explain 
why HIV patients have a higher rate of chronic HBV infection in low endemicity regions 
23, 24
. 
The present study showed a slightly higher prevalence of HBeAg (19%) among HBV/HIV co-infected 
patients when compared with our previous report on the prevalence of HBeAg among HIV-negative 
patients where only 12 % were HBeAg
 
-positive
25
. This however was not significantly different.  A 
similar trend was reported from Zambia where HBeAg was positive in 25% of HIV-positive patients 
compared to 8.5 % among HIV-negative patients 
26
.  It is possible  that HIV, by causing 
immunosuppression  may delay or prevent seroconversion to the inactive carrier phase in patients with 
chronic HBV infection 
23
.  It has been demonstrated that efficient restoration of immunity after the 
introduction of ART leads to high rates of seroconversion, especially in patients in the immunoactive 
phase of HBV infection
27
.  However, there is also the possibility that the HIV co-infected patients, 
who were significantly younger than the mono-infected liver disease patients did not have enough time 
to seroconvert or were recently infected with HBV.   Patients infected with HBV/HIV had higher HBV 
viral loads compared to HBV mono-infected patients (p<0.05) 
25
 and also lower ALT levels, within the 
normal range, compared to the patients infected with HBV only (p<0.05) 
25
.  The relatively low ALT 
levels have also been demonstrated in studies from South Africa where there was no significant 
difference in ALT levels among HIV patients serologically positive or negative for HBV infection 
28
. 
The immunosuppression caused by the HIV infection is responsible for these differences 
29
 and can 
account for the low rate of clinical manifestation of liver disease in the study population.
  
 
Despite the lower ALT levels, these patients have a higher risk of progression to liver cirrhosis 
30
. In 
addition to this risk, ART may cause further liver damage, either through direct toxicity or through 
idiosyncratic reactions
  31
. HBV/HIV co-infection is known to increase the risk of hepatotoxicity from 
ART when compared to other HIV patients without HBV or HCV co infection
13, 32
.   In sub-Saharan 
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Africa, however, this is risk is not entirely attributable to ART but may be as a result of elevated levels 
of HBV DNA in the serum
33
.    
HIV infection is also a known risk factor for development of OBI
  34
; this is characterized by two main 
criteria: absence of HBsAg and low viral replication. This  has been reported in several clinical 
contexts, the most common being chronic carriage with HBsAg too low to be detected by current 
serological tests and the presence of anti-HBc IgG as the only serological evidence of exposure to the 
virus, referred to as  "isolated anti HBc" 
35
. In this study, 96 patients (26.8%) had detectable HBV 
DNA on PCR, all of them were HBcIgG-positive, 11.7% were HBsAg-positive and 54 patients 
(15.1%) were HBsAg -negative indicating “occult” infection.  OBI has been further defined by the 
Taormina consensus conference in 2008 as "presence of HBV DNA in the liver (with detectable or 
undetectable HBV DNA in serum) of individuals testing HBsAg- negative with currently available 
assays and a serum HBV DNA of < 2.3 log10 IU/ml (< 200 IU/ml) when detectable) 
36
.   In this study, 
35 (9.8%) HBsAg-negative patients had a viral load < 2.3 log10 IU/ml (< 200 IU/ml)  and 19 (5.3%) 
had viral loads > 2.3 log10 IU/ml (>200 IU/ml).  Some individuals with chronic HBV infection may be 
HBsAg-negative but have HBV DNA levels comparable to patients with positive HBsAg (>2.3 log10 
IU/ml ; >200 IU/ml).  These individuals may infected with HBV variants with S gene escape mutants, 
which do not express HBsAg on serology as  preS mutations may prevent HBsAg secretion
37
.  In many 
HIV patients with OBI,  the viral load may be higher than suggested by the Taormina conference, 
which did not deal explicitly with HIV co-infection. A similar study from South Africa has reported 
positive HBV DNA in 23.8% of HIV patients, 8.7% were HBsAg- positive and 15.7% were HBsAg-
negative, with a viral load of  < 2.3 log10 IU/ml (< 200 IU/ml)  detected in 6.7% of HBsAg- negative 
patients
28
.  OBI has been demonstrated in 21.3% of HIV infected patients from the Cote d' Ivoire 
38
 
and in 10.5 % of cases from the United States 
39
. There is evidence that OBI may be associated with 
progression to chronic liver disease, liver cirrhosis and hepatocellular carcinoma 
40
.  
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While HIV is treated with a combination of three drugs which includes Lamivudine, Stavudine , 
Efavirenz and Nevirapine
13
, only Lamivudine is active against HBV, which may lead to rapid 
emergence of Lamivudine resistant HBV strains
41, 42.
  This is particularly important with the cognition 
that many HIV patients may test negative on screening with HBsAg but still harbor occult HBV 
infection, 
 
as has been demonstrated in this and other studies
28,
 
34
.  However,  recent reports have 
suggested that although Lamivudine resistance, can occur in the setting of incomplete HBV 
suppression, this was infrequently observed among HBV/HIV co- infected patients
 
 in sub-Saharan 
Africa
43
.  As of 2010 the World Health Organization has recommended introduction of ART which 
includes Tenofovir and Lamivudine (or emtricitabine) as first line therapy in all HBV/HIV co- infected 
patients needing treatment
44
.  
Interestingly, in this study, out of 96 patients with detectable HBV DNA on PCR, HIV/HBV/HCV tri-
infection was detected in 2 patients (2%), with none having HIV/HBV/HDV tri- infection. This is 
different from other studies were HIV/HBV/ HCV was detected in 6% and HIV/HBV/HDV was 
detected in 4% of patients
45
.  It is generally thought that HBV replication is significantly reduced in 
HCV and HDV tri- infection. The low HCV tri- infection in this study could be explained by the low 
HCV prevalence of only 2.2-4.8% found  in Sudan
10,
 
11
.   However,  the absence of HDV tri-infection 
is difficult to explain considering that HDV antibodies were detected in 9.0 % of patients with chronic 
HBV mono- infection
46
.   The determination of anti-HBs (to determine imunity to HBV in HBsAg-
negative patients), CD4 counts, HIV viral loads and nucleic acid testing for HCV and HDV would 
have strenghtherned this study and their absence are thus limitations of the present study.   
 
In conclusion in Sudan exposure rates to HBV infection and prevalence of HBsAg and HCV 
antibodies among adult HIV infected patients was similar to exposure rates in HIV-negative patients 
from previous studies.  HBsAg-negative HBV infection was detected in 15.1% of patients. Prevention 
12 
 
of HBV and HIV through education and vaccination against HBV is essential in our setting.  All HIV- 
infected patients should be carefully screened for HBV infection, with HBsAg and anti-HBc Ig G 
antibodies prior to starting ART, which should include Tenofovir and Lamivudine (or emtricitabine) as 
first line therapy.  Although PCR testing would detect OBI,  which would be missed by serological 
testing alone, it is too expensive to include as a routine screening test in Sudan.   
 
ACKNOWLEDGMENTS 
We acknowledge financial support from the Deutsche Forschungsgemeinschaft (DFG; German 
Research Foundation) of the special African-German Collaborative programme, “Africa Initiative”, 
(grant GL595/3-1 to HM, AK, and DG). The funding agency had no role in the study.  We thank the 
staff at Omdurman AIDS care unit and Bashair hospital for their assistance with the study.  The 
authors have no conflict of interest to declare.  The study was approved by the Ethics committee of the 
Faculty of Medicine, University of Khartoum, the National Ethics committee, Federal Ministry of 
Health, Sudan and by the Human Ethics Committee of the University of the Witwatersrand, South 
Africa. Written consent was obtained from all participants before their enrollment. 
 
 
 
 
 
 
  
13 
 
REFERENCES 
1.UNAIDS. UNAIDS Report on the global AIDS epidemic. Accessed July 2013. 
http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/2
2012. .. t_2012_en.pdf0121120_UNAIDS_Global_Repor 
2.WHO. Hepatitis B Fact sheet N°204. Accessed July 2013.  
2013. .http://www.who.int/mediacentre/factsheets/fs204/en/ 
3.WHO. Hepatitis C Fact sheet N°164. Accessed July 2013. 
2013. .http://www.who.int/mediacentre/factsheets/fs164/en/ 
4.Lewden C, Salmon D, Morlat P, Bévilacqua S, Jougla E, Bonnet F, Héripret L, Costagliola D, May 
T, Chêne G. Causes of death among human immunodeficiency virus (HIV)-infected adults in 
the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of 
AIDS. International journal of epidemiology 2005;34:121-30. 
5.Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009;49:S138-
S45. 
6.Graham C, Baden L, Yu E, Mrus J, Carnie J, Heeren T, Koziel M. Influence of human 
immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. 
Clinical Infectious Diseases 2001;33:562-9. 
7.Mudawi HM, Smith HM, Rahoud SA, Fletcher IA, Saeed OK, Fedail SS. Prevalence of hepatitis B 
virus infection in the Gezira state of central Sudan. Saudi J Gastroenterol 2007;13:81-3. 
14 
 
8.McCarthy MC, Hyams KC, el-Tigani el-Hag A, el-Dabi MA, el-Sadig el-Tayeb M, Khalid IO, 
George JF, Constantine NT, Woody JN. HIV-1 and hepatitis B transmission in Sudan. AIDS 
1989;3:725-9. 
9.Hyams KC, al-Arabi MA, al-Tagani AA, Messiter JF, al-Gaali AA, George JF. Epidemiology of 
hepatitis B in the Gezira region of Sudan. Am J Trop Med Hyg 1989;40:200-6. 
10.Mudawi HM, Smith HM, Rahoud SA, Fletcher IA, Babikir AM, Saeed OK, Fedail SS. 
Epidemiology of HCV infection in Gezira state of central Sudan. Journal of medical virology 
2007;79:383-5. 
11.Mudawi H, Smith H, Fletcher I, Fedail S. Prevalence and common genotypes of HCV infection in 
Sudanese patients with hepatosplenic schistosomiasis. Journal of medical virology 
2007;79:1322-4. 
12.UNAIDS. Report on the global AIDS epidemic. 
. Accessed http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf
July 2013 2010. 
13.Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with 
nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. 
Hepatology 2002;35:182-9. 
14.WHO. WHO case definitions of HIV for surveillance and revised clinical staging and 
immunological classification of HIV-related disease in adults and children. Accessed 
September 2013. World Health Organization; 2006. 
15 
 
15.HIV/AIDS programme- World Health Organization: WHO case definitions of HIV for surveillance 
and revised clinical staging and immunological classification of HIV-related disease in adults 
and children.  
. 
16.Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. Hepatitis B/C and HIV in sub-Saharan Africa: an 
association between highly prevalent infectious diseases. A systematic review and meta-
analysis. International Journal of Infectious Diseases 2010;14:e1024-e31. 
17.Shimelis T, Torben W, Medhin G, Tebeje M, Andualm A, Demessie F, Mulu A, Tegbaru B, Gebre-
Selassie S. Hepatitis B virus infection among people attending the voluntary counselling and 
testing centre and anti-retroviral therapy clinic of St Paul’s General Specialised Hospital, Addis 
Ababa, Ethiopia. Sexually transmitted infections 2008;84:37-41. 
18.Bwogi J, Braka F, Makumbi I, Mishra V, Bakamutumaho B, Nanyunja M, Opio A, Downing R, 
Biryahwaho B, Lewis RF. Hepatitis B infection is highly endemic in Uganda: findings from a 
national serosurvey. African health sciences 2009;9. 
19.Cunha L, Plouzeau C, Ingrand P, Gudo JPS, Ingrand I, Mondlane J, Beauchant M, Agius G. Use of 
replacement blood donors to study the epidemiology of major blood‐borne viruses in the 
general population of Maputo, Mozambique. Journal of medical virology 2007;79:1832-40. 
20.Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and 
Africa. The Lancet infectious diseases 2007;7:402-9. 
21.Burnett RJ, Francois G, Kew MC, Leroux-Roels G, Meheus A, Hoosen AA, Mphahlele MJ. 
Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call 
for further investigation. Liver Int 2005;25:201-13. 
16 
 
22.Soriano V, Mocroft A, Peters L, Rockstroh J, Antunes F, Kirkby N, de Wit S, Monforte A, Flisiak 
R, Lundgren J. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients 
with chronic hepatitis B in Europe. J Antimicrob Chemother 2010;65:548-55. 
23.Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 
infection on the development of the hepatitis B virus carrier state. Journal of Infectious 
Diseases 1991;163:1138-40. 
24.Hadler SC, Judson FN, O'Malley PM, Altman NL, Penley K, Buchbinder S, Schable CA, Coleman 
PJ, Ostrow DN, Francis DR. Outcome of hepatitis B virus infection in homosexual men and its 
relation to prior human immunodeficiency virus infection. Journal of Infectious Diseases 
1991;163:454-7. 
25.Yousif M, Mudawi H, Bakhiet S, Glebe D, Kramvis A. Molecular characterization of hepatitis B 
virus in liver disease patients and asymptomatic carriers of the virus in Sudan. BMC infectious 
diseases 2013;13:328. 
26.Oshitani H, Kasolo F, Mpabalwani M, Mizuta K, Luo N, Suzuki H, Numazaki Y. Prevalence of 
hepatitis B antigens in human immunodeficiency virus type 1 seropositive and seronegative 
pregnant women in Zambia. Transactions of the Royal Society of Tropical Medicine and 
Hygiene 1996;90:235-6. 
27.Matthews GV, Ali RJ, Avihingsanon A, Amin J, Hammond R, Bowden S, Lewin SR, Sasadeusz J, 
Littlejohn M, Locarnini SL, Ruxrungtham K, Dore GJ. Quantitative HBsAg and HBeAg 
predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected 
individuals. PLoS One 2013;8:e61297. 
17 
 
28.Bell TG, Makondo E, Martinson NA, Kramvis A. Hepatitis B virus infection in human 
immunodeficiency virus infected southern African adults: occult or overt–that is the question. 
PloS one 2012;7:e45750. 
29.Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural 
history, and treatment.Seminars in liver disease: Copyright© 2002 by Thieme Medical 
Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.:+ 1 (212) 584-4662; 
2003, pp. 125-36. 
30.Colin JF, Cazals‐Hatem D, Loriot MA, Martinot‐Peignoux M, Pham BN, Auperin A, Degott C, 
Benhamou JP, Erlinger S, Valla D. Influence of human immunodeficiency virus infection on 
chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-10. 
31.Kaplowitz N. Drug-induced liver injury. Clinical infectious diseases 2004;38:S44-S8. 
32.Puoti M, Torti C, Ripamonti D, Castelli F, Zaltron S, Zanini B, Spinetti A, Putzolu V, Casari S, 
Tomasoni L, Quiros-Roldan E, Favret M, Berchich L, Grigolato P, Callea F, Carosi G. Severe 
hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and 
outcome. J Acquir Immune Defic Syndr 2003;32:259-67. 
33.Hoffmann CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, Chaisson RE, Grant AD, 
Fielding KL, Thio CL. Hepatitis B virus infection and response to antiretroviral therapy (ART) 
in a South African ART program. Clin Infect Dis 2008;47:1479-85. 
34.Mphahlele MJ, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. High risk of occult 
hepatitis B virus infection in HIV-positive patients from South Africa. Journal of clinical 
virology 2006;35:14-20. 
35.Allain J-P. Occult hepatitis B virus infection. Transfusion clinique et biologique 2004;11:18-25. 
18 
 
36.Raimondo G, Allain J-P, Brunetto MR, Buendia M-A, Chen D-S, Colombo M, Craxì A, Donato F, 
Ferrari C, Gaeta GB. Statements from the Taormina  expert meeting on occult hepatitis B virus 
infection. Journal of hepatology 2008;49:652-7. 
37.Melegari M, Bruno S, Wands JR. Properties of hepatitis B virus pre-S1 deletion mutants. Virology 
1994;199:292-300. 
38.Attia KA, Eholié S, Messou E, Danel C, Polneau S, Chenal H, Toni T, Mbamy M, Seyler C, 
Wakasugi N. Prevalence and virological profiles of hepatitis B infection in human 
immunodeficiency virus patients. World journal of hepatology 2012;4:218. 
39.Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. JAIDS 
Journal of Acquired Immune Deficiency Syndromes 2004;36:869-75. 
40.Hu KQ. Occult hepatitis B virus infection and its clinical implications. Journal of viral hepatitis 
2002;9:243-57. 
41.Zollner B, Petersen J, Puchhammer-Stockl E, Kletzmayr J, Sterneck M, Fischer L, Schroter M, 
Laufs R, Feucht HH. Viral features of lamivudine resistant hepatitis B genotypes A and D. 
Hepatology 2004;39:42-50. 
42.Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, Katlama C, 
Poynard T. Long-term incidence of hepatitis B virus resistance to lamivudine in human 
immunodeficiency virus-infected patients. Hepatology 1999;30:1302-6. 
43.Kim HN, Scott J, Cent A, Cook L, Morrow RA, Richardson B, Tapia K, Jerome KR, Lule G, John-
Stewart G, Chung MH. HBV lamivudine resistance among hepatitis B and HIV coinfected 
patients starting lamivudine, stavudine and nevirapine in Kenya. J Viral Hepat 2011;18:e447-
52. 
19 
 
44.HIV/AIDS programme- World Health Organization (WHO). Antiretroviral therapy for HIV 
infection in adults and adolescents. Recommendations for a public health approach, 2010 
revision. . 
45.Boyd A, Lacombe K, Miailhes P, Gozlan J, Bonnard P, Molina JM, Lascoux-Combe C, Serfaty L, 
Gault E, Desvarieux M, Girard PM. Longitudinal evaluation of viral interactions in treated 
HIV-hepatitis B co-infected patients with additional hepatitis C and D virus. J Viral Hepat 
2010;17:65-76. 
46.McCarthy MC, Burans JP, Constantine NT, el-Hag AA, el-Tayeb ME, el-Dabi MA, Fahkry JG, 
Woody JN, Hyams KC. Hepatitis B and HIV in Sudan: a serosurvey for hepatitis B and human 
immunodeficiency virus antibodies among sexually active heterosexuals. Am J Trop Med Hyg 
1989;41:726-31. 
 
 
  
20 
 
Table 1: Demographic criteria and risk factors for HBV exposure in 358 HIV-positive Sudanese 
adults 
Variable 
Number of patients 
tested (358) 
Number positive 
for anti-HBc IgG 
(225) 
Number negative  
for Anti-HBc 
IgG 
P value 
Gender 
Male 203 (56.7%) 139 (61.8%) 64(48.1%) 
0.012* 
Female 155 (43.3%) 86(38.2%) 69(51.9%) 
Marital status 
Married 214 (59.8%) 136(60.4%) 78(58.6%) 
0.896 
Single 82(22.9%) 50(22.2%) 32(24.1%) 
Divorced
/widowe
d 
62(17.3%) 39(18.8%) 
23(17.3%) 
Multiple 
sexual partners 
Yes 144 (40.2%) 95(42.2%) 49(36.8%) 
0.316 
No 214(59.8%) 130(57.8%) 84(63.2%) 
Surgery 
Yes 65(18.2%) 37(16.4%) 28(21%) 
0.274 
No 293(81.8%) 188(83.6%) 105(79%) 
Blood 
transfusion 
Yes 38(10.6%) 20(8.9%) 18(13.5%) 
0.168 
No 320(89.4%) 205(91.1%) 115(86.5%) 
Dental 
procedures 
Yes 92(25.7%) 54(24.0%) 38(28.6%) 
0.339 
No 266(74.3%) 171(76.0%) 95(71.4%) 
Intravenous 
drug use 
Yes 5(1.4%) 1(0.4%) 4(3%) 
0.046* 
No 353(98.6%) 224(99.6%) 129(97%) 
History of 
Jaundice 
Yes 111(31.0%) 78(34.7%) 33(24.8%) 
0.51 
No 247(69.0%) 147(65.3%) 100(75.2%)  
HBV 
vaccination 
Yes 4(1.1%) 2 (0.9%) 2(1.5%) 
0.593 
No 354(98.9%) 223(99.1%) 131(98.5%) 
WHO 
classification 
Stage 
1&2 
126(35.2%) 66(29.3%) 
60(45.1%) 
0.168 
Stage 
3&4 
232(64.8%) 159(70.7%) 73(54.9%) 
* Significant risk factor 
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Table 2: Comparison between patients who were HBV DNA positive and patients who were 
HBV DNA negative on PCR, among 358 HIV infected patients 
Variable 
Number of 
patients 
tested (358) 
HBV DNA 
positive (96) 
HBV DNA 
negative 
(262) 
P value 
Gender 
Male 203 (56.7%) 59 (61.5%) 144(55%) 
0.272 
Female 155 (43.3%) 37(38.5%) 118 (45%) 
Marital status 
Married 214 (59.8%) 62 (64.6%) 152(58%) 
0.342 Single 82(22.9%) 24(25%) 58(22.1%) 
Divorced/widowed 62(17.3%) 10(10.4%) 52(19.8%) 
Multiple sexual 
partners 
Yes 144 (40.2%) 42(43.8%) 102(38.9%) 
0.410 
No 214(59.8%) 54(56.2%) 160(61.1%) 
History of surgery 
Yes 65(18.2%) 17(17.7%) 48(18.3%) 
0.894 
No 293(81.8%) 79(82.3%) 214(81.7%) 
Blood transfusion 
Yes 38(10.6%) 5(5.2%) 33(12.6%) 
0.044* 
No 320(89.4%) 91(94.8%) 229(87.4) 
Dental procedures 
Yes 92(25.7%) 16(16.7%) 76(29%) 
0.018* 
No 266(74.3%) 80(83.3%) 186(71%) 
Intravenous drug 
use 
Yes 5(1.4%) 0 5(1.9%) 
0.173 
No 353(98.6%) 96 (100%) 257(98.1%) 
History of Jaundice 
Yes 111(31.0%) 38(39.6%) 73(27.9%) 
0.034* 
No 247(69.0%) 58(60.4%) 189(72.1%) 
HBV vaccination 
Yes 4(1.1%) 1 (1%) 3(1.1%) 
0.934 
No 354(98.9%) 95(99%) 259(98.9%) 
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WHO 
classification 
Stage 1 &2 126(35.2%) 23(24%) 103(39.3%) 
0.037* 
Stage 3&4 232(64.8%) 73(76%) 159(60.7%) 
* Significant risk factor 
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Table 3: Comparison between HBsAg-positive and HBsAg-negative patients among 96 HIV 
infected patients with detectable HBV DNA on PCR 
Variable 
 Number of 
patients tested 
(96) 
HBsAg 
positive (42) 
HBsAg 
negative 
(54) 
P 
value 
Gender 
Male 59 (61.5%) 24(57.1%) 35(64.8%) 
0.444 
Female 37(38.5%) 18(42.9%) 19(35.2%) 
Marital status 
Married 62 (64.6%) 28(66.7%) 34(63%) 
0.819 Single 24(25%) 11(26.2%) 13(24%) 
Divorced/widowed 10(10.4%) 3(7.2%) 7(13%) 
Multiple sexual 
partners 
Yes 42(43.8%) 18(42.9%) 24(44.4%) 
0.876 
No 54(56.2%) 24(57.1%) 30(55.6%) 
Surgery 
Yes 17(17.7%) 8(19%) 9(16.7%) 
0.762 
No 79(82.3%) 34(81%) 45(83.3%) 
Blood transfusion 
Yes 5(5.2%) 3(7.1%) 2(3.7%) 
0.452 
No 91(94.8%) 39(92.9%) 52(96.3%) 
Dental procedures 
Yes 16(16.7%) 9(21.4%) 7(13%) 
0.270 
No 80(83.3%) 33(78.6%) 47(87%) 
Intravenous drug 
use 
Yes 0 0 0 
- 
No 96 (100%) 42(100%) 54(100%) 
History of 
jaundice 
Yes 38(39.6%) 23(54.8%) 15(27.8%) 
0.007* 
No 58(60.4%) 19(45.2%) 39(72.2%) 
HBV vaccination 
Yes 1(1%) 1(2.4%) 0 
0.254 
No 95(99%) 41(97.6%) 54(100%) 
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WHO 
classification 
Stage 1 &2 23(24%) 11(26.2%) 12(22.2%) 
0.947 
Stage 3 &4 73(76%) 31(73.8%) 42(77.8%) 
* Significant risk factor 
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Table 4: Median HBV viral loads in 96 HIV infected patients with detectable HBV DNA on PCR 
 
HBsAg status 
Number 
Median viral 
load 
(log10IU/ml) 
Interquartile range 
IQR (log10IU/ml) 
P value 
 
HBsAg-positive 
42 3.2 3.3 - 6.6 
0.000* 
 
HBsAg-negative 
54 1.7 1.3 -2.7 
* Significant risk factor 
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Appendix C 
 
 
 
 
 
 
Informed Consents   
 Department of Internal Medicine, Faculty of Medicine  
University of Khartoum 
 
Study on Characterization of HBV genotyping in Sudanese patients 
Consent form for participation in the study 
 
We are Researchers from the department of Internal Medicine, Faculty of Medicine, 
University of Khartoum. We are conducting a study on the characterization of 
hepatitis B virus (HBV). We will collect a blood sample to assess whether you have 
been exposed to HBV infection in the past. All data will remain confidential and will 
not be accessible except for the main investigators and co- investigators. The samples 
will be analyzed in Sudan and in partner labs in South Africa. We will inform you 
about the result of the study after its completion .We will not use these samples in any 
other study without your agreement. You will not get any payment to participate in 
this study and your participation is completely voluntarily and you could drop out of 
the study at any time. If you have any questions please contact Dr. Hatim Mudawi, 
Faculty of Medicine, University of Khartoum on Tel. 0912202600 
I……………………………… read and understood the content of this form ,and 
voluntarily want to participate in this study  
Date __________________________Signature __________________________ 
Interviewer …………………………………….. 
Date __________________________Signature __________________________ 
 
 Department of Internal Medicine, Faculty of Medicine  
University of Khartoum 
 
Study on Characterization of HBV genotyping in Sudanese subjects infected 
with the human immunodeficiency virus  
Consent form for participation in the study 
 
We are Researchers from the department of Internal Medicine, Faculty of Medicine, 
University of Khartoum. We are conducting a study on the characterization of 
hepatitis B virus (HBV) in patients with HIV infection. We will collect a blood 
sample to assess whether you have been exposed to HBV infection in the past. All 
data will remain confidential and will not be accessible except for the main 
investigators and co- investigators. The samples will be analyzed in Sudan and in 
partner labs outside Sudan. We will inform you about the result of the study after its 
completion .We will not use these samples in any other study without your agreement. 
You will not get any payment to participate in this study and your participation is 
completely voluntarily and you could drop out of the study at any time. If you have 
any questions please contact Dr. Hatim Mudawi, Faculty of Medicine, University of 
Khartoum on Tel. 0912202600 
I……………………………… read and understood the content of this form ,and 
voluntarily want to participate in this study  
Date __________________________Signature __________________________ 
Interviewer …………………………………….. 
Date __________________________Signature __________________________ 
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Appendix D 
 
 
 
 
 
 
Clinical Report Form  
University Of Khartoum 
Faculty of Medicine-Department of Medicine 
Questionnaire 
Project title: HBV genotyping in Sudan 
   Number:  
Sex:    Male      Female  
Age:     Occupation: ……………………………………………………… 
Residence: …………………………………………………………………………… 
Tribe: ………………………………………………………………………………… 
Marital status: ………………………………………………………………………… 
Phone No: ………………………………………………………………………….. 
_____________________________________________________________________ 
Parental therapy for Malaria:   Yes   No  
Parental therapy for Schistosomiasis:  Yes   No  
History of hospitalization:    Yes   No  
(If yes) Date and condition of admission:…………………………………………… 
History of surgery:               Yes   No  
(If yes) Date and condition of Surgery:……………………………………………… 
History of haematemesis/maelana: Yes   No  
History of blood transfusion:  Yes   No  
Previous dental treatment:   Yes   No  
History of Jaundice:    Yes   No  
(If yes) Date of incidence:…………………………………………………………… 
History of Alcohol intake:   Yes   No  
(If yes)………………………………………………………………………………… 
History of vaccination to HBV:  Yes   No  
(If yes) Date of vaccination:…………………………………………………………. 
_______________________________________________________________________ 
Clinical examination: 
Pale:      Yes   No  
Jaundice:     Yes   No  
Tattoos/Scarification:   Yes   No  
Clubbing:     Yes   No  
Palmar erythema:    Yes   No  
Dupuytren’s contractures:   Yes   No  
Gynaecomastia:    Yes   No  
Liver:…………cm   Enlarged:    Not enlarged  
Spleen:………..cm  Enlarged:    Not enlarged  
Ascitis:     Yes   No  
LL odema:     Yes   No  
Investigation:  
U/S:…………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
……………………………………………………………………………………………… 
ALT:………………………………………………………………………………………. 
Albumin:………………………………………………………………………………….. 
Bilirubin: …………………………………………………………………………………. 
Platelet counts:……………………………………………………………………………. 
PT:…………………    Control:…………………          INR:…………………….  
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Appendix E 
1. Table 1: Primer sequences and PCR conditions used throughout the study  
 
Name  Position  Nuclotide sequence orientation 
PCR 
round  
Thermocycling conditions 
Denaturation Annealing extension cycles 
2410(+) 2401-2439 5'-TCA ATC GCC GCG TCG CAG AAG ATC TCA ATC-3' Forward 
First 
94 °C for 1 
min 
66 °C for 1 
min 
72 °C for 3 
min 
40 
1314(-) 1314-1291 5'-TCC AGA CCK GCT GCG AGC AAA ACA-3' Reverse 
2451(+) 2451-2482 5-'AAT GTT AGT ATT CCT TGG ACT CAT AAG GTG GG-3' Forward 
Second 
94 °C for 1 
min 
65 °C for 1 
min 
72 °C for 3 
min 
40 
1280(-) 1286-1254 5-'AGT TCC GCA GTA TGG ATC GGC AGA GGA-3' Reverse 
1606(+) 1606-1625 5'-GCA TGG AGA CCA CCG TGA AC-3' Forward 
First 
94 °C for 1 
min 
55 °C for 1 
min 
72 °C for 2 
min 
30 
1974(-) 1955-1974 5'-GGA AAG AAG TCA GAA GGC AA-3' Reverse 
1653(+) 1653-1672 5'-CAT AAG AGG ACT CTT GGA CT-3' Forward 
Second 
94 °C for 1 
min 
55 °C for 1 
min 
72 °C for 2 
min 
30 
1959(-) 1940-1959 5'-GGC AAA AAC GAG AGT AAC TC-3' Reverse 
255(+) 253-275 5'-CTC GTG GTG GAC TTC TCT CAA TT-3'  Forward 
First 
94 °C for 30 
sec 
56 °C for 
50 sec 
72°C for 1 
min 
40 
759(-) 759-739 5'-CCC CAA TAC CAC ATC ATC CAT-3'  Reverse 
459(+) 460-480 5'-TAT GTT GCC CGT TTG TCC TCT-3'  Forward 
Second 
94 °C for 30 
sec 
56 °C for 
50 sec 
72 °C for 
50 sec 
40 
710(-) 711-691 5'-AGC CCT ACG AAC CAC TGA ACA-3'  Reverse 
P1 1821-1841 5'-TTT TTC ACC TCT GCC TAA TCA-3' Forward  NA 98 °C for 10 
sec 
57 °C for 
30 sec 
72 °C for 1 
min 
35 
P2 1825-1806 5-'AAA AAG TTG CAT GST GST GG-3'  Reverse   
230(+) 230 -249 5'-TCA CAA TAC CGC AGA GTC T-3' Forward 
First 
94 °C for 1 
min 
55 °C for 1 
min 
72 °C for 2 
min 
40 
800(-) 820-800 5'-AAC AGC GGT ATA AAG GGA CT-3' Reverse 
P7 25 -278 5'-GTG GTG GAC TTC TCT CAA TTT TC-3' Forward 
Second 
94 °C for 1 
min 
55 °C for 1 
min 
72 °C for 2 
min 
40 
P8 796-776 5'-CGG TAT AAA GGG ACT CAC GAT-3' Reverse 
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2. Table 2: Sequences of sequencing Primers used throughout the study 
Name  Position  Nucleotide sequence Orientation 
2497F 2497-2516 5'-TTC CTT GGA CTC ATA AGG TG-3' Forward 
3188F 3188-3206 5'-AGT CAG GAA GGC AGC CTA C-3' Forward 
591F 591-611 5'-ATT GCA CCT GTA TTC CCA TCC-3'  Forward 
1069F 1069-1088 5'- TGT ATT CAA TCT AAG CAG GC-3' Forward 
2022F 2022-2041 5'-CCT TAG AGT CTC CTG AGC AT-3'  Forward 
Post-Bgl III 2000-2017 5'-CCG ATA CAG AGC TGA GGC-3'  Reverse 
2480R 2461-2480 5'-CAC CTT ATG AGT CCA AGG AA-3' Reverse 
BCPS1 1698-1717 5‘-GAG GCA TAC TTC AAA GAC TG-3‘ Forward 
BCPS2 1928-1947 5‘-AGT AAC TCC ACA GTA GCT CC -3‘ Reverse 
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Appendix F 
 
Laboratory Protocols  
Complete genome amplification  
The Expand High Fidelity PCR system (Roche Diagnostics, Mannheim, Germany) was used 
for the amplification of complete HBV genomes. The reaction mixture consisted of 10 μl of 
5X phusion Expand High Fidelity (HF) buffer (7.5 mM MgCl2, 1 μl of 10 mM dNTP mix), 3 
μl of 10 μM  primer P1 and P2, 2.5 μl of 100% Dimethyl Sulfoxide (DMSO) and 5 μl of ex-
tracted DNA and 45 μl with distilled water. The enzyme mixture constituted 4.5 μl 5X HF 
buffer mixed with 0. 5 μl of phusion Expand HF DNA polymerase enzyme. The reaction was 
preheated to 98° C for 1 minute and cooled to 80°C for 30 seconds at which time 5 μl of en-
zyme mixture was added. This was followed by heating to 98° C for 1 minute.  Thirty five 
cycles were performed, with PCR conditions as indicated in Appendix E.  Both HBV-positive 
and -negative controls were included, the latter consisting of best quality water (BQW) in-
stead of DNA in the PCR reaction mixture. The reaction was carried out in a Techgene pro-
grammable thermo-cycler (Techne Inc., Princeton, NJ). 
 
Complete S region amplification 
Nested PCR was performed on the complete surface gene using HotStarTaq Master Mix Kit 
(QIAGEN-Netherlands). The reaction mixture for the first round consisted of 12.5 μl of 
HotStarTaq master mix (250 units HotStarTaq DNA Polymerase, PCR Buffer with 3 mM 
MgCl2, and 400 µM of each dNTP), 0.375 µl each of 10 µM primer 2410 (+) and 1314 (-), 
2.5 μl of DNA, with the reaction topped up to 25 μl with distilled water. The reaction mixture 
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for the second round consisted of 25 μl HotStar Taq master mix,  0.75 μl of each 10 μM 
primer 2451 (+) and 1280 (-), 5 μl of first round PCR product and topped up to 50 μl with 
distilled water. For primer sequences and PCR conditions, see Appendix E. 
 
BCP/PC region amplification  
 
Nested PCR was performed on the BCP/PC region (1742 to 1900 from the EcoR1 site) using 
BIOLINE PCR kits (London, UK). The reaction mixture for the first round consisted of 2.5 
μl of 10X NH4 PCR buffer, 0.75 μl of 50mM MgCl2, 2 μl of 10 mM dNTPs, 1.25 μl of each 
10 μM primer 1606 (+) and 1974 (-), 0.1 μl of Taq DNA polymerase, 2.5 μl of DNA and 
topped up to 25 μl with distilled water. The reaction mixture for the second round consisted 
of 5 μl of 10X NH4 PCR buffer, 1.5 μl of 50mM MgCl2, 4 μl of 10mM dNTPs, 2.5 μl of each 
10 μM primer 1606 (+) and 1974 (-), 0.2 μl of Taq DNA polymerase, 5 μl of DNA and topped 
up to 50 μl with distilled water. For primer sequences and PCR conditions, see Appendix E 
 
Short S PCR 
 
Nested PCR was performed on a short region in the S region (459-710 from EcoR1 site) 
using BIOLINE PCR kits. The reaction mixture for the first round consisted of 2.5 μl of 10X 
NH4 PCR buffer, 0.75 μl of 50mM MgCl2, 2 μl of 10mM dNTPs, 1.25 μl of each 10 μM 
primer 255 (+) and 759 (-), 0.1 μl of Taq DNA polymerase, 2.5 μl of DNA and topped up to 
25 μl with distilled water. The reaction mixture for the second round consisted of 5 μl of 10X 
NH4 PCR buffer, 1.5 μl of 50mM MgCl2, 4 μl of 10mM dNTPs, 2.5 μl of each 10 μM primer 
459 (+) and 710 (-), 0.2 μl of Taq DNA polymerase,5 μl of DNA and topped up to 50 μl with 
distilled water. For primer sequences and PCR conditions, see Appendix E 
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Detection of amplicons (Gel Electrophoresis) 
A 10 μl aliquot of the amplicon was analyzed by agarose gel electrophoresis. The percentage 
of the agarose used varied between 0.8% and 3%, depending on the expected size of 
amplicon. Commercially available DNA ladders of 100 bp or 1 kb (Promega Madison, USA) 
were used to determine the size of the amplicon. HBV DNA from HBsAg-positive, DNA-
positive patients was used as a positive control. BQW or DNA extracted from HBsAg-
negative patients was used as a negative control. Gels were electrophoresed in 1X TBE 
(Appendix G) at 70 mA for 30-60 minutes. Ethidium bromide (Appendix G) was included in 
the preparation of the gel at a final concentration of 1 μg/ml. This allowed for viewing of 
DNA under UV illumination. The PCR products were stored at -20° C until sent for 
sequencing or further analysis. 
Restriction Fragment Length Polymorphsim (RFLP) PCR 
Nested PCR was performed to amplify the region 256 to 796 from the EcoR1 site, using 
BIOLINE PCR kits. The reaction mixture for the first round consisted of 2.5 μl of 10X NH4  
PCR buffer, 0.75 μl of 50mM MgCl2, 2 μl of 10mM dNTPs, 1.25 μl of each 10 μM primer 
230(+) and 800(-), 0.1 μl of Taq DNA polymerase, 2.5 μl of DNA and topped up to 25 μl with 
distilled water. The reaction mixture for the second round consisted of 5 μl of 10X NH4 PCR 
buffer, 1.5 μl of 50mM MgCl2, 4 μl of 10mM dNTPs, 2.5 μl of each 10 μM P7 and P8, 0.2 μl 
of Taq DNA polymerase, 5 μl of DNA and topped up to 50 μl with distilled water. For primer 
sequences and PCR conditions, see Appendix E 
Digestion 
RFLP analysis of the region 256 to 796 from EcoR1 site was undertaken on amplicons to 
determine the HBV genotype (Lindh et al., 1997). Fifteen μl of the PCR product was 
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dispensed into two separate 0.5 ml PCR tubes. To one of these tubes, 0.5 μl  of 5 U HinfI 
restriction enzyme (New England Biolabs, Inc, Ipswich, Mass), 2.0 μl NEBuffer and 7.5 μl  
of BQW was added, while to the other, 0.5 μl  of 5 U Tsp509I restriction enzyme (New 
England Biolabs), 2.0 μl NEBuffer and 7.5 μl BQW was added. Each reaction was overlaid 
with a thin layer of mineral oil before being incubated for 3 hours at 37 °C (for the HinfI 
restriction) or 65 °C (for the Tsp509I restriction). The reaction was terminated by adding 4 μl 
gel loading dye (Promega). The entire restriction reaction was loaded on a 3% agarose gel 
containing 10 mg/ml ethidium bromide (Bio Basics Inc., Markham, Ontario) at ~3.5 volts/cm 
along with 10 μl of a 100 bp DNA ladder (Promega) and 10 μl of a 50 bp DNA ladder 
(Promega) until the bromophenol blue tracking dye had migrated across approximately 80% 
of the length of the gel. An image of the gel was recorded using the Bio-Rad Gel Doc XR 
Imaging System (Bio-Rad Laboratories Inc., Hercules, Calif.) and the sizes of the restricted 
fragments compared to those in table 3 of (Lindh et al., 1997) to determine the genotype of 
the samples. 
 
Cloning  
The amplified region 1653 to 1959 from EcoR1 site was cloned with the InsTAclone™ PCR 
Cloning Kit. The final elongation step of the second round of the nested PCR amplification 
was increased from 10 minutes to 30 minutes to increase the number of 3‘-A overhangs on 
the ends of the amplicons. The amplicons were gel-purified using the QIAGEN QIAquick 
Gel Extraction Kit according to the manufacturer‘s instructions. A 1.0 μl aliquot of this elute 
was resolved on a 1% agarose gel together with a O‘GeneRuler 1 kb DNA ladder 
(Fermentas). This molecular weight marker is composed of fragments of known 
concentration and the concentration of the eluted DNA can be determined by comparing the 
intensity of the resolved fragment to the intensities of the fragments in the molecular weight 
marker. This concentration was used to determine the volume of extracted DNA equivalent to 
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the 0.52 pmol ends required for the cloning reaction which was set up according to the 
manufacturer‘s instructions and incubated overnight at 4° C. A 4.0 μl aliquot of the cloning 
reaction was transformed into One Shot® TOP10 chemically competent cells (Invitrogen, 
Life Technologies, United States of America), by adding by the whole reaction to 250 SOC 
medium (Sigma-Aldrich Inc., United States of America). Three different volumes of the 
transformation reaction (50 μl, 100 μl and 150 μl) were spread onto pre-warmed LB agar 
plates containing 50 μg/ml ampicillin (Appendix G) and X-gal and IPTG to differentiate 
between the positive and negative colonies (white for positive and blue for negative) and 
incubated overnight at 37° C. On the following day, individual colonies were selected and 
cultured overnight at 37° C in 5 ml Luria-Bertani (LB) medium containing either kanamycin 
or ampicillin, as required.  
On the following day, the cracking procedure was undertaken, by centrifugation of the 
harvest of 500 μl of bacterial suspension with 100 μl cracking buffer, which was then loaded 
onto a gel. The presence of BCP and vector DNA (about 3.1 kb) indicated a positive clone. 
This was followed by Plasmid DNA extraction using the remaining 4 ml culture using the 
GenElute™ Plasmid Miniprep Kit (Sigma-Aldrich Inc., United States of America)  according 
to the manufacturer‘s instructions. Finally, the RFLP technique was followed to separate the 
BCP product from the vector. A 3.0 μl aliquot of extracted plasmid DNA was restricted at 37° 
C for 1 hour with 20 U EcoR1 (New England BioLabs) with 1 μl NEBuffer EcoR1 and 4.0 μl 
of BQW. The restricted products were resolved overnight on a 1% agarose gel together with a 
1 kb DNA ladder (Promega) to determine whether the plasmids contained the fragment of 
interest. The plasmid has a length of  2.8 kb and the BCP product has a length of 300 bases. 
 
  
  
181 
Appendix G 
Solutions 
10 x TBE buffer PH 8.3 
108 g Tris base 
55 g Boric acid 
9,3 g EDTA 
Adjust volume to 1000 ml with distilled water. 
Sterilise by autoclaving and store at room temperature. 
 
1% Agarose gel 
1 g Agarose 
100 ml 1 x TBE buffer 
Dissolve agarose in 1 x TBE buffer by heating in a microwave oven for ~4 minutes, swirling 
occasionally, until all the agarose particles are completely dissolved. Care must be taken that 
especially the high percentage gels do not boil over. 
Cool to ~60 °C. 
Add 10μl mg / ml Ethidium Bromide and swirl to mix. 
Pour into a prepared casting tray and allow to solidify completely at room temperature. 
 
Luria-Bertani (LB) medium 
10 g Tryptone 
5 g Yeast 
10 g Sodium chloride 
Adjust volume to 1000 ml with distilled water. 
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Sterilize by autoclaving. 
Add 1 ml of either 50 mg/ml ampicillin or 50 mg/ml kanamycin as required. 
Store at 4 °C. 
 
LB agar plates 
10 g Tryptone 
5 g Yeast 
10 g Sodium chloride 
15 g Bacteriological agar 
Adjust volume to 1000 ml with distilled water. 
Sterilize by autoclaving. 
Cool to approximately 50° C before adding 1 ml of either 50 mg/ml ampicillin or 50 mg/ml 
kanamycin as required. After pouring, allow plates to solidify completely at room 
temperature before storing at 4° C. 
 
75% Ethanol 
To a RNase free, sterile bottle, add: 
75 ml Absolute ethanol 
25 ml sterile water 
Store at -20C. 
 
X-gal 
5-bromo-4-chloro-3-indolyl-_-D-galactoside (X-gal) 
50 mg/ml in dimethylformamide stored at -20°C. 
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IPTG stock solution (0.5 M) 
6 g isopropyl _-D-thiogalactopyranoside (IPTG) in 50 ml of deionised water.  
Filter sterilized with a 0.2 μm filter store at -20°C. 
 
Ampicillin 
100 mg/ml in deionised water (filter sterilize) 
 
1% cracking buffer 
SDS (2.5 g) 
2 mM EDTA Disodium Salt (0.19 g) 
400 mM Sucrose (34.22 g) 
50 mM Tris-HCl, pH 6.8 (125 ml) 
100 μg/ml RNase A, DNase- and Protease-Free (2.5 μl) 
0.01% (w/v) Bromophenol Blue Sodium Salt for Electrophoresis (0.025 g) 
0.01% (w/v) Xylene Cyanol FF  (0.025 g) 
UltraPure™ distilled water, deoxyribonuclease (DNase)- and RNase free was added to make 
up to a final volume of 250 ml, after which it was stored at room temperature until further 
used. 
 
5X loading dye 
200 μl 5X loading buffer 
100 μl _-mercaptoethanol 
100 μl Bromophenol Blue (saturated solution) 
 
10 mM dNTP Solution 
10 mM dATP (10 μl), 10 mM dCTP (10 μl), 10 mM dGTP (10 μl), 10 mM dTTP (10 μl) 
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The solution was made up to a final volume of 100 μl with BQW. The solution was briefly 
vortexed, and centrifuged, after which the solution was stored at -20 °C until further used. All 
four reagents were purchased as a dNTP Set (Bioline Reagents Ltd., London, United 
Kingdom) 
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